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ABSTRACT 
 
Multidrug-resistant Gram-negative bacteria pose a problem that 
infection control practitioners, hospital epidemiologists, clinicians, and 
hospital administrators are struggling to control. Failure of treatments (or 
failure of medical management of infections) with single antibiotics which 
are commonly used in Sudan is associated with dramatic increases in the 
Minimum Inhibitory Concentration (MIC). 
Achieving effective combinations of the commonly used antibiotics 
may kill resistant mutants, potentiating successful therapy. Theoretically and 
indeed in practice the Minimum Inhibitory Concentrations (MICs) of 
antibiotics can be reduced if combined with a second antibiotic acting 
synergistically or additively. 
Ten clinical drug resistant Gram negative bacterial isolates were 
selected for this study, from samples provided by out-patients for routine 
analysis to the Department of Microbiology of The University of Medical 
Sciences and Technology, Medical Center (Yastabsheroon). They belong to 
four genera namely, Escherichia, Klebsiella, Pseudomonas and 
Enterobacter. A sensitive strain of Pasteurella multocida was selected for 
comparison. The eleven isolates were identified using normal biochemical 
reactions and were confirmed using API 20E kits. 
The MIC’s for the isolates were determined for nine antibiotics alone 
(singly), and in the presence of a second one. These antibiotics which are 
commonly used in Sudan were provided as powder by Amipharma 
Pharmaceutical Company, Khartoum North. They were amoxicillin, 
 xvi
ampicillin, cephalexin, ciprofloxacin, cloxacillin, erythromycin, 
sulphamethoxazole , tetracycline and trimethoprim. 
Eight strains were found to have high MICs. Pseudomonas 
aeruginosa and Pasteurella multocida were sensitive to ciprofloxacin while 
the latter was sensitive to cloxacillin and erythromycin as well. Using 
different concentrations of MIC, 0.5 X MIC, 1 X MIC and 2 X MIC along 
time indicated that resistance to ciprofloxacin might not be a frequent 
occurrence if adequate multiples of the MIC for the infecting organism were 
obtained in serum and tissue. However, using sub-inhibitory concentrations 
of ciprofloxacin against Klebsiella sp. and Pseudomonas aeruginosa may 
lead to emergence of resistant strains. Trimethoprim along time has a 
bacteriostatic effect on strains of E. coli, Klebsiella pneumoniae and 
Enterobacter. Tetracycline had bacteriostatic effect at low concentrations 
and bacteriocidal effect at high concentrations against some strains of E. coli 
and Pasteurella multocida, while erythromycin was always bacteriostatic 
against Klebsiella pneumoniae and did not change to bacteriocidal at high 
concentrations.  
For some strains, the MICs of certain antibiotics were successfully 
reduced in the presence of another antibiotic. Eleven combinations were 
studied. As expected, some antibiotics caused no reduction in the MIC, as 
they were not active against the organisms. The combinations studied were:- 
(i)Ampicillin with ciprofloxacin, (ii)ampicillin with amoxicillin, 
(iii)ampicillin with cloxacillin, (iv)sulphamethaxazole with trimethoprim, 
(v)cephalexin with ciprofloxacin, (vi)cephalexin with amoxicillin, 
(vii)tetracycline with erythromycin, (viii)tetracycline with amoxicillin, 
(ix)tetracycline with sulphamethoxazole, (x)tetracycline with ciprofloxacin 
and (xi)tetracycline with trimethoprim. 
 xvii
The combination of erythromycin and tetracycline was synergistic and 
had bacteriocidal effect against some strains of E. coli, Enterobacter, 
Pseudomonas aeruginosa and Pasteurella multocida. A combination of 
tetracycline and ciprofloxacin was synergistic and has bacteriostatic effect 
on Klebsiella pneumoniae and Enterobacter. Using ampicillin in 
combination with ciprofloxacin against Klebsiella pneumoniae and 
Pseudomonas aeruginosa had synergistic as well as bacteriocidal effect on 
both isolates. Using cephalexin in combination with ciprofloxacin against 
Klebsiella pneumoniae had synergistic and bacteriocidal effect. 
Sulphamethoxazole with trimethoprim had synergistic and bacteriostatic 
effect on Pseudomonas aeruginosa. A combination of the two penicillins 
ampicillin and amoxicillin showed bacteriocidal and synergistic effects 
against Klebsiella pneumoniae along time. Tetracycline and trimethoprim 
combination was antagonistic against Klebsiella pneumoniae and 
Pseudomonas aeruginosa.  
It is recommended that every combination of antibiotics should be 
tested in vitro with regard to its action characteristics, to avoid undesirable 
effects of combinations.  Practical clinical experiences are needed to decide 
on possible clinical benefits of using any two antibiotics in combination. 
Requests for testing combinations could, therefore, be directed at excluding 
antagonistic effects between two antimicrobial agents. 
Using laboratory animals confirmed that the difference in efficacy of 
antibiotics in vitro either singly or in combination depends on the type of the 
antibiotic as well as the phase of growth of bacteria.  Maximum numbers of 
viable cells of Pasteurella multocida were killed when erythromycin was 
added to 6 hours growing cells. Addition of tetracycline resulted in decrease 
in the viable cell count at 1-2 hours and 6 hours. When a combination of 
 xviii
(any) two antibiotics was used with lower concentrations than each single 
dose, the maximum numbers of bacteria were killed at 2 hours and 6 hours  
The percentage of survival animals was high when the animals were 
treated with either erythromycin or tetracycline or combination of the two 
antibiotics if the dose was administered at the right time. All animals (100%) 
survived when the combination was used either half an hour after infection 
or after 8 hours. Using the combination after 3 hours of infection resulted in 
the cure of 67% of the infected animals. When using erythromycin alone 
administering the dose after 3 hours of infection, only 33% of the infected 
animals survived, whereas when using tetracycline alone, 33% of the 
animals survived when the dose is administrated at the beginning of 
infection. 
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 ﺍﻟﺬﻳﻦ ﻳﻌﻤﻠﻮﻥ ﻋﻠﻰ ﻣﻜﺎﻓﺤﺔ ﺍﻟﻌﺪﻭﻯ ﺕﺴﺘﺸﻔﻴﺎﺍﳌ ﻭﻣﺪﻳﺮﻱ ﺍﻻﺧﺼﺎﺋﻴﲔ ﻭﺍﻟﻔﻨﻴﲔ  ﻣﻦ ﻫﺎﺍﻧﺘﺸﺎﺭﺑﺎﻟﻮﺑﺎﺋﻴﺎﺕ ﻭ 
ﺇﻥ ﻓﺸﻞ ﻋﻼﺝ ﺍﻻﻟﺘﻬﺎﺑﺎﺕ ﺑﺎﺳﺘﺨﺪﺍﻡ ﻣﻀﺎﺩ ﺣﻴﻮﻱ ﻭﺍﺣﺪ ﻣﻦ ﺍﳌﻀﺎﺩﺍﺕ ﺍﳊﻴﻮﻳﺔ  .ﻭﺍﻟﺴﻴﻄﺮﺓ ﻋﻠﻰ ﺍﻟﻮﺑﺎﺋﻴﺎﺕ 
ﺗﺜﺒﻴﻄﺎﹰ ﻟﻨﻤـﻮ   ﻣﻦ ﺍﳌﻀﺎﺩ ﺍﳊﻴﻮﻱﺗﺮﻛﻴﺰﺃﻗﻞ  CIM  ﺍﻟﱵ ﺗﺴﺘﺨﺪﻡ ﰲ ﺍﻟﺴﻮﺩﺍﻥ ﺗﺰﺍﻣﻦ ﻣﻊ ﺯﻳﺎﺩﺓ ﻛﺒﲑﺓ ﰲ 
  .ﺍﻟﺒﻜﺘﲑﻳﺎ
ﳌﻀﺎﺩﺍﺕ ﺍﳊﻴﻮﻳﺔ  ﺍﻟﺸﺎﺋﻌﺔ ﺍﻻﺳﺘﺨﺪﺍﻡ ﺑﺪﻻﹰ ﻋﻦ ﺍﺳﺨﺪﺍﻡ ﻣﻀﺎﺩﺍﺕ ﺣﻴﻮﻳـﺔ ﺇﻥ ﺍﺳﺘﺨﺪﺍﻡ ﳎﻤﻮﻋﺔ ﻓﻌﺎﻟﺔ ﻣﻦ ﺍ 
 ﺍﳌﻘﺎﻭﻣﺔ ﻟﻠﻤﻀﺎﺩﺍﺕ ﺍﳊﻴﻮﻳﺔ ﺍﻟﱵ ﺗﺴﺘﺨﺪﻡ ﻓﺮﺍﺩﻯ ﻭﺑﺎﻟﺘـﺎﱄ ﻳـﺆﺩﻱ ﺇﱃ ﺍﳌﺴﻮﺥ ﻓﺮﺍﺩﻯ  ﻗﺪ ﻳﺆﺩﻱ ﺇﱃ ﻗﺘﻞ  
ﺗﺜﺒﻴﻄـﺎﹰ ﻟﻨﻤـﻮ ﺍﻟﺒﻜﺘﲑﻳـﺎ   ﺍﳌﻀﺎﺩﺍﺕ ﺍﳊﻴﻮﻳﺔ ﻛﻴﺰﺍ ﺗﺮ ﺃﻗﻞ  ﺇﻥ ﻋﻤﻠﻴﺎﻭﺑﻞ ﻣﻦ ﺍﻟﻨﺎﺣﻴﺔ ﺍﻟﻨﻈﺮﻳﺔ .  ﺍﳌﺮﺽ ﻋﻼﺝ
   .   ﺍﺳﺘﺨِﺪﻡ ﻣﻀﺎﺩﺍﻥ ﺣﻴﻮﻳﺎﻥ ﰲ ﻭﻗﺖ ﻭﺍﺣﺪ ﻳﻌﻤﻼﻥ ﻣﺘﺂﺯﺭﻳﻦ ﳝﻜﻦ ﲣﻔﻴﻀﻬﺎ ﺍﺫﺍsCIM
 ,aihcirehcsE :ﺭﺑﻌﺔ ﻭﻫﻲﺃ ﺃﺟﻨﺎﺱ ﺗﻨﺘﻤﻲ ﺍﱃ  ﺳﺎﻟﺒﺔ ﻟﺼﺒﻐﺔ ﻏﺮﺍﻡﺑﻜﺘﲑﻳﺎ ﻋﺸﺮ ﰲ ﺍﻟﺪﺭﺍﺳﺔ ﺍﺳﺘﺨﺪﻣﺖ
 alleruetsaP ﺕ ﺳـﻼﻟﺔ ﻣـﻦ  ﺍﺧـﺘﲑ  . .retcaboretnE ,sanomoduesP ,alleisbelK
 ﺑﺎﺳـﺘﺨﺪﺍﻡ ﺑﻜﺘﲑﻳـﺎ ﺍﻻﺣﺪﻯ ﻋﺸﺮﺓ ﻋﺮﻓﹶﺖ .  ﺍﳊﻴﻮﻳﺔ ﻣﻦ ﺃﺟﻞ ﺍﳌﻘﺎﺭﻧﺔ ﺔ ﻟﻠﻤﻀﺎﺩﺍﺕ  ﺣﺴﺎﺳ adicotlum
  .IPA  stik E02 ﺍﺳﺘﺨﺪﻡﻴﺪﺍﹰ ﻟﺬﻟﻚ ﺍﻟﺘﻌﺮﻳﻒ ﻭﺗﺄﻛﺔ ﻴﺋﺍﻟﺒﻴﻮﻛﻴﻤﻴﺎﺍﻻﺧﺘﺒﺎﺭﺍﺕ 
 ﺎﺩﺍﺕﻣـﻀ  ﺔ ﻟﺘﺴﻌsCIMﺗﺜﺒﻴﻄﺎﹰ ﻟﻨﻤﻮ ﺍﻟﺒﻜﺘﲑﻳﺎ   ﺍﳌﻀﺎﺩﺍﺕ ﺍﳊﻴﻮﻳﺔﻛﻴﺰﺍ ﺗﺮﺻﻤﻤﺖ ﺍﻟﺪﺭﺍﺳﺔ ﻟﺘﺤﺪﻳﺪ ﺃﻗﻞ
ﻣﻦ ﺍﳌﻀﺎﺩﺍﺕ   ﺍﻟﺘﺴﻌﺔ  ﻫﺬﻩ ﺍﳌﻀﺎﺩﺍﺕ ﺍﳊﻴﻮﻳﻪ .ﻓﺔ ﻣﻀﺎﺩ ﺣﻴﻮﻱ ﺛﺎﻥ ٍﻓﺮﺍﺩﻯ ﻛﻞ ﻋﻠﻰ ﺣﺪﺓ ﻭﺃﻳﻀﺎﹰ ﺑﺈﺿﺎ  ﺔﺣﻴﻮﻳ
 ﲝﺮﻱ ﺎﳋﺮﻃﻮﻡﺑﺎﺭﻣﺎ ﻔﺷﺮﻛﺔ ﺍﺩﻭﻳﻪ ﺍﻣﻴ  ﻣﺴﺤﻮﻕ ﻋﻠﻰ ﻫﻴﺌﺔ  ﰲ ﺍﻟﺴﻮﺩﺍﻥ ﻗﺪﻣﺘﻬﺎ ﺍﳊﻴﻮﻳﺔ  ﺍﻟﺸﺎﺋﻌﺔ ﺍﻻﺳﺘﺨﺪﺍﻡ 
ﺍﻳﺮﻭﺛﺮﻭﻣﺎﻳﺴﲔ، ﻴﻠﻠﲔ ، ﺳﺎﺴﲔ ، ﺳﻴﱪﻭﻓﻠﻮﻛﺴﺎﺳﲔ ، ﻛﻠﻮﻛﺴﺎﻟﻴﻜﻔﻴﺒﺳﻴﻠﻠﲔ ، ﺴ ﺍﻣﺒﻴﺃﻭﻣﻜﺴﻴﺴﻴﻠﲔ،: ﻭﻫﻲ
 )nixelahpec ,nillicipma ,nillicixoma ﻛﺎﺯﻭﱄ ، ﺗﻴﺘﺮﺳـﻴﻜﻠﲔ ﻭﺗﺮﳝﻴﺜـﻮﺑﺮﱘﺳـﻮﻟﺒﻬﺎﻣﻴﺜﺎ
 enilcycartet , elozaxahtemahplus ,nicymorhtyre ,nillicaxolc ,nicaxolforpic
 (  mirpohtemirt
     .sCIMﺗﺜﺒﻴﻄﺎﹰ ﻟﻨﻤـﻮ ﺍﻟﺒﻜﺘﲑﻳـﺎ   ﺍﳌﻀﺎﺩﺍﺕ ﺍﳊﻴﻮﻳﺔﻛﻴﺰﺍ ﺗﺮﺃﻗﻞ  ﻗﻴﻤﺔ ﻋﺎﻟﻴﺔ ﻣﻦﻟﺪﻳﻬﺎ ﲦﺎﱐ ﺳﻼﻻﺕ 
 ﺣـﺴﺎﺳﺘﺎﻥ ﻟﻠﻤـﻀﺎﺩ ﺍﳊﻴـﻮﻱ  adicotlum alleruetsaP  و asonigurea sanomoduesP
 .ﺍﻳﺮﻭﺛﺮﻭﻣﺎﻳﺴﲔ ﻴﻠﻠﲔ ﻭﻛﺬﻟﻚﺳﺎﺴﻜﻠﻮﻛﻟ ﺔﻣﻮﻟﺘﻮﻛﻴﺪﺍ ﺣﺴﺎﺳ  ﺑﺎﺳﺘﻴﻮﺭﻳﻠﻼﺑﻴﻨﻤﺎﺳﻴﱪﻭﻓﻠﻮﻛﺴﺎﺳﲔ 
xx 
 ,CIM X 5.0  )sCIMﺗﺜﺒﻴﻄﺎﹰ ﻟﻨﻤﻮ ﺍﻟﺒﻜﺘﲑﻳﺎ   ﺍﳌﻀﺎﺩﺍﺕ ﺍﳊﻴﻮﻳﺔﻛﻴﺰﺍ ﺗﺮﺃﻗﻞﻛﻴﺰ ﳐﺘﻠﻔﺔ ﻣﻦ ﺍﺍﺳﺘﺨﺪﺍﻡ ﺗﺮ
ﲢﺪﺙ  ﻗﺪ ﻻ nicaxolforpic ﺳﻴﱪﻭﻓﻠﻮﻛﺴﺎﺳﲔﺿﺪ  ﺍﳌﻘﺎﻭﻣﺔ ﺗﻮﺿﺢ ﺍﻥ CIM X 2 dna CIM X 1
. ﺔ ﰲ ﺍﳌﺼﻞ ﻭﺍﻻﻧـﺴﺠ ﺗﺜﺒﻴﻄﺎﹰ ﻟﻨﻤﻮ ﺍﻟﺒﻜﺘﲑﻳﺎ ﺍﳌﺴﺒﺒﺔ ﻟﻠﻤﺮﺽ ﻗﺪ ﺗﻮﻓﺮ   ﺍﳌﻀﺎﺩﺍﺕ ﺍﳊﻴﻮﻳﺔ ﻛﻴﺰﺍ ﺗﺮ ﺃﻗﻞﺍﺫﺍ ﻛﺎﻥ 
  ﺍﻟﺒﻜﺘﲑﻳﺎ ﺃﻗﻞ ﻣﻦ ﺍﻟﺘﺮﺍﻛﻴﺰ ﺍﳌﺜﺒﻄﺔ ﻟﻨﻤﻮ nicaxolforpic ﺍﻟﺴﻴﱪﻭﻓﻠﻮﻛﺴﺎﺳﲔ ﻣﻦ ﻭﻟﻜﻦ ﺍﺳﺘﺨﺪﺍﻡ ﺗﺮﻛﻴﺰﺍﺕ
. ﺔ ﻟﻠﻤـﻀﺎﺩ ﺍﳊﻴـﻮﻱ  ﻗﺪ ﻳﺆﺩﻱ ﺍﱃ ﻇﻬﻮﺭ ﺳﻼﻻﺕ ﻣﻘﺎﻭﻣ sanomoduesP ؛ ﺿﺪﻭ ﻛﻠﻴﺒﺴﻴﻴﻠﻼ ﺿﺪ
 retcaboretnE   ﻭiloc .E ﺳـﻼﻻﺕ ﻲ ﻳﻌﻤﻞ ﻋﻠﻰ ﻭﻗﻒ ﳕﻮﺗﺮﳝﻴﺜﻮﺑﺮﱘ ﻟﻪ ﺗﺄﺛﲑ ﺑﺎﻛﺘﲑﻳﻮﺳﺘﺎﺗﻴﻜ
  .alleisbelK
 ﺎﹰ ﻋﺎﻟﻴ ﻩﺗﺮﻛﻴﺰﻗﺎﺗﻞ ﻋﻨﺪﻣﺎ ﻳﻜﻮﻥ ﻭﺗﺄﺛﲑ  ﺎﹰ ﻣﻨﺨﻔﻀ ﻩ ﺗﺮﻛﻴﺰ ﻋﻨﺪﻣﺎ ﻳﻜﻮﻥ  ﻲﺑﺎﻛﺘﲑﻳﻮﺳﺘﺎﺗﻴﻜ ﺗﺄﺛﲑ ﺘﻴﺘﺮﺳﻴﻜﻠﲔ ﻟ 
ﺗﺄﺛﲑ ﺩﺍﺋﻤﺎ ﻻﺭﻭﺛﺮﻭﻣﺎﻳﺴﲔ ﺍ ، ﺑﻴﻨﻤﺎ  adicotlum alleruetsaP ﻭiloc .E ﺿﺪ ﺑﻌﺾ ﺳﻼﻻﺕ
ﻗﺎﺗﻞ ﻋﻨﺪﻣﺎ ﻳـﺴﺘﺨﺪﻡ  ﺗﺄﺛﲑ ﳛﺪﺙ ﺍﻱ ﻟﻜﻦ ﻻ  ﻭeainomuenp alleisbelK ﺿﺪ ﻲﺑﺎﻛﺘﲑﻳﻮﺳﺘﺎﺗﻴﻜ
   . ﻛﻴﺰ ﻋﺎﻟﻴﺔﺍﺘﺮﺑ
 ﺍﻟﺴﻼﻻﺕ ﻗﺪ ﺧﻔﻀﺖ ﻗﻴﻤﺘـﻬﺎ ﺑﻌﺾ ﰲ  .sCIM ﺒﻜﺘﲑﻳﺎ ﺗﺜﺒﻴﻄﺎﹰ ﻟﻨﻤﻮ ﺍﻟ  ﺍﳌﻀﺎﺩﺍﺕ ﺍﳊﻴﻮﻳﺔﻛﻴﺰﺍ ﺗﺮﺇﻥ ﺃﻗﻞ
ﺍﻫﺘﻤﺖ ﻫﺬﻩ ﺍﻟﺪﺭﺍﺳﺔ ﺑﺘﺄﺛﲑ ﻣﻀﺎﺩ ﺣﻴﻮﻱ ﰲ ﻭﺟﻮﺩ ﻣﻀﺎﺩ ﺣﻴـﻮﻱ ﺁﺧـﺮ . ﺧﺮﺁﰲ ﻭﺟﻮﺩ ﻣﻀﺎﺩ ﺣﻴﻮﻱ 
 ﻛﻤﺎ ﻛﺎﻥ ﻣﺘﻮﻗﻌﺎ ، ﺑﻌﺾ ﺍﳌـﻀﺎﺩﺍﺕ ﺍﳊﻴﻮﻳـﻪ .ﺔ ﻣﻦ ﺃﺯﻭﺍﺝ ﺍﳌﻀﺎﺩﺍﺕ ﺍﳊﻴﻮﻳﺔ  ﳎﻤﻮﻋ ﺓﺍﺣﺪ ﻋﺸﺮ ﻟﺘﺸﻤﻞ 
ﻥ  ، ﻻ .sCIM ﺗﺜﺒﻴﻄـﺎﹰ ﻟﻨﻤـﻮ ﺍﻟﺒﻜﺘﲑﻳـﺎ   ﺍﳌﻀﺎﺩﺍﺕ ﺍﳊﻴﻮﻳﺔﻛﻴﺰﺍ ﺗﺮﰲ ﺃﻗﻞﺗﺴﺒﺐ ﰱ ﺣﺪﻭﺙ ﺍﳔﻔﺎﺽ 
 ﺃﺯﻭﺍﺝ ﺍﳌﻀﺎﺩﺍﺕ ﺍﳊﻴﻮﻳـﺔ ﺍﻟـﱵ ﻋﻨﻴـﺖ ـﺎ ﳎﻤﻮﻋﺎﺕ . ﺍﻟﺒﻜﺘﲑﻳﺎﱂ ﺗﻜﻦ ﻓﻌﺎﻟﺔ ﺿﺪ ﺍﳌﻀﺎﺩﺍﺕ ﺍﳊﻴﻮﻳﺔ 
   ﻫﻲﺍﻟﺪﺭﺍﺳﺔ
 nicaxolforpic ﻣﻊ  nillicipmA  .1
 nillicixoma ﻣﻊ  nillicipma  .2
 nillicaxolc ﻣﻊ  nillicipma  .3
 mirpohtemirt ﻣﻊ  elozaxahtemahplus  .4
 nicaxolforpic ﻣﻊ  nixelahpec  .5
 nillicixoma ﻣﻊ  nixelahpec  .6
 nicymorhtyre ﻣﻊ  enilcycartet  .7
 nillicixoma ﻣﻊ   enilcycartet .8
 elozaxahtemahplus ﻣﻊ  enilcycartet  .9
  nicaxolforpic ﻣﻊ  enilcycartet .01
   mirpohtemirt ﻣﻊ enilcycartet  .11
ixx 
 ﺿﺪ ﺑﻌـﺾ ﺳـﻼﻻﺕ  ﳍﺬﺍ ﺍﳌﺰﻳﺞ ﺗﺄﺛﲑﻗﺎﺗﻞ ﻭﻛﺎﻥ ﺷﻜﻞ ﺗﺂﺯﺭﺍﹰ  ﻭﺗﻴﺘﺮﺳﻴﻜﻠﲔ ﺎﻳﺴﲔﺍﻳﺮﻭﺛﺮﻭﻣ ﻣﺰﻳﺞ ﻣﻦ 
.  adicotlum alleruetsaP dna asonigurea sanomoduesP ,retcaboretnE ,iloc.E
  ﻲ ﺃﻭﻗﻒ ﳕﻮ  ﺑﺎﻛﺘﲑﻳﻮﺳﺘﺎﺗﻴﻜﺗﺄﺛﲑﺍﹰﺯﺭﺍ ﻭﺂ ﺗﺷﻜﻞ  ﺗﻴﺘﺮﺳﻴﻜﻠﲔ ﺳﻴﱪﻭﻓﻠﻮﻛﺴﺎﺳﲔﺑﻴﻨﻤﺎ ﺷﻜﻞ ﻣﺰﻳﺞ ﻣﻦ 
  retcaboretnEو   eainomuenp alleisbelK  
  ﻭeainomuenp alleisbelK ﺳﻴﱪﻭﻓﻠﻮﻛ ــﺴﺎﺳﲔ ﺿ ــﺪ ﻭﻴﻠﻠﲔ ﺴ ﺍﻣﺒﻴ ــ ﻣ ــﺰﻳﺞ ﻣ ــﻦ
. ﺒﻜﺘﺮﻳﺎﺍﻟ  ﳍﺬﺍ ﺍﳌﺰﻳﺞ ﺗﺄﺛﲑﻗﺎﺗﻞ ﺿﺪ ﺍﻟﺴﻼﻟﺘﲔ ﻣﻦﻭﻛﺎﻥ ﺗﺂﺯﺭﺍﹰ ﺷﻜﻼ  asonigurea sanomoduesP
ﺷﻜﻞ ﺗـﺂﺯﺭﺍﹰ  eainomuenp alleisbelK ﺳﻴﱪﻭﻓﻠﻮﻛﺴﺎﺳﲔ ﺿﺪ ﻭﲔ ﺴﻟﻴﻜ ﻣﺰﻳﺞ ﻣﻨﺴﻴﻔﺎﺑﺎﺳﺘﺨﺪﺍﻡ 
 ﻭﻛـﺎﻥ ﳍﻤـﺎ ﺗـﺄﺛﲑ  ﻣﻊ ﺗﺮﳝﻴﺜـﻮﺑﺮﱘ ﺗـﺎﺯﺭﺍ ﻝﻭﺯﺎﻣﻴﺜﺎﻔﺳﻮﻟ.  ﳍﺬﺍ ﺍﳌﺰﻳﺞ ﺗﺄﺛﲑﻗﺎﺗﻞ ﺿﺪ ﺍﻟﺒﻜﺘﲑﻳﺎ ﺎﻥﻭﻛ
 ﻦﻠﻴﻨﺃﻣﻴـﺴﻴ  ﻣـﺰﻳﺞ ﻣـﻦ asonigurea sanomoduesP ﺑﺎﻛﺘﻴﺘﲑﻳﻮﺳﺘﺎﺗﻴﻜﻲ ﺍﻭﻗﻒ ﳕـﻮ ﺍﻟﺒﻜﺘﲑﻳـﺎ 
ﺗﻴﺘﺮﺳـﻴﻜﻠﲔ  ﺑﻴﻨﻤﺎ ﺷﻜﻞ ﻣﺰﻳﺞ ﻣـﻦ . eainomuenp alleisbelKﺿﺪ ﺍﹰ  ﻭﺍﻇﻬﺮ ﺗﺂﺯﺭﻜﺴﻴﺴﻴﻠﲔﺍﳑ
 . asonigurea sanomoduesP  ﻭeainomuenp alleisbelK ﺿـﺪ ﻣﺰﳚﺎﹰ ﻋـﺪﺍﺋﻲ ﺑﺮﱘ ﺗﺮﳝﻴﺜﻮ
ﻣﻦ ﺍﳌﻀﺎﺩﺍﺕ ﺍﳊﻴﻮﻳﻪ ﰲ ﺍﳌﺨﺘﱪ ﻟﺘﺠﻨﺐ ﺍﻵﺛﺎﺭ ﻏﲑ ﻣﺰﻳﺞ ﻛﻞ  ﺧﺼﺎﺋﺺ ﻭ ﻋﻤﻞ ﺗﻮﺻﻲ ﻫﺬﻩ ﺍﻟﺪﺭﺍﺳﺔ ﺑﺎﺧﺘﺒﺎﺭ 
  . ﻟﻠﻤﺰﻳﺞﺍﳌﺮﻏﻮﺏ ﻓﻴﻬﺎ 
ﺍﻷﻧﺎﺑﻴﺐ ﺍﻣﺎ ﻣﻨﻔﺮﺩﻩ ﺍﻭ ﳎﺘﻤﻌـﺔ ﺍﺳﺘﺨﺪﺍﻡ ﺍﳊﻴﻮﺍﻧﺎﺕ ﺍﳌﺨﺘﱪﻳﻪ ﺍﻥ ﺍﻟﻔﺮﻕ ﰲ ﻓﻌﺎﻟﻴﺔ ﺍﳌﻀﺎﺩﺍﺕ ﺍﳊﻴﻮﻳﻪ ﰲ  ﺃﻛﺪ
 alleruetsaP ﻼﻳـﺎ ﺃﻛﱪ ﻋﺪﺩ ﻣـﻦ ﺍﳋ . ﺗﺘﻮﻗﻒ ﻋﻠﻰ ﻧﻮﻉ ﺍﳌﻀﺎﺩ ﺍﳊﻴﻮﻱ ﻭﻛﺬﻟﻚ ﻣﺮﺣﻠﺔ ﳕﻮ ﺍﻟﺒﻜﺘﲑﻳﺎ
ﺍﺿـﺎﻓﺔ .  ﺍﻟﺒﻜﺘﲑﻳـﺔ ﳕﻮ ﺍﳋﻼﻳﺎ ﻣﻦ ﺑﺪﺍﻳﺔ  ﺳﺎﻋﺎﺕ 6 ﺍﻳﺮﺛﺮﻭﻣﺎﻳﺴﲔ ﺑﻌﺪ ﺍﺿﻴﻒ ﲤﻮﺕ ﺇﺫﺍ .   adicotlum
.  ﺍﻟﺒﻜﺘﲑﻳﺔﳕﻮ ﺍﳋﻼﻳﺎ ﻣﻦ ﺑﺪﺍﻳﺔ  ﺳﺎﻋﺎﺕ6ﺳﺎﻋﺔ ﻭ  2-1 ﺍﳊﻴﺔ ﺑﻌﺪﺗﻴﺘﺮﺳﻴﻜﻠﲔ ﺍﺳﻔﺮ ﻋﻦ ﺍﳔﻔﺎﺽ ﰲ ﺧﻼﻳﺎ 
ﻓﺈﻥ ﺃﻛـﱪ ،  ﻣﻀﺎﺩ ﺣﻴﻮﻱ ﺇﺫﺍ ﺍﺳﺘﺨﺪﻡ ﲟﻔﺮﺩﻩ  ﻛﻞ  ﺍﻗﻞ ﻣﻦ ﺗﺮﻛﻴﺰ ﻛﻴﺰﺍﺘﺮﺑ ﲔ ﺣﻴﻮﻳ ﻳﻦﻡ ﻣﻀﺎﺩ ﺍﻋﻨﺪ ﺍﺳﺘﺨﺪ 
  . ﺍﻟﺒﻜﺘﲑﻳﺔﳕﻮ ﺍﳋﻼﻳﺎﻣﻦ ﺑﺪﺍﻳﺔ  ﺳﺎﻋﺎﺕ 6 ﺳﺎﻋﺔ ﻭ 2 ﻋﻨﺪ  ﻴﺔ ﻳﻘﺘﻞ ﺍﻟﺒﻜﺘﲑﻳﻋﺪﺩ  ﻣﻦ ﺍﳋﻼﻳﺎ
 ﺗﻴﺘﺮﺳﻴﻜﻠﲔ ﺃﻭ ﺇﺫﺍ  ﻋﻮﳉﺖ ﺍﳊﻴﻮﺍﻧﺎﺕ ﺍﳌﺼﺎﺑﺔ ﺑﺎﻳﺮﺛﺮﻭﻣﺎﻳﺴﲔ ﺃﻭ ﺮﺗﻔﻌﺔ  ﻣ  ﺍﳊﻴﺔ ﻴﻮﺍﻧﺎﺕﺍﳊﻧﺴﺒﺔ ﺑﻘﺎﺀ  ﺗﻈﻞ 
ﻋﻠﻰ  ﻇﻠﺖ (  ٪ 001)ﻴﻊ ﺍﳊﻴﻮﺍﻧﺎﺕ ﲨ. ﺮﻋﺔ ﰲ ﺍﻟﻮﻗﺖ ﺍﳌﻨﺎﺳﺐ ﻭﺍﻋﻄﻴﺖ ﺍﳉ  ﲔ ﺍﳊﻴﻮﻳ ﻳﻦﺍﳌﻀﺎﺩﻣﺰﻳﺞ ﻣﻦ 
ﻣـﻦ   ﺳـﺎﻋﺎﺕ 8 ﺍﻣﺎ ﺑﻌﺪ ﻧﺼﻒ ﺳﺎﻋﺔ ﺍﻭ ﺑﻌـﺪ ﲔ ﺍﳊﻴﻮﻳ ﻳﻦﺍﳌﻀﺎﺩﻣﻦ  ﻗﻴﺪ ﺍﳊﻴﺎﺓ ﻋﻨﺪﻣﺎ ﻳﺴﺘﺨﺪﻡ ﻣﺰﻳﺞ 
 ٪ ﻣﻦ ﺍﳊﻴﻮﺍﻧﺎﺕ 76 ﰲ ﺷﻔﺎﺀ ﻓﺈﻥ ﺫﻟﻚ ﻳﺘﺴﺒﺐ  ﺳﺎﻋﺎﺕ ﻣﻦ ﺍﻻﺻﺎﺑﺔ 3ﺰﻳﺞ ﺑﻌﺪ ﺍﳌﺳﺘﺨﺪﺍﻡ ﺍﺇﺫﺍ . ﺍﻻﺻﺎﺑﺔ
 ﻣﻦ ﺍﳊﻴﻮﺍﻧﺎﺕ  ﻓﻘﻂ  ٪ 33 ﺗﺒﻘﻰ ﺳﺎﻋﺎﺕ ﻣﻦ ﺍﻻﺻﺎﺑﺔ ، 3 ﺑﻌﺪ ﺍﻳﺮﺛﺮﻭﻣﺎﻳﺴﲔ ﲟﻔﺮﺩﻩ  ﻋﻨﺪ ﺍﺳﺘﺨﺪﺍﻡ .ﺔﺍﳌﺼﺎﺑ
ﺎ  ٪ ﻣﻦ ﺍﳊﻴﻮﺍﻧﺎﺕ ﻋﻠﻰ ﻗﻴﺪ ﺍﳊﻴـﺎﺓ ﻋﻨـﺪﻣ 33 ﻇﻠﺖ ﺣﺪﻩﻭ، ﺑﻴﻨﻤﺎ ﻋﻨﺪ ﺍﺳﺘﺨﺪﺍﻡ ﺗﻴﺘﺮﺳﻴﻜﻠﲔ ﺔﺣﻴﺔﺍﳌﺼﺎﺑ
 .ﺔﺍﳉﺮﻋﻪ  ﰲ ﺑﺪﺍﻳﺔ ﺍﻻﺻﺎﺑﺃﻋﻄﻴﺖ 
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INTRODUCTION 
Antibiotics are widely used to treat infectious diseases in both humans 
and animals, but the emergence of antibiotic resistance in previously 
susceptible bacterial populations is a very serious threat and now a major 
public health issue. The emergence and spread of antibiotic resistance must 
thus be fully understood in order to take the appropriate measures 
Resistance to antimicrobials is a natural biological phenomenon that 
can be amplified or accelerated by a variety of factors, including human 
practices. The use of an antimicrobial for any infection, real or feared, in any 
dose and over any time of period, forces microbes to either adapt or die in a 
phenomenon known as "selective pressure". The microbes which adapt and 
survive carry genes for resistance, which can be passed on. 
In the past, medicine and science were able to stay ahead of this natural 
phenomenon through the discovery of potent new classes of antimicrobials, 
a process that flourished from 1930-1970 and has since slowed to a virtual 
standstill, partly because of misplaced confidence that infectious diseases 
had been conquered, at least in the industrialized world. In just the past few 
decades, the development of resistant microbes has been greatly accelerated 
by several concurrent trends. These have worked to increase the number of 
infections and thus expand both the need for antimicrobials and the 
opportunities for their misuse. Such trends include: 
• Urbanization with its associated overcrowding and poor sanitation, 
which greatly facilitate the spread of such diseases as typhoid, 
tuberculosis, respiratory infections, and pneumonia. 
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• pollution, environmental degradation, and changing weather patterns, 
which can affect the incidence and distribution of infectious diseases,  
• demographic changes, which have resulted in a growing proportion of 
elderly people needing hospital-based interventions and thus at risk of 
exposure to highly resistant pathogens found in hospital settings;  
• the AIDS epidemic, which has greatly enlarged the population of 
immuno-compromised patients at risk of numerous infections, many 
of which were previously rare;  
• the resurgence of old foes, such as malaria and tuberculosis, which are 
now responsible for many millions of infections each year;  
• The enormous growth of global trade and travel which have increased 
the speed and facility with which both infectious diseases and resistant 
microorganisms can spread between continents.  
Factors that encourage the spread of resistance: 
The emergence and spread of antimicrobial resistance are complex 
problems driven by numerous interconnected factors, many of which are 
linked to the misuse of antimicrobials and thus amenable to change. In turn, 
antimicrobial use is influenced by interplay of the knowledge, expectations, 
and interactions of prescribers and patients, economic incentives, 
characteristics of a country's health system, and the regulatory environment. 
Patient-related factors are major drivers of inappropriate antimicrobial 
use. For example, many patients believe that new and expensive medications 
are more efficacious than older agents. In addition to causing unnecessary 
health care expenditure, this perception encourages the selection of 
resistance to these newer agents as well as to older agents in their class. 
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Self-medication with antimicrobials is another major factor 
contributing to resistance. Self-medicated antimicrobials may be 
unnecessary, are often inadequately dosed, or may not contain adequate 
amounts of active drug, especially if they are counterfeit drugs. In many 
developing countries, antimicrobials are purchased in single doses and taken 
only until the patient feels better, which may occur before the pathogen has 
been eliminated. Inappropriate demand can also be stimulated by marketing 
practices. Direct-to-consumer advertising allows pharmaceutical 
manufacturers to market medicines directly to the public via television, 
radio, print media, and the Internet.  
Prescribers' perceptions regarding patient expectations and demands 
substantially influence prescribing practice. Physicians can be pressured by 
patient expectations to prescribe antimicrobials even in the absence of 
appropriate indications. In some cultural settings, antimicrobials given by 
injection are considered more efficacious than oral formulations. Such 
perceptions tend to be associated with the over-prescribing of broad-
spectrum injectable agents when a narrow-spectrum oral agent would be 
more appropriate. Prescribing just to be on the safe side" increases when 
there is diagnostic uncertainty, lack of prescriber knowledge regarding 
optimal diagnostic approaches, lack of opportunity for patient follow-up, or 
fear of possible litigation. In many countries, antimicrobials can be easily 
obtained in pharmacies and markets without a prescription. 
Patient compliance with recommended treatment is another major 
problem. Patients forget to take medication, interrupt their treatment when 
they begin to feel better, or may be unable to afford a full course, thereby 
creating an ideal environment for microbes to adapt rather than be killed. In 
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some countries, low quality antibiotics (poorly formulated or manufactured, 
counterfeited or expired) are still sold and used for self-medication or 
prophylaxis. 
Hospitals are a critical component of the antimicrobial resistance 
problem worldwide. The combination of highly susceptible patients, 
intensive and prolonged antimicrobial use, and cross-infection have resulted 
in nosocomial infections with highly resistant bacterial pathogens. Resistant 
hospital-acquired infections are expensive to control and extremely difficult 
to eradicate. Failure to implement simple infection control practices, such as 
handwashing and changing gloves before and after contact with patients, is a 
common cause of infection spread in hospitals throughout the world. 
Hospitals are also the eventual site of treatment for many patients with 
severe infections due to resistant pathogens acquired in the community. In 
the wake of the AIDS epidemic, the prevalence of such infections can be 
expected to increase. 
The Situation in Sudan 
In Sudan and many other developing countries, antibiotics are 
uncontrolled and unregulated – easy to get and easy to misuse. With such 
wide availability, it is not surprising that the prevalence of bacteria resistant 
to one or more antibiotics has increased in many developing countries. Even 
so, when access to drugs is easier than access to doctors, or when people 
may be able to pay for one but not both, the issue might not be quite so 
straightforward. But we should not forget there may be benefits of easy 
access – people may be treated sooner. We need a greater understanding of 
antimicrobial resistance, and in working out how to deal with this problem 
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we need to appreciate that we live in the real world where unregulated use is 
the  
further spread of resistance are required as there are few if any new 
and affordable antibiotics on the way. In some diseases there is certainly the 
possibility of complete resistance developing and a return to the pre-
antibiotic era." 
Drug use is strongly influenced by cultural preferences and beliefs. 
Prescribers, dispensers, and consumers share similar perceptions on health, 
illness, and antibiotics. Antibiotics are often perceived as 'strong' almost 
magical medicines, capable of curing nearly any kind of disease. Many 
cultures believe that antibiotics also have the ability to prevent disease. 
Local cultural traditions have also developed related to the use of specific 
antibiotics, e.g., based on color or imitating methods used in traditional 
medicine. People are willing to pay high prices for antibiotics, and if they 
cannot afford a full course, will purchase them in smaller quantities. Self-
medication is often seen as an important determinant of improper antibiotic 
use. However, a patient's decisions about whether and how to use antibiotics 
are themselves influenced by more fundamental factors, e.g. lack of access 
to appropriate health care, poverty, or the stigma associated with having 
certain illnesses. Interventions should address these underlying determinants 
of self-medication, rather than focusing exclusively on the phenomenon 
itself. The decision to self-medicate or to seek care from other sources is 
determined by perceived symptoms, knowledge about treatment options, and 
their availability and accessibility. Advice may be sought from physicians, 
pharmacists, pharmacy clerks, paramedics, traditional healers, family, or 
friends at any time during an illness. Each group of advisers has its own 
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specific characteristics, advantages, and disadvantages. Physicians influence 
antibiotic use in three ways: by giving verbal recommendations to buy 
antibiotics, by writing prescriptions, or by prescribing and directly 
dispensing drugs. Doctors' practices can legitimize popular choices of 
antibiotics, and their previous prescribing can be an important factor in 
determining self-medication. Despite their importance, there is evidence that 
some people prefer not to consult physicians for day-to-day health problems, 
because of the high cost and time investment, lack of trust, or the easier 
availability of pharmacies. In most legal systems, qualified pharmacists must 
manage pharmacies, and dispensing should be restricted to drugs prescribed 
by a qualified physician. In practice, drugs are frequently sold without 
prescription, and many pharmacies conduct physical examinations or make 
treatment recommendations. 
Traditional practitioners often lack access to sophisticated medical 
technology, but some have started to include western medicine, including 
antibiotics, in their daily practice. They never receive training in antibiotic 
prescribing, and their information about drugs comes mostly from informal, 
non-medical sources, or from pharmaceutical representatives. Economic 
considerations are also important determinants of community antibiotic use. 
The decision to buy medicines, and the amount of it, is often influenced by 
factors such as a drug's price and a consumer's ability to pay. Poverty, lack 
of access to appropriate health care, and drug company marketing are also 
often believed to cause improper use of antibiotics, but these factors have 
not been well examined in research studies. 
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Aim and objectives 
In our few working Sudanese microbiological laboratories, sensitivity testing 
for isolated organisms is usually performed using the disc method.   The disc 
method tests for the sensitivity of a single antibiotic at different 
concentrations. Accordingly the antibiotics are judged whether they are 
effective (sensitive) or ineffective (resistant). In this test, the bacteria used 
are always in the stationary phase or declining phase. This situation does not 
answer several important questions. 
 Is it possible to overcome bacterial resistance by using different 
combinations of commonly used antibiotics? Do bacteria at different phases 
of growth, starting from lag phase to declining or death phase behave 
similarly in their sensitivity to various combinations of antibiotics? Are the 
effects of these combinations the same in vivo as in vitro? 
The aim of the present study is to render available a clue about the use 
of combinations antibiotics so as to find out the most effective time of 
starting the treatment by antibiotics, at the beginning of onset of disease or 
latter when symptoms have clearly developed in both man and animals. This 
aim can be achieved through the following objectives 
1. To test the sensitivity of selected resistant Gram negative organisms 
to combinations of commonly used antibiotics in Sudan. 
2. To compare the sensitivity of bacteria at different phases of growth 
to antibiotics when using single antibiotic or combinations of antibiotics.  
3. To monitor in vivo the sensitivity of selected bacteria at different 
phases of growth to single and combinations of antibiotics, which were 
found to be effective in vitro.  
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CHAPTER ONE 
LITERATURE  REVIEW 
 
In 1937, Florey and his colleagues showed that penicillin was effective in 
treating staphylococcal and streptococcal infections (Wilson, 1976).  
Since then antimicrobial drugs have proved remarkably effective for the 
control of bacterial infections. However, it was soon evident that bacterial 
pathogens were unlikely to surrender unconditionally, because some 
pathogens rapidly became resistant to many of the first effective drugs. For 
example, the development of resistance to penicillin in Staphylococcus 
aureus by the production of a β-lactamase quickly decreased the usefulness 
of penicillin for serious staphylococcal infections, especially among 
hospitalized patients, in whom resistant strains are frequently found before 
they spread to the community (Murray, 1978) 
Streptomycin, the second great antibiotic, was discovered in 1944 (Schatz 
et al., 1944). The initial enthusiasm for this drug was so great and medical 
opinion so dominated by therapeutic empiricism that streptomycin and 
penicillin were often administered together in a single injection. 
Unfortunately, streptomycin-resistant bacteria emerged rapidly, even during 
therapy (Paine  et al.,1947) the combination product was eventually removed 
from the market because the potential for vestibular damage from 
streptomycin was not outweighed by the therapeutic benefit of the 
combination (Kunin and Hewitt, 1969). Streptomycin soon became almost 
obsolete and is used today only to treat tuberculosis and some esoteric 
infections.  
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In 1983, just two years after the introduction of the oxymino-beta-lactams 
to the market, the first extended-spectrum beta-lactamases were isolated in 
Germany from Klebsiella pneumoniae strains. Since then several outbreaks 
have been reported in many European countries and the USA, and nowadays 
in several places worldwide the problem seems to reach endemic 
dimensions, with rates exceeding 50% in some countries, such as Portugal 
and Turkey. On the other hand not only K. pneumoniae but also Escherichia 
coli strains, with Enterobacter aerogenes predominating among the other 
Enterobacteriaceae species, are increasingly reported as ESBL producers 
(Giamarellou, 2005). 
Initially, the problem of bacterial resistance to antimicrobial drugs was 
solved by the discovery of new classes of drugs, such as the 
aminoglycosides, macrolides, and glycopeptides, as well as by the chemical 
modification of previously existing drugs. Unfortunately, there is no 
assurance that the development of new antimicrobial drugs can keep pace 
with the ability of bacterial pathogens to develop resistance. 
As we have learned more about the mechanisms and epidemiology of 
resistance to antimicrobial drugs, it has become clear that bacteria have a 
remarkable array of tools at their disposal to overcome antibiotics. A single 
genetic mutation may lead to resistance without altering the pathogenicity or 
viability of a bacterial strain. The development of resistance to 
antituberculous drugs such as streptomycin is a classic example of this type 
of change (Snider, 1991). 
Today multi-drug resistant Gram-negative bacteria are a problem that 
infection control practitioners, hospital epidemiologists, clinicians, and 
hospital administrators are struggling to control. In the United states of 
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America, The National Nosocomial Infections Surveillance System has 
reported that the prevalence of multidrug-resistant Gram-negative bacteria is 
increasing. The prevalences of imipenem-resistant Pseudomonas 
aeruginosa, quinolone-resistant P. aeruginosa, third-generation 
cephalosporin–resistant P. aeruginosa, third generation cephalosporin–
resistant Enterobacter species, and third generation cephalosporin–resistant 
Klebsiella pneumoniae among clinical isolates collected from patients in 
intensive care units (ICUs) have all increased by 120% in 2003, compared 
with prevalences in 1998–2002 (NNIS, 2004). Similar increases in 
multidrug-resistant Gram-negative bacteria prevalence are being seen 
worldwide (Paterson, Rossi, and Baquero, 2005), (Sader et al., 2005) and 
(Dipersio et al., 2005). 
Theoretically, it should be possible to overcome resistance by 
administering a combination of drugs in sufficient dosage and long enough 
to eradicate the infection, thus preventing person-to-person dissemination of 
resistant bacteria. The worldwide emergence of multidrug-resistant 
Mycobacterium tuberculosis demonstrates that this goal may not be easy to 
achieve (Jacobs, 1994). 
Until recently, a new drug or drug combination has always appeared when 
it is needed. New cephalosporins and ß-lactamase inhibitors were available 
shortly after ampicillin-resistant gonococci emerged from Thailand and the 
Philippines and spread rapidly around the world (Brown  et al.,1982) The 
plasmid bearing the TEM ß-lactamase gene appears to have originated in 
Escherichia coli, to have spread across taxonomic boundaries to gonococci 
and Haemophilus influenzae, and to have been selected by the pressure from 
excessive use of ampicillin (Jacoby and Archer, 1991).  
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We have now reached a situation were in some hospitals and communities 
strains of invasive Gram-negative enteric bacteria and enterococci are not 
susceptible to any available antibiotic. 
1.1. Antibiotic Resistance 
Antibiotic resistance among many pathogenic microbes has been increasing 
during the last decade. It is mostly associated with:  
a)  Overuse of antibiotics in outpatient settings;  
b)  Unwarranted use of very broad spectrum antibiotics;  
c)  Poor standards for bacterial identification and patient monitoring; 
d) Ineffective hospital infection control over nosocomial transmission of 
resistant strains. 
Resistance to antibiotics can be intrinsic or acquired. Intrinsic 
resistance dictates the spectrum of activity of the antibacterial and it is 
always present (Thornsberry, 1991). For example, Gram-negative bacteria 
are intrinsically resistant to cloxacillin and vancomycin due to the Gram-
negative cell wall being multi-layered with a lipoprotein-lipopolysaccharide 
phospholipid outer membrane external to the relatively thin peptidoglycan 
layer that protects the cell wall from many antibiotics and enzymes 
(lysozyme) (Thornsberry, 1991).  
Of increased clinical significance is acquired resistance, in which 
bacteria that were previously sensitive to antibiotics become resistant. 
Bacteria can acquire resistance through chromosomal mutations or 
acquisition of genetic material (e.g., plasmids, transposons), which confers 
resistance to antibiotics (Thornsberry, 1991). Transfer of these plasmids 
from one organism to another can lead to widespread resistance. Of great 
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concern is the potential for one species of bacteria (e.g. Enterococcus) to 
transfer plasmids to a different species of bacteria (e.g., Staphylococcus) 
(Thornsberry, 1991).  
 Changes in resistance patterns can occur after years of exposure to an   
antibiotic (e.g., penicillin-resistant pneumococcus) or can develop during the 
course of therapy for an infection (e.g., extended-spectrum β-lactamases that 
are seen in certain Gram-negative bacilli).  
The mechanism by which bacteria become resistant to antibiotics 
often reflects the mechanisms by which antibiotics kill bacteria. After an 
antibiotic penetrates the cell wall or membrane of the bacteria, it targets a 
specific bacterial enzyme (e.g. penicillin-binding protein, DNA gyrase) or 
ribosome, thereby interfering with bacterial protein synthesis or replication. 
The mechanisms of resistance to different antibiotics, therefore, include the 
following:  decreased penetration through the bacterial cell membrane, 
enzymatic degradation or inactivation of the antibiotic, alteration of the 
target site and active efflux of the antibiotic out of the bacteria (Medeiros, 
1997).  
Resistance to a given class of antibiotics can occur by several 
mechanisms. Furthermore, as drugs of a similar class have the same 
mechanism of action, cross-resistance between drugs within the same class 
is often expected. 
The most common mechanism of antimicrobial resistance is the 
production of enzymes that inactivate or modify the antibiotic (Medeiros, 
1997). Examples include the production of β- lactamases by many Gram-
positive and Gram-negative organisms as well as aminoglycoside modifying 
enzymes in Gram-negative pathogens (Livermore et al., 2001). Within the 
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Gram negative bacteria, many different β-lactamases have been identified. 
While some classes of β- lactamases may cause degradation of an entire 
class of β-lactam antibiotic (e.g. penicillinase, cephalosporinase, 
carbapenemase), others are more specific to a smaller group of antibiotics 
(e.g. development of resistance to 3rd generation cephalosporins in certain 
Klebsiella species) (Livermore  et al., 2001).  
An alteration in the target site is another common mechanism through 
which bacteria become resistant to antibiotics. β-lactam antibiotics bind to 
PBPs, enzymes involved in cell wall synthesis of bacteria. By binding to 
PBPs, the antibiotic interferes with cell wall synthesis, resulting in inhibition 
of bacterial cell division. Changes in PBPs have resulted in the development 
of penicillin-resistant Streptococcus pneumoniae and methicillin-resistant 
Staphylococcus aureus. Similarly, an alteration in DNA gyrase, the target 
site of quinol1 activity, is responsible for resistance in Gram-negative 
bacteria. (Livermore et al., 2001). 
1.2. Antibiotics 
1.2.1. What are Antibiotics? 
The word “antibiotics” comes from the Greek anti (“against”) and bios 
(“life”). Antibiotics are drugs that either destroy bacteria or prevent their 
reproduction. Antibiotics that kill bacteria are called “bactericidal” and the 
ones that stop the growth of bacteria are called “bacteriostatic”. 
Since penicillin’s introduction during the 1940s, scientists developed 
numerous other antibiotics. Today, over 100 different antibiotics are 
available. About 90% of antibiotics are made from living organisms such as 
bacteria; others are produced synthetically, either in whole or in part. 
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1.2.2. Classifications  
Although there are several classification schemes for antibiotics, based on 
bacterial spectrum (broad versus narrow) or route of administration 
(injectable versus oral versus topical), or type of activity (bactericidal vs. 
bacteriostatic), the most useful is based on chemical structure.( Alfred  et al., 
1992) Antibiotics within a structural class will generally show similar 
patterns of effectiveness, toxicity, and allergic potential.  
Most commonly used types of antibiotics are: Penicillins, Fluoroquinolones, 
Cephalosporins, Macrolides, and Tetracyclines. While each class is 
composed of multiple drugs, each drug is unique in some way. 
1.2.3. Penicillins 
Penicillin was discovered by Alexander Fleming in 1928. It became 
available for general use in the late 1940s.  
1.2.3.1. Mechanism of Action 
Penicillins are bactericidal, killing bacterial cells by impairing cell wall 
synthesis. Penicillin prevents cross-binding of the peptidoglycan polymers 
necessary for cell wall formation (Tomasz, 1979). As part of this process, it 
binds the penicillin-binding-proteins (PBPs), which include 
carboxypeptidases, endopeptidases, and transpeptidases, all of which 
participate in cell wall synthesis. Although the exact mechanisms involved 
are not known, the end result is that the cell wall is structurally weakened 
and it lyses, leading to cell death. The basic form of penicillin is structured 
around the beta-lactam ring (a thiazolidine ring), and can be altered by 
substituting side chains. By doing so, the antimicrobial spectrum, absorption 
characteristics, and resistance to beta-lactamase deactivation can be altered. 
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Bacterial resistance to penicillins can take different forms. The most 
significant is the bacterial production of beta-lactamases, which can destroy 
the beta-lactam ring by means of hydrolysis, effectively preventing 
antimicrobial activity by the agent (Livermore, 1995). In addition, some 
bacteria are able to prevent binding to the PBPs by various means, including   
altered binding sites for the penicillins (Georgopapadakou, 1993). 
Various strategies have been employed to circumvent these microbial 
adaptations. Altering the structure of the penicillins to produce agents that 
are more resistant to the hydrolysis from the beta-lactamases has resulted in 
the development of the extended-spectrum penicillins.   
Another strategy has been to combine penicillins with other agents that 
either block bacterial betalactamases, or have an alternate method for killing 
bacteria that are resistant to penicillin. Examples include amoxicillin plus 
clavulanic acid, ampicillin plus sulbactam, piperacillin plus tazobactam, and 
ticarcillin plus clavulanic acid. Clavulanic acid is produced by Streptomyces 
clavuligerus. Sulbactam and tazobactam are derived from the basic 
penicillin ring. These agents have little intrinsic antimicrobial activity, but 
they bind irreversibly to many betalactamases, preventing their hydrolytic 
activity against the beta-lactam ring. 
1.2.3.2. Pharmacokinetics 
Penicillins can be separated into groups based on their pharmacokinetics and 
antibacterial activity. These groups are the natural penicillins, the 
aminopenicillins, the penicillinase-resistant penicillins, and the anti 
pseudomonal penicillins (Nathwani and Wood, 1993). 
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1.2.3.2.1. The Natural Penicillins 
The natural penicillins include penicillin G and penicillin V. Penicillin G is 
very unstable in stomach acid and must be given parenterally. Penicillin V 
was developed to be more stable in stomach acid and is given orally. The 
natural penicillins are active against Gram positive organisms, such as many 
staphylococci, many streptococci, Enterococcus faecalis, and Listeria 
monocytogenes. The natural penicillins are also active against anaerobic 
species such as Bacteroides species and Fusobacterium species. They are 
effective against some Gram-negative bacteria, such as E. coli, H. 
Influenzae, Neisseria gonorrhoeae, Treponema pallidum, and susceptible 
Pseudomonas species. They are indicated for use in infections caused by 
penicillin-sensitive organisms. The sensitivity should be proven for 
moderate to severe infections if resistant organisms are likely. Labeled uses 
include treatments for infections of the upper and lower respiratory tract, 
throat, skin, and genitourinary tract. (Nathwani and Wood, 1993). 
1.2.3.2.2. The Aminopenicillins 
The aminopenicillins have about the same activity as the natural penicillins, 
plus improved coverage of Gram-negative cocci and Enterobacteriaceae. 
These agents are not active against Treponema sp. or Actinomyces sp., but 
amoxicillin/clavulanic acid and ampicillin/sulbactam have better coverage 
against Haemophilus influenzae and Klebsiella sp. than the natural 
penicillins and the aminopenicillins alone. The aminopenicillins include 
ampicillin and amoxicillin. Ampicillin can be given parenterally or orally. 
Amoxicillin was specifically designed to be stable in stomach acid and its 
absorption is considerably better than ampicillin. Improved absorption also 
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means that amoxicillin causes fewer diarrheas than other oral penicillins. 
(Nathwani and Wood, 1993). 
1.2.3.2.3. The Penicillinase-Resistant Penicillins 
The penicillinase-resistant penicillins were developed in response to the 
discovery of resistant staphylococcal bacteria that could inactivate the drug. 
These penicillins are resistant to hydrolysis by the lactamase produced by 
the staphylococci. These include nafcillin and oxacillin, which are parenteral 
formulations, and dicloxacillin, which is given orally. These agents are 
notable for their added usefulness for penicillin-resistant Staphylococcus and 
Streptococcus species. (Nathwani and Wood, 1993). 
1.2.3.3. Absorption/Elimination 
The bioavailability of penicillins varies considerably. Penicillin V, 
amoxicillin, dicloxacillin and carbenicillin can be given orally. Food can 
interfere with absorption with all oral penicillins, except carbenicillin and 
penicillin V. The remaining penicillins are too unstable in the acidic 
environment of the stomach and must be given parenterally. Once absorbed, 
these agents are widely distributed throughout the body. Therapeutic 
concentrations of penicillins are readily achieved in tissues and secretions, 
e.g. joint fluid, pleural fluid, pericardial fluid, and bile. Low concentrations 
are found in prostatic secretions, brain tissue, intraocular fluid and 
phagocytes. Cerebrospinal fluid (CSF) concentrations are variable, but less 
than 1% of serum concentration when the meninges are normal. When the 
meninges are inflamed, CSF concentrations may rise to 5% and can be 
increased by co-administration of probenecid (Richards, 1981). 
Concentration in urine is high due to renal secretion. 
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Penicillins are eliminated rapidly by the kidneys as a result of glomerular 
filtration and renal tubular secretion. Probenecid markedly reduces the 
tubular secretion of the penicillins and decreases the apparent volume of 
distribution, resulting in higher serum levels. All the penicillins are excreted 
to some degree in the bile, but biliary excretion is most important for anti-
pseudomonal penicillins and nafcillin (Tan and File, 1995). 
1.2.4. Cephalosporins 
The first cephalosporin was discovered in 1948 by Guiseppe Brotzu, who 
observed that the fungus Cephalosporium acremonium produced a substance 
that inhibited the growth of Staphylococcus aureus and other bacteria. The 
initial substance was identified and modified to create the cephalosporins 
that are now used. The cephamycins were created by adding a methoxy 
group on the beta-lactam ring of the original compound, based on the 
structure of cefoxitin, produced by Streptomyces lactam durans. By altering 
the chemical groups substituted on the basic molecule, greater antimicrobial 
activity and longer half-lives have been obtained (Kees and Grobecker, 
1995). 
1.2.4.1. Mechanism of Action 
Like penicillins, the cephalosporins are betalactams. In these agents, the 
beta-lactam ring is joined to a dihydrothiazine ring. Their antimicrobial 
effect is based on the same mechanism of action as the penicillins. They 
inhibit bacterial cell wall synthesis by blocking the transpeptidases and other 
PBPs involved in the synthesis and cross-linking of peptidoglycan (Wise, 
1990; Fontana et al., 2000). 
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Because each bacterial species has a unique chemical structure in its cell 
wall, the effects of the cephalosporins may have different mechanisms by 
which they inhibit the cell wall synthesis. As with penicillins, resistance to 
the action of cephalosporins can result from mutations in the penicillin-
binding proteins, so the cephalosporins cannot bind to them, and from the 
production of extended-spectrum beta-lactamases that inactivate the drug 
(Koch, 2000). An additional source of resistance in Gram-negative bacteria 
is alteration in the cell membrane porins that normally allow passage of the 
cephalosporins (Hopkins and Towner, 1990). Of these mechanisms, the 
production of betalactamase is the most clinically significant. This form of 
resistance can occur through mutations or can be carried on plasmids 
(Gootz, 2004). 
1.2.4.2. Pharmacokinetics 
The cephalosporins have been classified in different ways, based on 
chemical structure and pharmacologic activities. The most commonly used 
classification system groups the agents into “generations” based on their 
similarities in antimicrobial coverage.  
1.2.4.2.1. First-Generation Cephalosporins 
The first-generation drugs are most active against aerobic Gram-positive 
cocci. These agents include cefazolin, cephalexin, cephradine, and 
cefadroxil. These drugs are often used for skin infections that are caused by 
Staphylococcus aureus and Streptococcus species. They have activity 
against Escherichia coli, some activity against Haemophilus influenzae, and 
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Klebsiella species, but because of the limited Gram negative coverage, they 
are not first-line agents for infections that are likely to be caused by Gram 
negative bacteria. (Mosby’s Drug Consult, 2005)  
1.2.4.2.2. Second-Generation Cephalosporins 
Second-generation drugs are more active against gram-negative organisms, 
such as Moraxella, Neisseria, Salmonella, and Shigella. Cefoxitin and 
cefotetan also have more coverage against anaerobic bacteria. They are 
included in this group under this classification system although they are 
technically cephamycins. The true cephalosporins that are also part of this 
class are cefprozil, cefuroxime, cefaclor, loracarbef, cefoxitin, and cefotetan. 
These drugs are used primarily for respiratory tract infections because they 
are better against some strains of beta-lactamase producing Haemophilus 
influenzae. (Mosby’s Drug Consult, 2005) 
1.2.4.2.3. Third-Generation Cephalosporins 
Third-generation drugs have the most activity against Gram-negative 
organisms including Neisseria sp., M. catarrhalis, and Klebsiella, while 
some are active against Pseudomonas aeruginosa (ceftazidime, and 
cefoperazone). These agents have less coverage of the gram-positive cocci, 
notably methicillin sensitive Staphylococcus aureus. In addition to the two 
agents with anti-pseudomonas coverage, this class includes cefotaxime, 
ceftizoxime, ceftriaxone, cefixime, cefpodoxime proxetil, ceftibuten, and 
cefdinir. These drugs are useful for more severe community-acquired 
respiratory tract infections, for resistant infections, and for nosocomial 
infections (because of the high incidence of resistant organisms) (Neu, 
1990). 
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1.2.4.2.4. Fourth-Generation Cephalosporins 
Cefepime is classed as a fourth-generation drug because it has good activity 
against both Gram positive and Gram-negative bacteria, including P. 
aeruginosa and many Enterobacteriaceae. The Gram negative and anaerobic 
coverage makes it useful for intra-abdominal infections as well as 
respiratory tract infections and skin infections. (Mosby’s Drug Consult, 
2005) 
1.2.4.3. Absorption/Elimination 
The orally administered cephalosporins include cefaclor, cefadroxil, 
cephalexin, cephradine, loracarbef, cefprozil, cefuroxime axetil, cefixime, 
cefpodoxime proxetil, ceftibuten, and cefdinir. In general, the orally 
administered cephalosporins are absorbed rapidly. Cephalexin, cefadroxil, 
cefaclor, cefixime, ceftibuten and cefdinir are nonesterified and are absorbed 
from the gastrointestinal (GI) tract by active transport in the small intestine. 
Once absorbed into the cells lining the small intestine, they are hydrolyzed 
and then excreted into the blood stream as an active cephalosporin (Mazzei 
and Dentico, 2000). The presence of food or antacids may increase or 
decrease the absorption, depending on the drug. Cefuroxime axetil and 
cepodoxime proxetil have increased absorption when taken with food. 
Cefaclor, cefadroxil, cephalexin and cephradine have slowed absorption 
when food is in the stomach.  
 
 
1.2.5. Macrolides and Telithromycin 
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The original macrolide, erythromycin, was discovered in 1952 by McGuire. 
It is produced by Saccharopolyspora erythrae (formerly known as 
Streptomyces erythreus). Semisynthetic derivatives (clarithromycin, 
azithromycin, and dirithromycin) have been derived from the original 
erythromycin, with modifications that improve acid stability, antibacterial 
spectrum and tissue penetration.  
1.2.5.1. Mechanism of Action 
The macrolides are bacteriostatic, inhibiting protein synthesis by binding at 
the 50S ribosomal unit, blocking transpeptidation and translocation. At high 
concentrations or with rapid bacterial growth, the effects can be bactericidal 
(Goldman, Fesik, and Doran, 1990). 
 Many bacteria that are resistant to the penicillins are also resistant to 
erythromycin. Bacterial resistance may result from decreased permeability 
of the cell membrane; in addition, an increase in active efflux of the drug can 
occur by incorporating a transporter protein into the cell wall [Sun  et 
al.,2004). The gene for this mechanism is transferred on plasmids between 
bacteria. Mutations of the 50S ribosomal receptor site can also develop, 
preventing binding of the erythromycin. Lastly, bacterial enzymes have been 
described that can inactivate erythromycin (Matsuoka and Saski, 2004). It is 
likely that this form of resistance is also transferred on plasmids. Many 
strains of Haemophilus influenzae are resistant to erythromycin alone but are 
susceptible to a combination with a sulfonamide (Doern, 1988).  
 
 
1.2.5.2. Pharmacokinetics 
 23
Erythromycin has a wide spectrum of activity. Gram-positive bacteria that 
are usually susceptible to erythromycin include the Streptococcus species. 
Erythromycin is a second-line agent for Gram negative bacteria such as 
Haemophilus influenzae and Moraxella catarrhalis. Macrolides are 
particularly useful for their coverage of atypical bacteria, such as 
Mycoplasma and Chlamydia. Some spirochetes and mycobacteria are also 
susceptible to the macrolides. These drugs are indicated for upper respiratory 
tract infections, such as sinusitis, otitis media, pharyngitis, and bronchitis. 
Erythromycin base is inactivated by gastric acid, so it is formulated in 
enteric-coated tablets or capsules, which protect the drug until it reaches the 
duodenum, where it is absorbed. Eating increases stomach acid secretion and 
may slow absorption as a result. The ester forms of the erythromycin base, 
stearate, estolate and ethylsuccinate, were all formulated to improve 
absorption. The estolate is the best absorbed of the three after eating; the 
ethylsuccinate form is absorbed the best in the fasting state (Malmborg, 
1979). Erythromycin can also be given intravenously.  
All the macrolides have extensive tissue distribution, with less than adequate 
penetration into the brain tissue and the CSF (Periti, 1989). Erythromycin, 
azithromycin, and troleandomycin are primarily excreted unchanged into the 
bile. 
1.2.6. Quinolones 
The first quinolone was nalidixic acid, introduced in 1962. It was developed 
as a result of chloroquine synthesis. Later, derivatives with broader spectrum 
antimicrobial coverage were developed, leading to the current class of 
quinolone drugs. As with other classes of synthetic and semi-synthetic 
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antimicrobials, alterations of side chains affect antimicrobial activity and 
pharmacokinetics (Andersson and MacGowan, 2003). 
1.2.6.1. Mechanism of Action 
Quinolones cause bacterial cell death by inhibiting deoxyribonucleic acid 
(DNA) synthesis. The drugs inhibit DNA gyrase and DNA topoisomerase, 
enzymes that mediate DNA supercoiling, transcription, and repair (Drlica 
and Zhao, 1997) Bacterial resistance develops as a result of spontaneous 
mutations that change the binding sites for quinolones on the DNA gyrase 
and the DNA topoisomerase (Willmott and Maxwell, 1993). Mutations that 
decrease the ability of quinolones to cross the cell membrane also occur. 
Some of these resistances can be transferred from other bacteria by means of 
plasmids (Mammeri  et al.,2005). 
1.2.6.2. Pharmacokinetics 
The quinolones are active against many Gram negative cocci, Gram-
negative bacilli, atypical bacteria (e.g., Legionella and Mycoplasma), and 
staphylococci. Activity against streptococci and anaerobes is not as strong, 
although newer agents, such as moxifloxacin and trovafloxacin, have better 
coverage for these (Blondeau, 1999). Gram-negative coverage includes 
Campylobacter, Enterobacter, Escherichia coli, Haemophilus influenzae, 
Klebsiella, Salmonella typhi, Shigella, and Vibrio cholerae. Indications for 
the use of quinolones include urinary tract infections, N. gonorrhoeae 
infections of the urethra and cervix, pneumonia, sinusitis, soft-tissue 
infections, and prostatitis. Ciprofloxacin is also indicated for post-exposure 
prophylaxis for anthrax and levofloxacin has an indication for the treatment 
of inhalation anthrax infection. The quinolones are absorbed well from the 
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gastrointestinal tract. Food may delay the time to reach peak serum 
concentration, but does not decrease total absorption. The drugs are 
distributed well throughout all tissues, including the prostate, although the 
levels in the CSF and prostatic fluid are lower than serum levels (Sorgel and 
Kinzig, 1993) 
Clearance mechanisms vary between the quinolones. Gatifloxacin, 
levofloxacin, lomefloxacin, and ofloxacin are mainly cleared by renal 
excretion   and have minimal hepatic clearance (Sorgel and Kinzig, 1993). 
Norfloxacin, and ciprofloxacin, and have mixed routes of elimination. 
Norfloxacin has some hepatic metabolism to active metabolites; the 
metabolites and parent drug are excreted by the kidney. About 30% of the 
dose of norfloxacin is excreted in the stool, in the bile and as unabsorbed 
drug. As much as 50% of ciprofloxacin’s dose is excreted renally and 40% is 
excreted in the bile after hepatic metabolism. In renal insufficiency, the 
quinolones that are primarily excreted renally and those with mixed routes of 
elimination require dosage adjustments (Fillastre  et al.,1990) 
1.2.6.3. Toxicities/Side Effects 
The most common side effect is gastrointestinal upset. Less common side 
effects include headache, insomnia, dizziness, peripheral neuropathy, tendon 
rupture, elevated liver enzymes, and interstitial nephritis (Cohen, 2001; 
Zabraniecki  et al., 1996). Rarely, hematologic toxicities have occurred, 
resulting in hemolytic anemia (more likely to occur in patients with glucose-
6-phosphate dehydrogenase deficiency) and aplastic anemia, and 
granulocytosis (Oh et al., 2003). 
1.2.7  Sulfonamides/Trimethoprim  
Sulfonamides, the first true antibiotics, are derived from azo dyes. The first 
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 agent was sulfachrysoidine, used in 1935, which released sulfanilamide in 
vivo (Woods, 1940). Modifications were made to the sulfanilamide to reduce 
side effects, resulting in the development of the modern sulfonamides which 
had broader antimicrobial activity and less toxicity. Many of the 
sulfonamides are no longer used as parenteral agents. The combination of 
trimethoprim, a diaminopyrimidine antimicrobial, with a sulfonamide was 
shown to be synergistic in the late 1960s, and this combination is now used 
widely in clinical practice ( Connie, and Powell, 2000) 
1.2.7.1. Mechanism of Action 
The sulfonamides are bacteriostatic, exerting their effect as competitive 
antagonists of para-aminobenzoic acid (PABA). They inhibit 
dihydropteroate synthase from using PABA to synthesize dihypdropteroic 
acid, a precursor of folic acid. The lack of folic acid intermediates ultimately 
results in impaired synthesis of nucleotides. Unfortunately, bacterial 
resistance to sulfonamides is common, with cross-resistance between agents 
frequently occurring. Mutations that result in additional production of PABA 
or changes in the enzyme binding sites for sulfonamides are responsible for 
the resistance (Radstrom  et al.,1992). Genes for these resistant mutations 
can be carried on plasmids, allowing rapid transfer to other similar bacteria, 
resulting in more rapid development of resistance patterns than through 
random mutation alone (Then, 1982).  
One method for improving bacterial activity against potentially resistant 
strains is the addition of trimethoprim (Bushby, 1973). Trimethoprim is a 
competitive inhibitor of dihydrofolate reductase, another enzyme active in 
the synthesis of folate. Trimethoprim resistance is also common (Houvinen, 
1987). 
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1.2.7.2. Pharmacokinetics 
The sulfonamides can be divided into four groups based on absorption and 
excretion attributes. They are classified as short- to medium-acting agents, 
long-acting agents, agents limited to activity in the gastrointestinal tract, and 
topical agents   
1.2.7.2.1. The Short to Medium Acting Sulfonamides 
The first group, the short- to medium-acting agents, includes sulfisoxazole, 
sulfamethoxazole, and sulfadiazine. Sulfisoxazole is partly metabolized to 
N-acetyl sulfixazole; both the drug and the metabolite are excreted in the 
urine (Hekster and Vree, 1982) . Because of a limited spectrum of action, 
sulfisoxazole is indicated primarily for uncomplicated urinary tract infection 
and chloroquine-resistant malaria. Sulfamethoxazole is combined with 
trimethoprim and is indicated for Pneumocystis jiroveci prophylaxis and 
treatment, upper respiratory tract infections, and urinary tract infections.  
1.2.7.2.2. The Long-Acting Sulfonamides 
The long-acting agents were associated with severe allergic reactions and 
were replaced in use by the less-toxic sulfonamides. The only long-acting 
agent still available is sulfadoxine, which is given as a combination with 
pyrimethamine. This drug is reserved for use for the treatment of drug 
resistant malaria and can be used for treatment of Toxoplasma gondii. 
Pyrimethamine inhibits dihydrofolate reductase in Plasmodium species 
during the erythrocytic stage. Sulfadoxine/pyrimethamine is absorbed 
quickly from the small intestine and, like the shorter acting agents, is widely 
distributed in tissue and body fluids. 
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1.2.7.2.3. Sulfonamides Limited to the Gastrointestinal Tract 
The agents limited to the gastrointestinal tract are very poorly absorbed and 
were used for reducing bacterial flora in the bowel before surgery. The only 
currently available agent in this class is sulfasalazine, which is used in the 
treatment of ulcerative colitis. Although absorption of sulfasalazine from the 
intact intestine is very low, inflammation in the bowel can result in 
significant absorption of the metabolite sulfapyridine.   
1.2.8. Tetracyclines 
Chlortetracycline, the first tetracycline, was developed in 1948 as a product 
of Streptomyces aureofaciens. Chlortetracycline was altered to produce 
tetracycline. Doxycycline and minocycline are semisynthetic derivatives.  
Tetracyclines bind to the 30S ribosomal subunit, blocking the binding of 
aminoacyl transfer-RNA. This results in inhibition of protein synthesis, with 
bacteriostatic effects. Bacterial resistance is typically the result of mutations 
that prevent entrance of tetracyclines into the cell or that increase the export 
of tetracycline out of the cell (Schnappinger and Illen, 1996). The resistance 
can be transmitted by plasmids (Speer,  et al. 1992). 
1.2.8.1. Pharmacokinetics 
The tetracyclines have a broad range of antibacterial effects, covering Gram-
positive, Gram-negative, aerobic and anaerobic bacteria. In addition, they        
also have activity against spirochetes and atypical bacteria such as 
Mycoplasma and Chlamydia species. The tetracyclines can be divided into 
three groups based on their pharmacokinetic traits. These groups are the 
short-acting group, an intermediate-acting group and a long-acting group. 
The half-lives are the result of different rates of renal excretion. 
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1.2.8.1.1. Short-Acting Tetracyclines 
The short-acting members of the tetracyclines are oxytetracycline and 
the namesake of the class, tetracycline. Frequent dosing is needed because of 
the very short half-life of these agents. Tetracycline has a broad spectrum of 
activity, with coverage of many aerobic Gram-negative bacilli, atypical    
bacteria such as Chlamydia trachomatis, Chlamydia psittaci, and 
Mycoplasma pneumoniae, and spirochetes such as Borrelia burgdorferi. It is 
also a second-line agent for Treponema pallidum. It is indicated by the FDA 
for treatment of rickettsial infections, typhus, Rocky Mountain spotted fever, 
trachoma, nongonococcal urethritis, and lymphogranuloma venereum. It is 
also commonly used for the treatment of acne. 
1.2.8.1.2. Intermediate-Acting Tetracyclines 
The only currently available intermediate-acting agent is 
demeclocycline. Demeclocycline is no longer used as an antibiotic. 
1.2.8.1.3. Long-Acting Tetracyclines 
The long-acting agents are the more recently developed drugs, 
doxycycline and minocycline. 
The main difference between these and the short acting agents is that these 
can be dosed less    frequently. The spectrum of bacterial coverage is 
essentially the same as tetracycline and the indications are the same, with the 
additional indication for the treatment of inhalation anthrax as part of a 
multi-drug regimen. 
1.2.8.2. Absorption/Elimination 
Tetracycline is well-absorbed after an oral dose taken in the fasting 
state. Doxycycline and minocycline are well-absorbed after an oral dose and 
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may be given with or without food. Oxytetracycline is only available in a 
topical ophthalmic preparation. 
The tetracyclines are well distributed throughout body tissues and 
fluids; distribution in the cerebrospinal fluid is adequate for the treatment of 
some infections (Karlsson  et al.1996; Yim  et al.,1985). The excellent tissue 
penetration results in the ability of the drug to cross into the dentin, bone and 
tooth enamel, where the tetracycline permanently chelates with the calcium 
(Forti and Benincori, 1969). 
Most of the tetracycline dose is excreted unchanged into the urine by 
glomerular filtration, although there is some biliary excretion as well. 
Doxycycline and minocycline are mostly excreted by non-renal, possibly 
hepatic, routes. Only 20% to 26% of doxycycline and 4% to 19% of 
minocycline is excreted in the urine (Saivin, and Houin , 1988) 
Tetracycline should be avoided in the presence of renal insufficiency 
because it accumulates rapidly in the serum in the presence of decreased 
renal function. Doxycycline can be used in renal failure, as it will be 
excreted into the bile (Houin G,  et al.1983) 
1.3. Antibiotic Resistance 
There are a variety of ways that bacteria can become resistant to the effects 
of antibiotics. They include means to decrease the intracellular 
concentrations of the drug, inactivation of the drug, changes in the binding 
sites for the drug, and adaptations that bypass the need for the binding site 
targeted by the antibiotic (Kaye, 2000). 
Methods to decrease intracellular concentrations of the drug include 
changes in the cell wall to increase the efflux of the antibiotic from the cell. 
This is seen in tetracycline and quinolone resistance. Another method is 
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decreasing the cell membrane permeability, seen as a bacterial defense in 
beta lactam antibiotic and quinolone resistance. 
    In addition, bacteria can prevent influx of the antibiotics by decreasing 
cytoplasmic membrane transport as seen with the use of aminoglycosides. 
Examples of enzymes that deactivate the drug are the lactamases that 
deactivate beta-lactams, and the phosphotransferases and actyltransferases 
that deactivate aminoglycosides (Kaye, 2000). 
There are numerous methods for altering or bypassing the binding site of 
antibiotics. The target of the antibiotic can be altered in such a way that the 
antibiotic can no longer bind to and inactivate it. Examples include 
alterations in the DNA gyrase that prevent the binding of quinolones and 
methylation of ribosomal ribonucleic acid (rRNA) so macrolides cannot bind  
to them. An example of an adaptation that bypasses a binding site is the 
ability of some bacteria to use an alternate metabolic route in folate 
synthesis, avoiding the effects of trimethoprim (Neu, 1989). 
These resistances can be acquired through mutations in the genes that 
encode for the target or affected transport proteins. As the bacterial cells 
without the adaptive mutations are killed as a result of an antibiotic, the cells 
that have the mutation continue to replicate, replacing the original 
population with a resistant one (Kaye,  2000). 
The resistances can also be acquired as a result of the transfer of plasmids 
or transposons and similar agents. These are small segments of DNA that are 
readily exchanged between bacteria. A plasmid that contains a gene for an 
adaptive mutation can be shared with a large number of nearby bacteria, 
which may or may not be the same species. In this manner, resistance can 
quickly spread from species to species (Normark and Normark, 2002). 
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Many strategies have been used in an attempt to circumvent the multiple 
mechanisms of resistance that have developed in bacteria. Adding 
betalactamase inhibitors to penicillin drugs, combining sulfa drugs with 
pyrimethamine, trimethoprim, and erythromycin, and chemically altering 
cephalosporins to create the additional generations of the drugs, are 
examples of these strategies (Normark and Normark, 2002) 
In addition, new categories of antibiotics are being created in an attempt to 
stay ahead of the rapid evolution of bacterial resistance. Linezolid, the first 
oxazolidinone, is an example of this. It is a unique drug that prevents 
formation of the 70S protein synthesis complex in bacteria and can be useful 
in the treatment of vancomycin-resistant Enterococcus and methicillin-
resistant S. aureus. 
Nonetheless, the development of bacterial resistance is relentless. In light 
of the efficient means by which bacteria develop resistances, it is important 
to avoid practices that contribute to the process. The Centers for Disease 
Control and Prevention (CDC) has issued a position paper outlining 
recommendations for minimizing nosocomial infection and the emergence 
of resistant organisms (Raymond, 2002). In this position paper, they 
recommend several general strategies based on a multi-step approach. 
The first step in the strategy is to prevent infection. Many infections in 
hospitalized or institutionalized patients are the direct result of indwelling 
urinary catheters, central venous catheters …etc. These invasive medical 
devices should be avoided unless they are clearly indicated. In addition, 
proper vaccination of medical staff and patients to prevent infection is an 
effective method to prevent the spread of S. pneumoniae, H. influenzae, and 
N. meningitidis. 
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The next step in the strategy involves tailoring medical treatment to fit the 
infection. Antimicrobial therapy should be based on the likely pathogens or 
culture results, so broad-spectrum antibiotics can be avoided when possible. 
Consideration should be given to pathogens common to the area of infection 
(e.g., skin, intra-abdominal) and to pathogens common in the environment 
locally (e.g., hospital environment). Prolonged treatment regimens can allow 
more time for the development of resistance, so the duration of therapy must 
be considered as well. The last step is to prevent transmission of resistant 
bacteria between patients. A very effective, and simple, method of infection 
containment is handwashing. As noted in the CDC position paper, 
participation in hospital infection control programs is also necessary. A 
coordinated effort to contain pathogens within hospital infection control 
guidelines makes it easier to prevent the spread of multi-drug resistant 
bacteria. 
Despite the remarkable rate of the development of new antibiotics, the 
emergence of drug-resistant bacteria continues unabated. It is important to 
use these agents wisely to maintain their usefulness for the future. 
1.4. Use of Combination Antibiotics 
For a variety of reasons, the use of antibiotic combinations is a common 
practice in clinical medicine, particularly in the treatment of seriously ill 
patients. For the most part, such use has been empirical, occasionally based 
on general principles derived from well-defined bacterial traits or predictable 
antibiotic activities. Only infrequently has it been necessary to request the 
assistance of the clinical microbiology laboratory to confirm specifically any 
beneficial effects of such combinations. (Eliopoulos, and Eliopoulos, 1988) 
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Recent developments, however, now justify a re-examination of the role of 
the laboratory in testing antibiotic combinations. First, the dissemination of 
antibiotic resistance determinants which also confer resistance to synergism 
has made it necessary to reconsider the predictability of certain antibiotic 
interactions, such as penicillin-gentamicin synergism against enterococci. In 
addition, there has been increasing awareness of the fact that some antibiotic 
combinations may be actually antagonistic. This appreciation of undesirable 
antibiotic interactions has arisen in parallel with a more sophisticated 
understanding of bacterial resistance mechanisms such as inducibility 
(derepression) of betalactamase production upon exposure to beta-lactam 
antibiotics. (Eliopoulos, and Eliopoulos, 1988) 
Requests for testing combinations could, therefore, be directed at excluding 
antagonistic effects between two antimicrobial agents. Finally, growing 
concerns about hospital costs in general and antibiotic expenditures in 
particular have provided some motivation to justify the superiority of 
antibiotic combinations in comparison with monotherapy. 
This is particularly true when combinations are associated with greater costs 
of antibiotics or management of drug related toxicities or both. (Eliopoulos, 
and Eliopoulos,1988)  
1.4.1. Antimicrobial Combinations: Clinical Rationale 
Any attempt to justify the use of antimicrobial combinations must begin with 
an understanding of why such combinations are used. This area has been the 
subject of extensive examination ( (Eliopoulos, and Moellering, 1982), 
(Giamarellou, 1986),  and (Klastersky, Regnier, and  Acar, 1986). 
1.4.1.1. Extension of Antimicrobial Spectrum 
One of the most commonly encountered reasons for the use of antibiotic 
combinations is the desire to provide a broad spectrum of activity during 
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empirical therapy of severely ill patients or when polymicrobial infection is 
recognized or suspected. The best known example of the former situation 
involves empirical therapy of the febrile neutropenic patient with suspected 
gram-negative bacillary sepsis. Here, a delay in the initiation of appropriate 
antibiotic treatment is likely to be associated with a poor outcome (Young, 
1982). In such circumstances, the exact choice of drugs will often be guided 
by attempts to provide synergistic bactericidal activity against the etiologic 
agent (Anderson, Young, and Hewitt, 1978)  
1.4.1.2. Minimization of Toxicity 
On theoretical grounds, regimens that use two or more drugs in 
combination, at lower doses than would be used in monotherapy, could 
circumvent drug toxicity if deleterious effects of individual agents were 
independent while antimicrobial effects were at least additive. This concept 
is best illustrated by the use of triple-sulfonamide combinations to avoid the 
crystalluria observed when relatively insoluble sulfonamides were used in 
full doses ((Eliopoulos, and Moellering, 1982)). This tactic was effective 
because the solubility of one agent was not influenced by the presence of the 
other drugs, while the antimicrobial activities were additive. The 
development of more soluble sulfonamides and the availability of alternative 
antimicrobial agents have relegated the triple sulfonamides to a topic of 
historical curiosity. While other attempts to exploit combinations, to 
minimize toxicity have been made ((Eliopoulos, and Moellering, 1982)), in 
current practice it is rarely possible to titrate doses of individual agents with 
this purpose in mind. Nevertheless, rationally or not, clinicians not 
uncommonly use a related maneuver in intentionally under dosing (i.e., 
aiming for peak serum levels in the low therapeutic range or occasionally 
lower) potentially toxic drugs such as aminoglycosides while using the 
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"safety net" of a co-administered antibiotic, usually a penicillin or 
cephalosporin. 
1.4.1.3. Minimization of Resistance 
The use of antibiotics in combination to prevent or minimize the 
likelihood of emergence of drug-resistant subpopulations is a tactic which 
has been used for decades in the treatment of tuberculosis (Alford and 
Manian, 1987). Success of this approach is predicated upon independent 
mechanisms of resistance to the agents. That is, the probability of selecting 
colonies resistant to both drugs of a combination is approximately equal to 
the product of the probabilities of resistance to individual agents. Clinical 
use of drugs such as rifampin, which is highly active and bactericidal against 
a number of troublesome pathogens but to which resistance develops easily, 
as therapeutic agents is generally feasible only in combination regimens.  
The extent to which use of antibiotic combinations may forestall the 
emergence of drug-resistant subpopulations during therapy of serious gram-
negative bacillary infections has been a matter of controversy. Nevertheless, 
combination therapy is frequently used with this goal in mind. (Eliopoulos, 
and Eliopoulos, 1988) 
Support for this approach is provided by some animal studies. In a 
model of Pseudomonas aeruginosa infection in granulocytopenic mice, 
addition of ticarcillin to therapy with gentamicin prevented the emergence of 
aminoglycoside-resistant morphologically variant bacterial colonies (Gerber,  
et al.,1982.). In neutropenic rats with P. aeruginosa bacteremia, resistance 
arose to azlocillin, ticarcillin, and amikacin administered as single agents, at 
frequencies depending upon the size of the bacterial inoculum used. 
Significantly fewer animals treated with azlocillin-amikacin combinations 
developed breakthrough bacteremia with resistant strains, and a similar 
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(although not statistically significant) trend was seen with ticarcillin-
amikacin combinations (Johnson and Thompson, 1986.). Studies by 
Bamberger  et al.,(1986) examining drug activities against P. aeruginosa and 
Serratia marcescens in implanted subcutaneous chambers revealed that 
combination of ciprofloxacin with azlocillin, ceftizoxime, or amikacin 
reduced, but did not eliminate, the frequency at which    isolates resistant to 
the fluoroquinolone were detected. Further evidence in support of 
combination therapy to reduce emergence of resistance is provided by the 
work of Pechere  et al.,(1986). Short-term therapy with amikacin, 
ceftriaxone, or pefloxacin as single agents resulted in development of 
resistance in 25 to 75% of mice treated for peritoneal infection due to P. 
aeruginosa, Serratia marcescens, Enterobacter cloacae, and Klebsiella 
pneumoniae. For all two-drug combinations of these antimicrobial agents, 
resistance was detected at lower rates than seen with the individual agents. 
In other systems, however, it has not been possible to demonstrate any clear-
cut advantages of combination therapy. For example, in a rabbit model of P. 
aeruginosa aortic valve endocarditis, concurrent administration of 
ceftazidime appeared to offer little protection against the development of 
amikacin resistance, with subsequent treatment failure, during therapy with 
this aminoglycoside (Bayer  et al.,1985). Whether or not two-drug 
combination therapy of Gram negative bacterial infections offers any 
protection against the development of drug resistance in humans is still not 
completely settled. Examples can be cited in which combination therapy 
does appear to offer benefit in this regard. In a prospective randomized trial 
comparing azlocillin, azlocillin plus tobramycin, and ticarcillin plus 
tobramycin in the treatment of acute exacerbations of pulmonary disease in 
patients with cystic fibrosis, drug-resistant isolates emerged during therapy 
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in 53% (8 of 15) of patients receiving azlocillin but in 21% (3 of 14) treated 
with azlocillin-tobramycin. This difference did not reach statistical 
significance, however (McLaughlin, 1983). In a prospective comparison of 
piperacillin monotherapy versus carboxypenicillin-aminoglycoside 
combination therapy for serious infections, 12 resistant Gram negative 
isolates emerged among 26 piperacillin-treated patients but in none of 24 
receiving the combination (Gribble,  et al.,1983). The obvious difficulty in 
this comparison is, of course, that there is no way to determine whether the 
observed difference was due to the addition of an aminoglycoside or to the 
choice of penicillin. 
 On the other hand, other studies fail to support a benefit of 
combination therapy. In a large (ca. 150 patients in each arm) prospective 
study comparing aztreonam-vancomycin, aztreonam- amikacin-vancomycin, 
and moxalactam-ticarcillin, two episodes of superinfection due to resistant 
Gram-negative organisms occurred in the beta-lactam-aminoglycoside group 
but none occurred in the aztreonam-vancomycin  group (Jones, 1986). 
Further, Chandrasekar et al., (1986) reported that, among 14 non-
neutropenic patients with P. aeruginosa infection treated with combinations 
of cefsulodin or ticarcillin plus an aminoglycoside, resistance to the 
betalactam occurred in 7 patients. From a retrospective analysis of 410 
episodes of P. aeruginosa bacteremia, Bodey  et al. (1985) concluded that 
addition of an aminoglycoside to an antipseudomonal beta-lactam yielded no 
improvement in survival. Although this study did not specifically examine 
the issue of emergence of resistance during therapy, any net clinical benefit 
of the combination in this regard must have been quite limited.  While it is 
clear that neither beta-lactam-aminoglycoside nor beta-lactam-beta-lactam 
combinations can completely prevent the emergence of resistant Gram-
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negative isolates during therapy (Goldstein  et al.,1983; DeJongh, 1986;), 
many clinicians continue to use the former combinations in the hope that 
development of resistance will be suppressed or delayed, especially in the 
treatment of Pseudomonas infections. 
1.4.2. Synergism. 
 Antibiotic combinations are sometimes used with the specific intent 
of obtaining a synergistic antimicrobial effect: that is, demonstration of 
either inhibitory or bactericidal activity which is greater than would be 
expected merely from the sum of the activities of the individual agents 
(Moellering, 1979). 
1.4.2.1 Mechanisms of Bactericidal Synergism in Gram-Negative Bacilli  
Although antimicrobial agents can interact to produce synergistic 
inhibitory activity, by far the more interesting interactions are those which 
result in enhanced rates or absolute magnitudes of bacterial killing by the 
combination compared with either drug alone.  
1.4.2.1.1 Cell Wall-Active Agents Plus Aminoglycosides  
 In 1962, Plotz and Davis, examined interactions between penicillin G 
(at high concentrations) and streptomycin against Escherichia coli. Prior 
penicillin exposure enhanced the bactericidal activity of streptomycin and 
augmented the uptake of [14C] streptomycin by bacterial cells. These authors 
proposed that injury to the cell envelope by penicillin resulted in increased 
penetration by the aminoglycoside. Since that time, numerous studies 
utilizing various techniques and definitions have provided evidence for beta-
lactam-aminoglycoside synergism against Gram-negative bacilli 
(Giamarellou, 1986). Although considerable attention has been given to the 
study of interactions against the Enterobacteriaceae  (D'Alessandri, et, al,  
1976 , Klastersky  et al., 1976; Jones and Packer, 1982; Glew and Pavuk, 
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1983; Glew and Pavuk, 1984). Much attention has also been focused on 
activities of combination regimens against P. aeruginosa, no doubt due to 
difficulties in treating many such infections in seriously ill patients (Bodey  
et al., 1985). 
Although it had been widely held (without proof) that mechanisms of 
beta-lactam-aminoglycoside synergism against other Gram-negative bacilli 
were similar to those elucidated in E. coli (Plotz, and Davis, 1962), other 
possibilities have been explored. Although, combination regimens might 
minimize the emergence of strains resistant to one or the other antibiotic 
(Eng, Smith and Cherubin 1986), documentation of synergistic effects 
between beta-lactams and aminoglycosides in the absence of resistance to 
the individual agents (Rusnak, 1984) supports the possibility of additional 
mechanisms of favorable interactions. Hancock  et al. (1981), Hancock and 
Wong (1984) and Loh  et al.(1984) demonstrated that exposure of intact 
organisms to aminoglycosides enhanced permeability of the outer cell 
membrane to various compounds, including the chromogenic cephalosporin 
nitrocefin. Further support for a primary role of aminoglycoside-mediated 
membrane damage arose from electron microscopic studies demonstrating 
major structural perturbations of the bacterial cell wall, beginning at the 
outer membrane, in P. aeruginosa exposed to gentamicin at or above the 
MIC (Martin and Beveridge, 1986). Unlike the intracellular uptake of 
aminoglycosides, which is an energy-dependent process (Bryan and Kwan, 
1983), the ultrastructural damage induced in these experiments proceeded 
even in the presence of metabolic inhibitors (potassium cyanate or sodium 
azide). 
Nevertheless, indirect evidence that aminoglycoside-induced outer 
membrane permeabilization could not fully account for synergism against P. 
 41
aeruginosa derived from studies showing that, while activities of 
carbenicillin and gentamicin individually were increased after treatment of 
test strains with ethylenediaminetetraacetic acid (which increases 
permeability), synergistic interactions were not affected by this maneuver 
(Scudamore and Goldner, 1982). Finally, direct evidence has now been 
presented that beta-lactam-aminoglycoside synergism against P. aeruginosa 
can occur by mechanisms directly analogous to those previously 
documented in E. coli, enterococci, and Staphylococcus aureus. Miller  et al. 
(1987) have demonstrated that both ticarcillin and cefsulodin could enhance 
the intracellular uptake of [3H] tobramycin by P. aeruginosa over a period 
of a few hours and, within the same time frame, result in bactericidal 
synergism by time-kill curve methods. While this study provides long-
awaited support for a widely held view, confirmation of such a mechanism 
certainly does not exclude aminoglycoside-mediated outer membrane 
damage or cooperative suppression of resistance as an important 
contributing factor to the overall effect of such combinations in clinical 
situations. 
A number of studies have examined potential synergistic activities of 
beta-lactam-aminoglycoside combinations against the Enterobacteriaceae. 
Several of these are against Klebsiella spp., synergism between cephems and 
aminoglycosides was noted in 65 to 95% of isolates, depending upon the 
method and particular combination used. With the newer beta-lactams, 
results vary even more widely. The frequency at which synergism is 
documented against the Enterobacteriaceae depends upon susceptibilities of 
organisms to the individual agents, ranging in one study from 70 to 80% for 
strains susceptible to one or both drugs to 40% when strains were resistant to 
both components of the combination (Glew and Pavuk, 1984). 
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Similar data for P. aeruginosa has been long appreciated that low-
level aminoglycoside resistance in this species does not preclude beta-
lactam-aminoglycoside synergism (Kluge  et al., 1974; Wald  et al., 1975); 
resistance to the betalactam component likewise does not exclude the 
possibility of synergistic interactions (Aronoff and Klinger, 1984,). In one 
study, among strains resistant to each component of a combination, 
synergism was seen in 13 to 57% of isolates, depending upon the particular 
combination used (Lyon et al., 1986). The main conclusion that can be 
drawn from such studies is that it is difficult to predict from strain 
characteristics and in vitro susceptibility to individual agents whether a 
particular combination will exhibit synergistic activity against any one 
clinical isolate at pharmacologically relevant concentrations.  
It has been difficult to draw firm conclusions relating in vitro 
synergism against Gram-negative bacilli to in vivo efficacy in animal 
models. There are at least three reasons for this: 
 (i) most papers, including those purporting to document benefits of 
synergism, study animal models with strains that have shown in vitro 
synergism, without comparative strains which are not affected 
synergistically; (Eliopoulos and Eliopoulos, 1988) 
 (ii) In vitro data, as presented, are often not adequate to differentiate true 
synergism (based on mechanisms discussed in this section) from mutual 
suppression of resistant subpopulations;  
(iii) There is no generally accepted standard definition of "in vivo 
synergism." For the most part, therefore, benefits of combination therapy in 
vivo are ascribed based on the statistical significance of comparative data 
(survival, sterilization of blood or infected sites, colony counts of residual 
bacteria, etc.). However, even if statistically significant, such differences are 
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not always of a magnitude likely to reflect clinical importance. This is 
understandable because, even in human clinical trials, superiority of one 
regimen relative to another by one measure of response (e.g., more rapid 
clearance of bacteremia) is not necessarily predictive of superior clinical 
efficacy (Korzeniowski, 1982). 
The predictive value of in vitro tests for in vivo outcome was 
examined by Andriole (1983) in a rat model of Klebsiella septicemia. 
Combinations of carbenicillin or cephalothin with tobramycin or gentamicin 
were examined in vivo against three isolates, one of which was 
synergistically killed by all combinations, another of which was resistant to 
synergism by any combination, and a third of which was synergistically 
killed by some but not all combinations. By using mortality rate 
comparisons between combinations and individual agents as indicators of in 
vivo synergism, the results of in vitro testing predicted experimental 
outcome for 11 of 12 organism-drug regimen combinations. Other examples 
of animal models which suggest a benefit for synergistic combinations 
(Andriole, 1983; Calandra and Glauser, 1986; Chadwick  et al., 1986). 
However, not all studies clearly indicate advantages of synergistic regimens. 
Norden and Shaffer (1982) found no benefit of combination therapy for P. 
aeruginosa osteomyelitis in comparison with single-drug therapy despite 
documentation of in vitro synergism by two methods. 
1.4.2.1.2. Enzyme Inhibitors (Beta-lactamase inhibitors) .  
The elaboration of beta-lactamases is a major mechanism of resistance 
to beta-lactam antibiotics in both gram-positive and Gram-negative bacteria. 
For the most part, attempts to overcome this mechanism of resistance have 
focused on the development of new betalactam antibiotics with greater 
resistance to beta-lactamase mediated hydrolysis. Another approach has 
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been to combine a hydrolysable (but otherwise intrinsically active) 
betalactam with another beta-lactam of higher affinity for the enzyme, the 
latter acting as an inhibitor of the enzyme. 
Synergism by combinations such as ampicillin-cloxacillin and 
hetacillin-dicloxacillin against Gram-negative bacilli has been demonstrated 
in vitro (Bornside, 1968) and (Bulger and Nielson, 1968) and such 
combinations have been successfully used in the treatment of urinary tract 
infections caused by beta-lactamase-producing organisms resistant to the 
aminopenicillin (Sabath  et al., 1967). In such cases, isoxazolyl penicillins 
serve as competitive enzyme substrates (because they are slowly 
hydrolyzed) (Bush and Sykes, 1983.). However, high concentrations of these 
drugs required for activity render them essentially useless for infections 
beyond the urinary tract. Much more potent inhibitors of various beta-
lactamases of both gram-positive and -negative organisms are two naturally 
occurring substances, clavulanic acid and sulbactam, which themselves 
possess only weak intrinsic antimicrobial activity (Bush and Sykes, 1983; 
Neu and Fu, 1978). These compounds act as suicide inactivators of the 
bacterial enzymes, meaning that both drug and enzyme are destroyed 
subsequent to their interaction (Bush and Sykes, 1983). Combination of 
potassium clavulanate with amoxicillin extends the spectrum of the latter to 
include many beta-lactamase-producing strains of Staphylococcus aureus, 
Haemophilus influenzae, Bacteroides fragilis, K. pneumoniae, and some 
other members of the Enterobacteriaceae (Van Landuyt et al., 1981). 
Combined with ticarcillin, the inhibitor increased the proportion of the 
Enterobacteriaceae susceptible to the former from 72 to 91% (Barry et al., 
1984). Sulbactam extends the spectrum of ampicillin in much the same way 
as clavulanic acid does, with minor differences in drug potency and activity 
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against specific enzymes (Allan and Moellering, 1985). Ampicillin and 
sulbactam moieties have been linked chemically (sultamicillin) in the form 
of an orally well-absorbed, mutual prodrug ester compound hydrolyzed in 
vivo to yield the parent drugs in higher serum concentrations than would be 
attainable with either alone at equivalent dosage (Eliopoulos, 1986). 
Unfortunately, neither potassium clavulanate nor sulbactam provides useful 
inhibitory activity against the Richmond and Sykes class I inducible, 
chromosomally mediated enzymes which confer resistance to beta-lactams 
in some species of Gram-negative bacteria, including P. aeruginosa and 
Enterobacter cloacae (Allan and Moellering, 1985). 
Bactericidal synergism is occasionally seen with combinations of 
hydrolysable beta-lactams plus agents affecting beta-lactamase synthesis. 
Combinations of chloramphenicol at low concentration with beta-lactams 
were found to be synergistic against 20% of Gram-negative bacilli resistant 
to the latter by virtue of beta-lactamase production. Failure of 
chloramphenicol to inactivate enzyme directly suggested that the synergistic 
effect was due to inhibition of enzyme production (Michel et al., 1975). 
However, such effects are very concentration dependent; higher 
concentrations of bacteriostatic agents such as chloramphenicol may 
antagonize bactericidal activities of beta-lactams. Sanders  et al. (1983) have 
shown that clindamycin has the potential to inhibit derepression of the 
inducible chromosomal beta-lactamases found in P. aeruginosa and 
Enterobacter cloacae. Constitutive production of enzyme by a fully 
derepressed mutant strain of Enterobacter cloacae was unaffected by 
addition of clindamycin. Combination of clindamycin (as an inhibitor of 
beta-lactamase derepression) with cefamandole enhanced the bactericidal 
activity of the latter against Enterobacter cloacae both in vitro and in vivo  
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1.4.2.1.3. Aminoglycoside-Modifying Enzyme Inhibitors.  
Compounds have been discovered which inhibit the activity of 
aminoglycoside- modifying enzymes. One such compound is 7- 
hydroxytropolone, an inhibitor of the 2"-O-adenylylating enzyme found in 
some gram-negative bacteria (Allen et al., 1982). This compound potentiates 
the activity of gentamicin against enzyme-producing strains of E. coli.  
1.4.2.1.4. Sequential Blockade of Metabolic Pathways 
Trimethoprim-sulphamethoxazole. The combination of trimethoprim 
and sulfamethoxazole exemplifies synergism resulting from blockade of 
sequential steps of one critical metabolic pathway. Antimicrobial activity of 
the combination extends to cover a wide range of Gram-positive and Gram-
negative organisms, including many multiple resistant nosocomial pathogens 
(Sattler and Remington, 1983; Sattler and Remington, 1984).  
1.4.2.1.5. Double Beta-Lactam Interactions 
Recognition that beta-lactam antibiotics have preferential affinities for 
specific targets (PBPs) on the bacterial inner cell membrane (Tomasz, 1979) 
has led to the concept that combinations of agents with high affinities for 
complementary PBPs may produce synergistic effects (Neu, 1983). This is 
best illustrated by combinations of amdinocillin, an agent with specific 
activity for PBP 2 of E. coli, with agents such as aztreonam which bind 
preferentially to PBP 3. At concentrations of the latter which are only 
bacteriostatic, addition of amdinocillin results in rapid cell lysis (Gutmann,  
et al., 1986). Further support for this hypothesis derives from work with 
mutant strains possessing thermosensitive PBP 2 or 3 and compounds with 
specific affinities for PBPs complementary to the nonfunctioning targets. 
Other combinations of beta-lactam antibiotics have been cited as showing 
synergism against a variety of Gram negative bacilli (Gutmann, et al. 1986). 
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In most cases, mechanisms of such interactions have not been studied. 
Presumably, in such situations, synergism is due either to binding to 
complementary PBPs or to one agent serving as a beta-lactamase inhibitor, 
protecting the second intrinsically more active drug from hydrolysis. The 
latter explanation is the more likely for combinations of penicillins with 
expanded-spectrum cephalosporins. 
Beta-lactam combinations may also exhibit antagonistic effects (Allan 
and Moellering, 1985; Gutmann, et al., 1986).). Unlike beta-lactam- 
aminoglycoside combinations (with which antagonism has been reported but 
appears to be distinctly uncommon), antagonism of one beta-lactam by 
another is not rare (Fass, 1982; Jones and Packer, 1982). For example, Neu 
and Fu (1978) detected antagonism between azlocillin and cefazolin against 
16% of gram-negative bacilli tested. Frequencies of reported antagonism 
vary widely depending upon methods used, antibiotics combined, and 
species examined (Moellering et al., 1982). While other mechanisms of 
antagonism are theoretically possible, the most common reason for 
antagonism appears to be derepression of beta-lactamase production in the 
presence of a potent inducer (with poor intrinsic antimicrobial activity), with 
subsequent inactivation of the more active member of the combination 
(Allan and Moellering, 1985; Gutmann et al., 1986.). 
An example of this phenomenon is the antagonism of the activity of 
cefamandole against Enterobacter cloacae in the presence of cefoxitin, 
which occurs both in vitro and in vivo (Sanders et al., 1983). 
1.4.3. Methods for Assessing Drug Interactions 
This section will, summarize methods which  have been used most 
commonly in studies relevant to clinical practice, indicating potential 
advantages and limitations of each method.  
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1.4.3.1 Checkerboard Titrations 
The most frequently used method to study antimicrobial interactions 
involves formation of a checkerboard array representing all possible 
combinations of two antibiotics serially diluted within a desired range 
(Krogstad and Moellering, 1986). Most commonly, the test is designed to 
assess inhibitory effects only, in which case it can be carried out with either 
broth or agar media. Serial twofold dilutions of antibiotics have been 
generally used; however, some authors have recommended smaller 
concentration intervals to permit greater precision (Hamilton-Miller, 1985; 
Horrevorts  et al., 1987). 
With this technique, synergism is usually defined as occurring when 
combinations of two drugs, each at one-fourth MIC or lower, inhibit growth. 
This is often expressed in terms of a fractional inhibitory concentration 
(FIC) index equal to the sum of FICs for each drug, defined as: FIC = MIC 
of the drug in combination divided by MIC of the drug used alone 
(Berenbaum, 1978). By this definition, synergism is said to occur when the 
FIC index is 0.5. Beyond definitions of synergism, there is little unanimity 
of opinion regarding classification of other interactions. For example, while 
the most commonly used criterion for antagonism has been a FIC index of 
0.2, criteria ranging from a FIC index of >1 to one of >4 have been used 
(Krogstad and Moellering, 1986). Another American Society for 
Microbiology journal, Antimicrobial Agents and Chemotherapy, has adopted 
as a definition of antagonism the latter criterion (FIC index of >4). 
    The checkerboard test can be extended to investigate bactericidal drug 
interactions by sampling from tubes or wells onto antibiotic-free media to 
determine Minimum Bactericidal Concentrations (MBCs) of each drug alone 
and in combination. Results can then be ex-pressed in terms of fractional 
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bactericidal concentration index, analogous to the FIC index described 
above. However, using the checkerboard test to assess bactericidal activity 
not only substantially increases the work involved, but also introduces 
additional difficulties. For example, in performing MIC broth tests, inocula 
of ca. 105 CFU/ml are preferred, (Krogstad and Moellering, 1986). On the 
other hand, use of inocula this low substantially reduces the accuracy of 
MBC testing when standard 10-pul aliquots are sampled (Pearson  et al., 
1980). Solutions to this dilemma (when both MIC and MBC data are 
desired) include repetition of the test at two inocula or use of larger sample 
volumes, in which case problems of antibiotic carryover must be dealt with. 
1.4.3.2. Time-Kill Techniques 
Time-kill techniques involve repeated sampling of tubes or  flasks 
containing the individual drugs and their combinations to determine colony 
counts of surviving bacteria over time ,( Krogstad, and Moellering, 1986). 
As with any test of antibiotic activity over time, inoculum size and growth 
phase, medium composition, and possible in vitro drug inactivation must be 
considered (Glew and Moellering, 1979; Medeiros et al., 1980 and Zuravleff   
et al., 1982). The last of these factors is particularly important when broad-
spectrum penicillins are combined with aminoglycosides. In this situation, 
significant inactivation can occur in vitro (Wallace and Chan, 1985) as well 
as in vivo (Davies et al., 1975). 
Although offering an advantage over checkerboard tests in that both 
rate and extent of killing can be assessed, the time-kill procedure is often 
more labor intensive. Therefore, for any organism studied, only a limited 
number of antibiotic concentrations (alone and in combination) can be 
examined. Proper execution of a synergism study by this technique may 
require one or more preliminary experiments to establish the concentrations 
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of individual agents most likely to permit detection of any synergistic 
interaction (Eliopoulos and Eliopoulos, 1988). 
Accurate assessment of bactericidal activity also requires that 
measures be taken to avoid carry-over of antimicrobial agents during 
sampling of broth media onto drug-free plates used for determination of 
colony counts. Obviously, inadvertent transfer of antibiotics at inhibitory 
concentrations   may lead to overestimation of bactericidal effects. Some 
drugs can be chemically or enzymatically inactivated. For example, many 
penicillins can be effectively removed either by addition of penicillinase 
directly to sample aliquots or by incorporation of enzyme into the counting 
plates. For agents which cannot be inactivated without destruction of viable 
bacteria, possible approaches include washing the sample aliquots over 
membrane filters prior to plating or demonstrating that residual antibiotic is 
diluted to insignificant (i.e., sub-inhibitory) concentrations upon transfer to 
counting plates. (Eliopoulos and Eliopoulos, 1988). 
Unfortunately, there does not currently exist any generally accepted 
standard method for performing time-kill studies on Gram-negative bacilli, 
(Moellering, 1979;Krogstad and Moellering, 1986).  
Definitions of synergism in time-kill methods generally require -100-
fold killing by the combination compared with the most active single agent 
at a designated sampling time. 
Antagonism is often defined as a 100-fold reduction in killing by the 
combination compared with that seen with the most active drug 
alone,(Krogstad and Moellering, 1986).  
Diffusion Tests: Disk diffusion tests easily assess net antimicrobial 
activities of combinations for which commercially prepared disks containing 
both drugs are available (trimethoprim-sulfamethoxazole, amoxicillin-
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clavulanate, ticarcillin-clavulanate). For other combinations, double-disk 
diffusion techniques have been devised to qualitatively determine drug 
interactions, (Krogstad and Moellering, 1986). Antibiotic-impregnated disks 
are approximated on the surface of an agar plate streaked with the test 
organism in a manner similar to that for Bauer-Kirby testing. 
Evidence of synergism is provided by elongation of the zones of 
inhibition of one or both drugs in the direction of the adjacent disk. 
Antagonism appears as truncation of the inhibitory zone(s) in the direction 
of the adjacent disk. (Eliopoulos and Eliopoulos, 1988) 
1.4.4. Correlation of Results by Various Methods 
It is obvious that each of the various tests described potentially 
measures quite distinct effects of antibiotic interactions against bacteria. 
Furthermore, for any one method, lack of standardized methodology or 
interpretative criteria contributes to the broad range of results presented in 
the literature (Eliopoulos, and Eliopoulos, 1988) 
As a consequence, correlation of results by different methods is often 
disappointing. For example, comparison of beta-lactam-aminoglycoside 
interactions against P. aeruginosa by checkerboard, MIC testing and 6- or 
24-h time-kill curves results in concordance rates of <50% between any pair 
of methods (Chan, and Zabransky, 1987; Chandrasekar, Crane, and Bailey, 
1987). 
On the other hand, several studies examining small numbers of strains 
have suggested rough correlations between results obtained by different 
methods (Kurtz,1981; Yu,1983). Klastersky  et al.(1976) found agreement 
between time-kill and MBC checkerboard assessment of cefazolin-amikacin 
interactions for 60% (13 of 20) of Klebsiella isolates. Norden  et al.(1979) 
illustrated discrepancies when various methods and criteria were applied in 
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examining cephalothin-gentamicin interactions against Klebsiella, but, in 
general, synergism by MIC checkerboard testing did predict synergism by 
time-kill methods (although the reverse was not true). In a study which 
examined several hundred Gram-negative bacilli, synergism by MIC 
checkerboard techniques predicted synergism by MBC criteria in 
approximately 80% of strains (Anderson, Young, and Hewitt, 1978). 
1.4.5. Rationale for Clinical Testing of Combinations. 
Several assumptions underlie decisions to perform in vitro tests of 
antimicrobial interactions in specific clinical settings. Foremost is the 
concept that, for whatever reason, the unnecessary use of more than one 
drug is undesirable. This approach is justified from the point of view of 
adverse reactions alone. Common adverse reactions including rashes from 
aminopenicillins (Shapiro, 1969) or nephrotoxicity from aminoglycosides 
(Eliopoulos, and Moellering, 1982) occur in 8 to 10% of patients receiving 
therapeutic courses of these drugs. Exposure to multiple drugs clearly places 
the patient at substantial risk of suffering a drug reaction or drug-induced 
toxicity.  
1.4.6. Value of Combination Therapy on Gram-Negative Bacilli 
There is still considerable debate about the role of antibiotic 
combinations in the treatment of infections due to Gram-negative bacilli. On 
the one hand, several studies provide evidence for comparable results 
between single-agent and combination therapy. In a review of over 400 
cases of Pseudomonas bacteremia, Bodey et al. (1985) noted that, whether 
or not patients were neutropenic, regimens consisting of an antipseudomonal 
beta-lactam alone were as effective as those utilizing combinations of such 
agents with aminoglycosides. Other studies have been unable to provide 
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convincing evidence of any correlation between in vitro synergism and 
clinical efficacy (Chandrasekar et al., 1987; Parry and Neu, 1978). 
On the other hand, support for a role of synergism in the treatment of 
gram-negative infections comes from several sources. Reyes  et al. (1979), 
examining 30 strains of P. aeruginosa obtained from patients with bacterial 
endocarditis, found that synergism (MIC checkerboard; in cation 
supplemented Mueller-Hinton broth; using the criterion of a fourfold 
reduction in the MIC of each antibiotic used in combination) was necessary 
for, but did not assure, medical cure with carbenicillin combined with 
gentamicin or tobramycin. Klastersky  et al.( 1977) performed a double-
blind trial comparing amikacin-penicillin with amikacin-carbenicillin 
combinations for treatment of serious Gram-negative infections in non-
neutropenic patients. Combinations synergistic in vitro against the pathogen 
being treated were associated with significantly better outcomes than were 
seen with non-synergistic regimens, although the differences were not 
striking (66 versus 48% favorable outcomes). An almost identical difference 
in response rates when synergistic or non-synergistic combinations 
(determined retrospectively) were used in the treatment of Gram-negative 
rod bacteremias was noted by Anderson  et al. (1978). Of 173 organisms 
susceptible to both antibiotics of a given combination, those patients whose 
organisms were synergistically inhibited (MICs reduced fourfold) responded 
in 80% of instances, while a 64% response was noted with non-synergistic 
combinations.   
These effects were particularly striking for P. aeruginosa infections, 
in which 10 of 12 responded to synergistic therapy, while none of the 6 
responded to non-synergistic therapy. (Bodey  et al., 1985). The presence or 
absence of synergism was also a significant factor relating to outcome in 
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patients with neutropenia, shock, and "rapidly or ultimately fatal" diseases. 
In the treatment of Gram-negative bacteremia in neutropenic patients, 
susceptibility to both components of a combination regimen appears to be 
beneficial (Klastersky and  Zinner, 1982). Love  et al. (1980), for example, 
noted responses in 75% of patients with pathogens susceptible to both 
components, while 44% responded if the organism had been susceptible to 
only one drug. These data are based on a review of patients entered in 
several clinical trials of various beta-lactam-aminoglycoside combinations. 
Even among patients treated with two antibiotics to which the pathogen was 
susceptible, synergism was still noted to be an independently beneficial 
factor. However, confounding the ability to draw firm conclusions about the 
merits of synergy per se from this study was the fact that, even in the group 
of persistently profound neutropenic patients, response occurred in 40% of 
patients treated with regimens containing one component to which the 
organism was so exquisitely susceptible that synergism could not be 
assessed. 
In view of the fact that single beta-lactams have been successfully 
used in patients with serious Gram-negative bacillary infections, even in 
those with neutropenia, it is not surprising that double beta-lactam therapy 
has met with some success. As more beta-lactam resistant strains emerge, 
there is some concern about whether double resistance will be encountered 
with increasing frequency. In fact, a possible decline in the response of P. 
aeruginosa infections to double beta-lactam therapy was discussed over 
twenty years ago (Dejace and Klastersky, 1986). However, it is difficult to 
comment on the significance of such reports in light of the numerous 
variables undoubtedly involved, in as much as the response to beta-lactam-
aminoglycoside combinations has not declined in parallel suggests that this 
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finding is not artifactually due to methodological changes over time 
(Eliopoulos and Eliopoulos, 1988). 
A special category of double beta-lactam interactions involves 
combinations of amdinocillin with a variety of other penicillins or 
cephalosporins, given the notable PBP affinities of this compound (Tomasz, 
1979). Synergistic effects of such combinations are highly strain specific 
(Neu, 1983). Furthermore, synergism, as determined by comparison of zone 
sizes from combination disks and single-drug disks, was not associated with 
enhanced clinical efficacy (King  et al., 1983). 
1.4.7. Testing of Combinations.  
In vitro tests of synergism against Gram-negative bacilli are 
problematic for several reasons, not the least of which is the uncertain 
significance of synergism, or lack thereof, in most clinical situations. 
Furthermore, for Gram-negative bacillary infections in critically ill patients 
(shock, neutropenia, rapidly fatal underlying disease, etc.) for whom 
synergism is most likely to be beneficial (Anderson,  et al.1978), the 
outcome is often determined long before results of formal synergy studies 
can be obtained for the individual patient. 
Prospective regimens for such therapy will usually include a beta-
lactam and an aminoglycoside, in an attempt to achieve bactericidal 
synergism. As a result, time-kill curve methods are preferable. Choice of 
antibiotic concentrations is purely arbitrary, but use of one drug in sub 
inhibitory concentrations will optimize the likelihood of distinguishing 
synergism from an additive effect(Eliopoulos and Eliopoulos, 1988) On the 
other hand, incorporation of clinically achievable (even if not necessarily 
sub inhibitory) concentrations of both drugs would permit an estimate of the 
maximum killing rates expected. For penicillins which may be inactivated 
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during prolonged incubation, sampling times at 6 to 7 h rather than 24 h may 
be preferable (Glew and Pavuk, 1983). An alternative approach, and one 
which is undoubtedly easier, is to choose therapy based on susceptibility 
studies and subsequently to use serum bactericidal titer determinations to 
assess the appropriateness of the selection (Eliopoulos and Eliopoulos, 
1988). Diffusion techniques are of little value in common practice, except 
when used in the form of commercially prepared combination disks used to 
assess activities of trimethoprim/sulfamethoxazole or penicillins with beta-
lactamase inhibitors (Eliopoulos and Eliopoulos, 1988) Disk approximation 
tests may be used to demonstrate antagonism between two beta-lactams, but 
results of such studies are unlikely to be the sole source of pivotal 
information on which to base major therapeutic decisions. 
1.4.8. Conclusions 
Antibiotic combinations are commonly used for patient therapy. In the 
vast majority of cases, such combinations are used to provide a broad 
spectrum of activity or in the hope of delaying or suppressing the emergence 
of drug-resistant subpopulations.  
Mechanisms of antibiotic interactions against Gram-negative bacilli 
are complex. There may well be an advantage to use of synergistic 
combinations in patients with prolonged profound neutropenia or in those 
with endocarditis. Even here, however, newer agents which achieve high 
serum bactericidal activity as single agents may prove comparable in 
efficacy to synergistic combinations of older drugs. (Eliopoulos and 
Eliopoulos, 1988) 
Selection of in vitro tests for interactions between antibiotics against 
Gram-negative organisms is complicated by lack of standardized techniques, 
although possible options have been suggested. Fixed-dose antibiotic 
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combinations, such as trimethoprim/sulfamethoxazole and beta-lactam/beta-
lactamase-inhibitor combinations, are often useful; testing of these is 
simplified by the availability of combination disks (microtiter wells, etc.).  
1.5. Effect of Phases of Growth on Efficacy of Antibiotics. 
The effectiveness of an antimicrobial agent is measured by its ability 
to inhibit and kill bacteria. However, tests of this ability are usually 
performed on log-phase bacteria or those in a very rapid-growth phase in 
media supplying all of the necessary nutrients for optimal growth (National 
Committee for Clinical Laboratories, 1990). Clinically, microorganisms in 
some infected tissues may be walled off quickly by host leukocytes, 
followed by fibrin deposits, and thus the growth of the bacteria may be less 
optimal and controlled by the limited access to nutrition (Sheldon, 1988). 
Other evidence for the importance of studying dormant organisms is 
available. For Staphylococcus epidermidis, Widmer  et al. (1990) showed 
that only data on antibiotic killing of organisms correlated with successful 
therapy. Isolates of S. aureus from chronic subcutaneous cage infections in 
rats were shown to be in a state of dormancy (Churd  et al., 1991). In these 
scenarios, the organisms multiply at a less-than-optimal rate and the 
effectiveness or lack of effectiveness of antibiotics against organisms in such 
a growth state is just being recognized. It is well known that a β-lactam 
antibiotic exerts its maximum effect on rapidly growing bacteria, but the 
limits of its activities against non-growing and slowly growing bacteria 
need to be defined (Robert, 1991). 
Most antibiotics, especially the older β-lactams, kill bacteria only 
during the growth phase (Tuomanen, 1986). During less-than optimal 
growth, a detailed study of a mutant auxotrophic E. coli strain showed that 
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the carbapenem imipenem may offer a substantial measure of bactericidal 
activity during a 6-h observation (Cozens, 1989). 
In Sudan, Saeed, (2002) in his Ph.D. thesis working on the effect of 
ciprofloxacin sensitive Gram negative bacilli found that the most critical 
time is at the beginning of the logarithmic phase. He also found that if the 
bacterium is resistant to an antibiotic in its lag phase it will remain resistant. 
 
1.6. Gram Negative Bacilli 
1.6. 1.Enterobacteriaceae 
Members of genera belonging to the Enterobacteriaceae family have 
earned a reputation placing them among the most pathogenic and most often 
encountered organisms in clinical microbiology. These Gram- negative rods 
are usually associated with intestinal infections, but can be found in almost 
all natural habitats. They are the causative agents of such diseases as 
meningitis, bacillary dysentery, typhoid, and food infection. As well as 
being oxidase negative, all members of this family are glucose fermenters 
and nitrate reducers Because many different species in this family can cause 
similar symptoms, biochemical tests are crucial to the identification, 
diagnosis, and treatment  
 
1.6.1.1. Principal Characteristics. 
 The Enterobacteriaceae is a large diverse family of bacteria commonly 
referred to as the fermentative, Gram-negative, enteric bacilli, indicating that 
they are gram-negative rods that can ferment sugars. Many are normal flora 
of the intestinal tract of humans and animals. Some infect the intestinal tract. 
Members of this family have the following five characteristics in common: 
1. They are Gram-negative rods 
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2. If motile, they possess a peritrichous arrangement of flagella 
3. They are facultative anaerobes 
4. They are oxidase negative, catalase positive 
5. All species ferment the sugar glucose but otherwise vary widely in their    
biochemical characteristics. 
1.6.1.2. Escherichia coli 
E. coli is the most encountered bacterium in the clinical laboratory. 
Besides being the number one cause of human urinary tract infections, E. 
coli has been linked to diseases in just about every other part of the body. 
Pneumonia, meningitis, and traveler's diarrhea are among the many illnesses 
that pathogenic strains of E. coli can cause. As part of the normal flora of the 
human intestinal tract, E. coli plays a crucial role in food digestion by 
producing vitamin K from undigested material in the large intestine. 
Pathogenic strains of E. coli, however, can cause severe cases of diarrhea in 
all age groups by producing a powerful endotoxin.  
Strains of E. coli that cause gastroenteritis and dysentery in humans have 
been grouped into many categories, four of which are: 
? enterohemorrhagic (EHEC),  
? enteroinvasive (EIEC), 
? enteropathogenic (EPEC),  
? enterotoxigenic (ETEC).  
Pathogenic E. coli are serotyped on the basis of their O (somatic), H 
(flagellar), and K (capsular) surface antigen profiles 
1.6.1.3. Enterobacter 
Gram-negative, capsulated, gas-producing rods found widely in nature. 
Both motile and non-motile strains exist. The species is closely related to 
Klebsiella pneumoniae and is frequently associated with nosocomial 
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infections. Enterobacter infections are becoming more common in intensive 
care. They are mainly found where:  
• Infection control is poor (little hand-washing) - many infections are 
acquired through cross-transmission Ready transmission occurs - for 
example, rapid disinfection of rectal thermometers with 80% alcohol 
does NOT prevent transmission of E. cloacae.  
• Substantially compromised patients are present - the very young, the 
very old, and, especially, those with severe underlying diseases, such 
as neoplasms, or immune suppression including human 
immunodeficiency virus infection - usually in the later stages of the 
disease.( Hopkins and Towner. 1990 ) 
1.6.1.4. Klebsiella  
Klebsiella is well known to most clinicians as a cause of community-
acquired bacterial pneumonia. (Carpenter, 1990) The vast majority of 
Klebsiella infections, however, are associated with hospitalization. As 
opportunistic pathogens, Klebsiella spp. primarily attack 
immunocompromised individuals who are hospitalized and suffer from 
severe underlying diseases such as diabetes mellitus or chronic pulmonary 
obstruction. Nosocomial Klebsiella infections are caused mainly by 
Klebsiella pneumoniae, the medically most important species of the genus. It 
is estimated that Klebsiella spp. cause 8% of all nosocomial bacterial 
infections in the United States and in Europe. No great geographical 
variations in frequency have been noted. In the United States, Klebsiella 
accounts for 3 to 7% of all nosocomial bacterial infections, placing them 
among the eight most important infectious pathogens in hospitals (Horan, 
1988), and data collected from the United Kingdom (Bergogne-Berezin, 
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1995) are remarkably similar to those reported by the Centers for Disease 
Control and Prevention.  
The urinary tract is the most common site of infection. Klebsiella accounts 
for 6 to 17% of all nosocomial urinary tract infections (UTI) and shows an 
even higher incidence in specific groups of patients at risk, e.g., patients with 
neuropathic bladders or with diabetes mellitus (Lye,  et al., 1990). As a cause 
of nosocomial Gram-negative bacteremia, Klebsiella is second only to 
Escherichia coli (Bryan,  et al., 1983).  
In pediatric wards, nosocomial Klebsiella infections are especially 
troublesome particularly in premature infants and intensive care units. 
 Due to the extensive spread of antibiotic-resistant strains, especially of 
extended-spectrum -lactamase (ESBL)-producing strains, there has been 
renewed interest in Klebsiella infections (Podschun and Ullmann, 1998) 
1.6.2 Pseudomonas 
Pseudomonas aeruginosa is an obligate aerobic, opportunistic pathogen. It is 
a common cause of nosocomial infections and can be found growing in a 
large variety of environmental locations. In the hospital environment, for 
example, it has been isolated from drains, sinks, cleaning solutions, 
medicines, and even disinfectant soap solutions. It is especially dangerous to 
the debilitated or immunocompromised patient. Like the opportunistic 
Enterobacteriaceae, Pseudomonas is a Gram-negative rod, it is frequently 
found in small amounts in the feces, and it causes similar opportunistic 
infections: urinary tract infections, wound infections, pneumonia, and 
septicemia.  
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P. aeruginosa is responsible for 12 percent of hospital-acquired 
urinary tract infections, 16 percent of nosocomial pneumonia cases, and 10 
percent of the cases of septicemia. In addition, P. aeruginosa is a significant 
cause of burn infections with a 60 percent mortality rate. Like other 
opportunistic Gram-negative bacilli, Pseudomonas aeruginosa also releases 
endotoxin and frequently possesses R plasmids. A number of other species 
of Pseudomonas have also been found to cause human infections. (Gales,  et 
al.1990), (Edgeworth  et al.,1990) 
1.6.3 Pasteurella 
Pasteurella multocida is a small, Gram-negative, non–spore-forming 
coccobacillus with bipolar staining, often existing as a commensal in the 
upper respiratory tract of many livestock, poultry, and domestic pet species. 
Infection in humans is often associated with an animal bite, scratch, or lick, 
but infection without epidemiologic evidence of animal contact may occur. 
Local wound infections from animal bites are the most common human 
infections caused by P multocida. Co-infection with multiple aerobic and 
anaerobic organisms is common in animal bite wound infections, and P 
multocida is one of the most common organisms found in culture.  
Freshly isolated P. multocida forms smooth, greyish glistening 
translucent colonies, approximately 1 mm in diameter, on blood agar after 
24 hours' incubation at 37°C. Colonies grown on CSY agar are larger. Old 
cultures, particularly those grown on media devoid of blood, may produce 
smaller colonies. Pasteurella multocida does not grow on MacConkey agar. 
Gram-stained blood or tissue smears show Gram-negative, short, ovoid, 
bipolar-staining coccoid forms. A degree of pleomorphism will be noted, 
particularly in old cultures, with longer rods of varying length. The bipolar 
staining will be more evident with methylene blue or Leishman's stain. 
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CHAPTER  TWO 
MATERIALS  AND  METHODS  
 
2.1.   Bacterial strains  
 Eleven clinical isolates were used throughout this study. All are Gram 
negative bacteria that are included in five genera were Escherichia, 
Klebsiella, Pseudomonas, Enterobacter and Pasteurella.  
2.1.1 Sources of the strains  
 Resistant strains were selected from samples provided by out-patients 
for routine analysis to the Department of Microbiology of The University of 
Medical Sciences and Technology, Medical Center (Yastabsheroon). The 
sensitive isolate (Pasteurella multocida.) was provided by Veterinary 
Research Centre, Soba ,Sudan.. 
The strains were given the following codes throughout the present study. 
 
Table 1 : Codes for studied strains 
No. Organism 
1. E. coli(1) 
2. E. coli(3) 
3. E. coli(5-1) 
4. E. coli(9) 
5. E. coli(K) 
6. Klebsiella pneumoniae/10 
7. Klebsiella pneumoniae/M 
8. Klebsiella pneumoniae/J 
9. Enterobacter 267 
10. Pseudomonas 5 
11. Pasteurella multocida 
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2. 2.   Microscopic examination of bacteria 
Smears were made from pure colonies of the cultures. The smears 
were then heated, stained by Gram’s method and examined microscopically 
for identification of bacteria.  
2. 3.   Isolate preparation and preservation of bacteria.  
All organisms were sub cultured in Petri-dishes containing blood and 
MacConkey agar incubated overnight at 35°C, inspected for purity; sub 
cultured a second time onto blood agar, and incubated overnight at 35°C. 
Colonies with identical morphologies were then preserved 
 Preservation was made by inoculation of the organisms into universal 
bottles containing Robertson’s cooked meat media incubated overnight at 
35°C and then stored at 4°C (Forbes et al 1998)  
2.3.1 Robertson’s Cooked Meat Medium. 
This medium was prepared by the addition of 1000 gram of minced 
meat to 1000 ml of 0.05N NaOH, mixed and heated to boiling for 20 
minutes with frequent stirring. The fat was skimmed off and the pH was 
checked to be about 7.5. The mixture was strained through gauze and the 
meat particles were dried at room temperature. The dried meat was 
distributed into screw –capped universal bottles to a depth of about 2.5 cm 
and sufficient Nutrient Broth was added to give a depth of about 5 cm. 
Sterilization was made by autoclaving at 115 °C for 20 minutes. 
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2.4. Media for Identification and Experiments  
2.4.1 Nutrient broth (Oxoid) – code: CM1 
. 
Formula 
Ingredients     Quantity (g/litre) 
Lab –lemco powder    1.00 
Yeast extract     2.00 
Peptone       5.00 
This medium was prepared by the addition of the above mentioned 
ingredients to one litre of distilled water .All the constituents were mixed 
well, distributed into the final containers and sterilized by autoclaving at 
121°C for 15 minutes. The pH of the medium was adjusted to be 7.4± 0.2. 
2.4.2 Nutrient Agar (Oxoid) – code: CM3 
Formula 
Ingredients     Quantity(g/litre) 
Lab –lemco powder    1.00 
Yeast extract     2.00 
Peptone       5.00 
Agar        20.00 
 
 The above ingredients were suspended in one litre of distilled water 
and boiled till dissolved completely .Sterilization was made by autoclaving 
at 121 °C for 15 minutes. The pH was adjusted to be 7.2-7.4 using 10N 
NaOH. The medium (20 ml) was distributed into sterile Petri dishes. 
 
 66
2.4.3 Milk Agar 
 The preparation of this media was done by addition of 10 ml of sterile 
skim milk to 90 ml nutrient agar. 
2.4.4 MacConkey’s Agar (Oxoid) – code: CM7 
Formula 
Ingredients     Quantity (g/litre) 
 Bile salts      5.00 
 Sodium chloride     5.00 
 Lactose      5.00 
Peptone      20.00 
Neutral red      0.075 
Agar       20.00 
 
The ingredients were suspended in one litre of distilled water and boiled till 
dissolved completely. Sterilization was done by autoclaving at 121 °C for 15 
minutes. 
 
2.4.5 Blood Agar  
Formula 
Ingredients     Quantity 
 Defibrinated blood     50 ml 
 Nutrient agar     950 ml 
Defibrinated blood was added aseptically to the melted cooled to 50 °C 
nutrient agar and then distributed into sterile Petri dishes containing 20 ml 
each. 
 
2.4.6. Peptone water (Oxoid)  
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Formula 
Ingredients     Quantity (g/litre) 
Peptone     10.00 
Sodium chloride      5.00 
The ingredients were added to one litre of distilled water, mixed well till 
dissolved. The pH of the above mixture was adjusted to be 7.2 ±0.2. 
Sterilization was done by autoclaving at 121 °C for 15 minutes.  
 
2.5.7. Peptone water sugars (Oxoid)  
Formula 
Ingredients     Quantity 
Peptone water    900 ml 
     (adjusted to pH 7.1-7.30 
Andrade’s Indicator    10 ml 
      (bring the pH 7.5) 
 Appropriate sugar     10 gm 
After adding the sugar, the mixture was mixed well, and was distributed into 
sterile test tubes, each containing about 5ml. All tubes were sterilized by 
autoclaving at 110 °C for 10 minutes. 
 
2.4.8 Voges Proskauer (Glucose phosphate medium) (Oxoid)  
Formula 
Ingredients     Quantity (g/litre) 
Peptone      5.00 
Glucose      5.00 
Dipotassium hydrogen phosphate (K2HPO4) 5.00 
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The peptone and the K2HPO4 were dissolved in one litre distilled water and 
then the mixture was filtered and the pH was adjusted to be 7.5 and after that 
the glucose was added and mixed well before the medium was distributed in 
Bijou bottles in equal amounts of 1.5 ml each. All the bottles were sterilized 
by autoclaving at 115°C for about 15 minutes. 
2.4.9. Mueller-Hinton Broth (Oxoid)  
Formula 
Ingredients     Quantity (g/litre) 
 Beef dehydrated infusion   300.0 g 
Casein hydrolysate    17.5 g 
Starch       1.5 g 
Divalent cation content  
Ca++       4.2 mg/L 
Mg++      5.124 mg/L 
Twenty-one gram of the above ingredients were added to one litre of 
distilled water. The pH of the above mixture was then adjusted to 7.3 ±0.1 
sterilized by autoclaving at 121°C for about 15 minutes.  
 
2.4.10. Motility medium  
Formula 
Ingredients     Quantity (g/litre) 
 Meat extract       3.0 
 NaCl        5.0 
 Agar        4.0 
 Gelatin      80.0s 
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The above ingredients were suspended in one litre distilled water and boiled 
till dissolved completely. The pH was adjusted to be 7.2. The medium was 
distributed in test tubes containing Craigie tubes and the preparation was 
sterilized by autoclaving at 115°C for about 15 minutes.  
  
 
2.4.11. Hugh and Leifson’s medium (Hugh and Leifson, 1963) 
Formula 
Ingredients     Quantity 
   
 Peptone      2.0 g 
 NaCl      5.0 g 
 K2HPO2     0.3 g 
 Agar       1.1 g 
 Distilled water         1000.0 ml 
 Bromothymol blue 0.2% aq. soln.         15.0 ml 
The solids were dissolved by heating in the water. Then the pH was adjusted 
to 7.1. The preparation was filtered and the indicator was added. 
Sterilization was done by autoclaving at 115°C for 20 minutes. 
Sterile solution of 10% glucose was added aseptically to give a final 
concentration of 1%.The medium was then distributed aseptically in 10 ml 
volumes into sterile test tubes. 
 
2.5. Isolate identification by API 20 E (Analytical Profile index) 
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API 20 E is a gallery of probes to identify microorganisms from the family 
Enterobacteriaceae and other Gram-negative bacilli.  
The identification of an organism with the API 20 E   ( bioMe`rieux  Vitek) 
system consists of: 
- carrying out 20 tests using the API 20 E strips, then, 
- interpreting the results obtained using the API 20 E data base. 
2.5.1. Principle: 
The API 20E system consists of a series of microtubes containing 
dehydrated substrates. The microtube is composed of a cupule (the upper 
portion of the microtube) and the tube (the lower portion of the 
microtube). The substrates are located in the tube portion of the 
microtube. These substrates are reconstituted by adding a bacterial 
suspension. The strip of reconstituted microtubes is incubated so that the 
bacterial strain reacts with the contents of the tubes. The strip is read after 
18-24 hours when the various indicator systems in the microtubes are 
affected by the metabolites or added reagents. 
The ONPG tube contains an ingredient that functions as an internal 
indicator. The ADH, LDC, ODC, and URE tubes contain phenol red as 
an indicator. The CIT, GLU, MAN, INO, SOR, RHA, SAC, MEL, AMY 
and ARA tubes contain bromthymol blue as an indicator, The GEL tube 
contains charcoal and the H2S tube contains iron salts as indicators. The 
TDA, IND and VP tubes contain no indicator. All of the tubes contain 
buffers, and all tubes, with the exception of the CIT and URE tubes, 
contain peptone 
2.5.2. Procedure: 
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1. An incubation tray and lid was set up, and with a plastic squeeze 
bottle tap water was dispensed into the incubation tray to provide a 
humid atmosphere during incubation. The API 20E strip was removed 
from the sealed envelope, and one strip was placed in the incubation 
tray. 
2. With a sterile swab, the center of a well-isolated colony was touched, 
and this inoculum thoroughly mixed with the tubed saline (5.0 ml) to 
obtain a homogenous suspension. 
3. The cap was removed from the tube containing the bacterial 
suspension and a sterile Pasteur pipette was inserted. 
4. The API 20E incubation tray was tilted and the tube section of the 
microtubes was filled by placing the pipette tip against the side of the 
cupule. The ADH, LDC, ODC, H2S, and URE reactions can be 
interpreted best when these microtubes are slightly underfilled. 
5. Both the tube and cupule section of the [CIT], [VP], and [GEL] tubes 
were filled. 
6. After inoculation, the cupule section of the ADH, LDC, ODC, H2S, 
and URE microtubes were completely filled with mineral oil. 
7. After inoculation, the plastic lid was place on the tray and the strip 
was incubated for 24 hours at 37°C. 
8. After the incubation period, all reactions not requiring the addition of 
reagent(s) were recorded. 
9.  The reagents were added to TDA and VP tubes. If positive, the TDA 
reaction was immediate; the VP reaction may be delayed up to 10 
minutes. The Kovac's reagent was added to the IND tube last.  
10. The Analytical Profile Index was used to determine the genus and/or 
species of the organism 
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2.5.3. Profile coding 
To use THE ANALYTICAL PROFILE INDEX, the biochemical profiles 
obtained are transformed into a NUMERICAL PROFILE i.e. a number which 
enables the easy transcription of all the results obtained for an organism and 
comparison with the profiles listed in the Index.  The principle of coding is 
to condense the binary pieces of information (+ or -) into a numerical 
profile. 
To do so the tests are derived into groups of three and each positive (+) 
reaction is given a value equal to 1,2 or 4 according to the position of the test 
in its group: first, second or third respectively. The sum of these three values 
(0 for negative) gives the corresponding digit with a value between 0 and 7. 
The API 20 E strip consists of 20 tests separated into 7 groups. 
The oxidase reaction forms the 21st test (+ = 4).  
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READING THE API 20E 
Table: 2 Reading the API 20E 
TESTS SUBSTRATE REACTION TESTED NEGATIVE  RESULTS POSITIVE   RESULTS 
ONPG  ONPG hydrolysis beta-galactosidase colorless yellow 
ADH arginine arginine dihydrolase yellow red/orange 
LDC lysine lysine decarboxylase yellow red/orange 
ODC ornithine ornithine decarboxylase yellow red/orange 
CIT citrate citrate  utilization pale green/yellow blue-green/blue 
H2S Na thiosulfate H2S production colorless/gray black deposit 
URE urea urea hydrolysis yellow red/orange 
TDA tryptophan deaminase yellow brown-red 
IND tryptophan indole production yellow red (2 min.) 
VP Na pyruvate acetoin production colorless pink/red (10min) 
GEL charcoal gelatin gelatinase no diffusion of black black diffuse 
GLU glucose fermentation/oxidation blue/blue-green yellow 
MAN mannitol fermentation/oxidation blue/blue-green yellow 
INO inositol fermentation/oxidation blue/blue-green yellow 
SOR sorbitol fermentation/oxidation blue/blue-green yellow 
RHA rhamnose fermentation/oxidation blue/blue-green yellow 
SAC sucrose fermentation/oxidation blue/blue-green yellow 
MEL melibiose fermentation/oxidation blue/blue-green yellow 
AMY amygdalin fermentation/oxidation blue/blue-green yellow 
ARA arabinose fermentation/oxidation blue/blue-green yellow 
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OX oxidase oxidase colorless/yellow violet  
In some cases, The 7- figure profile is not discriminant enough and 
supplementary tests have to be performed  
? reduction of nitrates to nitrites   (NO2) 
? reduction of nitrates to nitrogen   (N2) 
? motility      (MOB) 
? growth on MacConkey’s agar                           ( McC) 
? glucose  oxidation      (OF-O) 
? glucose fermentation    (OF-F)  
 
 
2.6. Effect of antibiotics on bacterial growth   
2.6.1. Antibiotics  
The following antibiotics which are commonly used in Sudan were provided 
as powder by (Amipharma Pharmaceutical Company, Khartoum North). 
1- Amoxicillin (Trihydrate) is a moderate-spectrum β-lactam 
antibiotic used to treat bacterial infections caused by susceptible 
microorganisms. It is usually the drug of choice within the class because it is 
better absorbed, following oral administration, than other beta-lactam 
antibiotics. Being susceptible to degradation by β-lactamase-producing 
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bacteria, Amoxicillin may be given with clavulanic acid to decrease its 
susceptibility. 
2- Ampicillin (Trihydrate)   β-lactam antibiotic that has been used 
extensively to treat bacterial infections since 1961. Allergic reactions that 
range in severity from a rash to potentially lethal anaphylaxis. 
3- Cephalexin (Micro) is a first-generation antibiotic in a class of 
drugs called cephalosporins.. Cephalexin is used to treat many different 
types of bacterial infections such as respiratory tract infections, bronchitis, 
tonsillitis, ear infections, skin infections, and urinary tract infections. 
Although it is not generally considered first-line therapy for any indication, 
it is a useful alternative to penicillins in patients with penicillin 
hypersensitivity.  
4- Ciprofloxacin (HCL): Ciprofloxacin is a broad-spectrum 
Fluoroquinolone antibiotic that is active against both Gram-positive and 
Gram-negative bacteria. The major adverse effect seen associated with its 
use is gastrointestinal irritation, common with many antibiotics. Because of 
its general safety, potency and broad spectrum activity, ciprofloxacin was 
initially reserved as a "last-resort" drug for use on difficult and drug-resistant 
infections. As with any antibiotic, however, increasing time and usage has 
led to an increase in ciprofloxacin-resistant infections, mainly in hospital 
settings. Also implicated in the rise of resistant bacteria is the use of lower-
cost, less potent fluoroquinolones, and the widespread addition of 
ciprofloxacin and other antibiotics to the feed of farm animals, which leads 
to greater and more rapid weight gain. 
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5- Cloxacillin (sodium monohydrate) a semisynthetic antibiotic in 
the same class as penicillin Cloxacillin is effective against bacteria like 
staphylococci that produce beta-lactamases 
6- Erythromycin (stearate) Macrolide antibiotic which has an 
antimicrobial spectrum slightly wider than that of penicillin, and is often 
used for people who have an allergy to penicillins. For respiratory tract 
infections, it has better coverage of atypical organisms, including 
mycoplasma. It is also used to treat outbreaks of chlamydia, syphilis, and 
gonorrhea. 
7- Sulphamethoxazole (Sulfa antibiotic) Sulphamethoxazole is a 
sulfonamide antibiotic. It can be used as an alternative to amoxicillin-based 
antibiotics to treat sinusitis. It is most often used as part of a synergistic 
combination with trimethoprim, which is also known as Bacterin or Septrin.  
8- Tetracycline is a broad-spectrum antibiotic produced by the 
streptomyces bacterium. It is used to produce several semi-synthetic 
derivatives, which together are known as the Tetracycline antibiotic group. It 
is indicated for use against many bacterial infections and commonly used to 
treat acne. 
9- Trimethoprim is a bacteriostatic antibiotic mainly used in the 
prophylaxis and treatment of urinary tract infections. It belongs to the class 
of chemotherapeutic agents known as dihydrofolate reductase inhibitors. 
 
2.7. Determination of Minimum Inhibitory Concentration 
(MIC). 
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 According to the NCCLS guidelines for broth macrodilution, the MIC 
was defined as the lowest concentration of antibiotic that completely 
inhibited the growth of the organism as detected with the naked eye. 
 The MIC of each drug was determined in duplicates by broth 
macrodilution procedure in cation- supplemented Mueller-Hinton broth 
(Oxoid CM0405 U.K.) according to the standards of the National Committee 
for Clinical Laboratory Standards (NCCLS, 2000).  
 Mueller-Hinton broth is recommended as the medium of choice for 
susceptibility testing of commonly isolated, rapidly growing aerobic, or 
facultative organisms (NCCLS, 2000). Mueller-Hinton broth demonstrates 
good batch- to batch reproducibility for susceptibility testing; is low in 
sulfonamide, trimethoprim, and tetracycline inhibitors; and yields 
satisfactory growth of most pathogens. In addition a large body of data and 
experience has been gathered about tests performed with this medium 
(NCCLS, 2000). 
 
 
2.7.1.Preparation of antibiotic stock solution 
 Ranges of antibiotics concentrations for the organisms to be tested were 
chosen so that to test the effect of the usage of very high concentration of 
antibiotics. 
Stock solution was prepared at concentrations of at least 1000 µg/ml or ten 
times the highest concentration to be tested or the highest dissolvable 
concentration, whichever is greater. Preparation of the stock solution was 
done by dissolving the antibiotic in 5ml of solvent and sterilized distilled 
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water was added to make 100 ml of stock solution, left in refrigerator for at 
least three days for self sterilization. 
The range of antibiotic concentrations used for determining MIC is 
universally accepted to be in doubling dilution steps up and down from 1 
µg/ml as required (Andrews , 2001). 
 
Table 3 : solvents and diluents used for different antibiotics  
Antibiotic Solvent Diluent 
Dilution range 
µg/ml 
Amoxycillin Saturated NaHCO3 solution Water 0.25-1024 
Ampicillin Saturated NaHCO3 solution Water 0.25-1024 
Cephalexin Water Water 0.25-1024 
Ciprofloxacin Water Water .000168-1024 
Cloxacillin Water Water 0.25-1024 
Erythromycin Ethanol Water 0.25-128 
Sulphamethoxazole Water+ 0.1 M NaOH Water 0.25-128 
Tetracycline Water Water 0.25-1024 
Trimethoprim 
Water(1ml)  
+ 10µL glacial acetic acid 
Water 0.25-1024 
 
2.7.2 Preparation of antibiotic working solution range  
Antibiotic ranges were prepared one step higher than the final dilution 
range required i.e. if a final range of 0.5, 1, 2, 4, 8, 16µg/ml is required 
then a range of 1, 2, 4, 8, and 32µg/ml was prepared to compensate for 
the addition of an equal volume of broth.  
 
2.7.3. Preparation of inoculum 
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At least two well- isolated colonies with identical morphologies were 
selected from an agar plate. The top of each colony was touched with a 
wire loop and the colonies were transferred to   bijou bottles each 
containing 10 ml of Mueller-Hinton broth. The bottles were incubated for 
overnight at 37°C and used as inoculum.  
 
 
2.7.4. Macrodilution (Tube) Broth Method. 
Sterile 13x100 mm test tubes were arranged in two rows to cover the range 
of antibiotic chosen in duplicate. The first tube for each organism tested was 
labeled as control contained broth without antimicrobial agent. Starting with 
the highest concentration the rest of the tubes were labeled with 
concentration of the antibiotic to be tested.  
One ml of Mueller Hinton broth was transferred to all tubes. One ml of the 
highest concentration of the antibiotic was transferred to the second tube 
labeled as the highest concentration. The tube was mixed thoroughly and 
one ml of it was transferred to the third tube to give half of the antibiotic 
concentration. The process goes on to give all the series of the 
concentrations to be examined. 
Each tube was inoculated with one to two drops of the inoculum prepared, 
incubated at 37°C for 24 hours. MIC is the lowest concentration of 
antimicrobial agent at which there was no visible growth in the tubes. 
The amount of growth in the tubes containing the antibiotic was compared 
with the amount of growth in the growth-control tubes (no antibiotic) used in 
each set of tests when determining the growth end point.  
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2.8. Determination of Fractional Inhibitory Concentrations 
(FICs) using checker board  
We investigated a possible synergistic effect of using a combination 
of two antibiotics by checkerboard. In spite of using all possible 
concentrations of each combination of two antibiotics, some of the studied 
organisms had shown resistance to these combinations. 
The stock solutions and serial twofold dilutions of each drug to at least 
double the MIC were prepared according to the recommendations of NCCLS 
(2000). A total of 1 ml of Mueller-Hinton broth was distributed into each test 
tube. The first antibiotic of the combination was serially diluted along the 
ordinate, while the second drug was diluted along the abscissa. An inoculum 
was prepared as for the determination of MIC from each isolate in Mueller-
Hinton broth. The checkerboard was achieved by combining in separate 
tubes 1 ml of each of the 11 concentrations of one antibiotic (0.25 to 4096 
µg/ml) with each of the 11concentrations of the second antibiotic. 
The resulting checkerboard contains each combination of two 
antibiotics. Thus, each of the tube held a unique combination of 
concentrations of the two antibiotics with tubes that contain the highest 
concentration of each antibiotic at opposite corners. Each test tube was 
inoculated with 1-2 drops of the bacterial inoculum, and the tubes were 
incubated at 37°C for 24 h under aerobic conditions. 
To evaluate the effect of the combinations, the FIC was calculated for each 
antibiotic in each combination. 
  The FICs were derived from the lowest concentration of antibiotic 
combination permitting no visible growth of the test organisms on Mueller –
Hinton Broth tubes after incubation for 24 h at 370 C. 
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The FICs were calculated as follows: 
FIC = FIC A + FIC B 
where: 
    FIC A is the MIC of drug A in the combination/MIC of drug A alone 
     FIC B is the MIC of drug B in the combination/MIC of drug B alone.  
The combination is considered synergistic when the FIC is 0.5, 
                 indifferent when the FIC is >0.5 to <2,  
        and antagonistic when the FIC is 2. 
The combination tested were ( Antibiotic A and Antibiotic B) 
i. Ampicillin and Amoxycillin     
ii. Ampicillin and Ciprofloxacin  
iii. Ampicillin and Cloxacillin 
iv. Sulphamethoxazole and Trimethoprim 
v. Cephalexin and Ciprofloxacin 
vi. Cephalexin and Amoxycillin 
vii. Tetracycline and Erythromycin 
viii. Tetracycline and Amoxycillin 
ix. Tetracycline and Sulphamethoxazole 
x. Tetracycline and Trimethoprim 
xi. Tetracycline  and Ciprofloxacin 
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Table 4: Checkerboard of the concentrations of the antibiotics (µg/ml) used. 
  A(conc) 
B(conc) 
0.25 0.5 1 2 4 8 16 32 64 128 256 512 1024 2048 4096 
0.25 0.25/0.25 0.5/0.25 1/0.25 2/0.25 4/0.25 8/0.25 16/0.25 32/0.25 64/0.25 128/0.25 256/0.25 512/0.25 1024/0.25 2048/0.25 4096/0.25 
0.5 0.25/0.5 0.5/0.5 1/0.5 2/0.5 4/0.5 8/0.5 16/0.5 32/0.5 64/0.5 128/0.5 256/0.5 512/0.5 1024/0.5 2048/0.5 4096/0.5 
1 0.25/1 0.5/1 1/1 2/1 4/1 8/1 16/1 32/1 64/1 128/1 256/1 512/1 1024/1 2048/1 4096/1 
2 0.25/2 0.5/2 1/2 2/2 4/2 8/2 16/2 32/2 64/2 128/2 256/2 512/2 1024/2 2048/2 4096/2 
4 0.25/4 0.5/4 1/4 2/4 4/4 8/4 16/4 32/4 64/4 128/4 256/4 512/4 1024/4 2048/4 4096/4 
8 0.25/8 0.5/8 1/8 2/8 4/8 8/8 16/8 32/8 64/8 128/8 256/8 512/8 1024/8 2048/8 4096/8 
16 0.25/16 0.5/16 1/16 2/16 4/16 8/16 16/16 32/16 64/16 128/16 256/16 512/16 1024/16 2048/16 4096/16 
32 0.25/32 0.5/32 1/32 2/32 4/32 8/32 16/32 32/32 64/32 128/32 256/32 512/32 1024/32 2048/32 4096/32 
64 0.25/64 0.5/64 1/64 2/64 4/64 8/64 16/64 32/64 64/64 128/64 256/64 512/64 1024/64 2048/64 4096/64 
128 0.25/128 0.5/128 1/128 2/128 4/128 8/128 16/128 32/128 64/128 128/128 256/128 512/128 1024/128 2048/128 4096/128 
256 0.25/256 0.5/256 1/256 2/256 4/256 8/256 16/256 32/256 64/256 128/256 256/256 512/256 1024/256 2048/256 4096/256 
512 0.25/512 0.5/512 1/512 2/512 4/512 8/512 16/512 32/512 64/512 128/512 256/512 512/512 1024/512 2048/512 4096/512 
1024 0.25/1024 0.5//1024 1//1024 2//1024 4/1024 8/1024 16/1024 32/1024 64/1024 128/1024 256/1024 512/1024 1024/1024 2048/1024 4096/1024 
2048 0.25/2048 0.5/2048 1/2048 2/2048 4/2048 8/2048 16/2048 32/2048 64/2048 128/2048 256/2048 512/2048 1024/2048 20482048/ 4096/2048 
4096 0.25/4096 0.5/4096 1/4096 2/4096 4/4096 8/4096 16/4096 32/4096 64/4096 128/4096 256/4096 512/4096 1024/4096 2048/4096 4096/409
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2.9 Growth curves 
2.9.1. Standard growth curve of bacterial isolates 
 The growth curve (measured in log10 CFU/ml) of all isolates was 
performed in Muller-Hinton broth. The standard growth curve of the 
organisms was determined by inoculating each of the tested organisms in a 
bottle containing 100 ml of Muller -Hinton broth. Sampling was performed 
at 0, 1, 2, 4, 6, 8 and 24 hours. Aliquots containing 0.1 ml were sub cultured 
by using serial dilutions in duplicate on nutrient agar, incubated at 37°C and 
colonies were counted after 24 h for all isolates except for Pasteurella 
multocida where the colonies were counted after 48 hours. 
 
2.9.2. Time-kill curve with single antibiotic.  
The time-kill method of synergy testing was performed by the broth 
macrodilution technique and followed the guidelines set by the National 
Committee for Clinical Laboratory Standards (NCCLS).  
This technique was chosen because previous studies suggested that, 
compared with disc diffusion or checkerboard titration methods ,time-kill 
assays correlate best with cure in animal models .( Cappellety and Rybak, 
1996; Visalli et al., 1998;) 
According to the results of the previous experiments (determination of 
MIC) the antibiotic that shows any slight effect on the studied organisms 
was used in this experiment (MIC ≤ 512µg/ml).The chosen organisms were 
inoculated in bottles containing Mueller-Hinton broth media and antibiotics 
at 0.5, 1, and 2 times the MIC to determine the effect of the use of lower or 
higher doses of the antibiotics on the rate of growth of the isolates. 
  Sampling was performed at 0, 1, 2, 4, 6, 8 and 24 hours. Aliquots 
containing 0.1 ml were sub cultured by using serial dilutions in triplicate on 
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nutrient agar, incubated at 37°C and colonies were counted after 24 h for all 
isolates except for Pasteurella multocida where the colonies were counted 
after 48 hours. 
Time - Killing curves were constructed by plotting log10 CFU per 
milliliter against time over 24 h. 
2.9.3. Time-killing curve with combination of two antibiotics: 
The purpose of this experiment was to compare the synergistic effects 
of the combinations of antibiotic used with that of using single antibiotic 
along 24 hours. The growth curve for all organisms which were found 
sensitive to a combination of two antibiotics were determined by inoculating 
the organisms in bottles containing 100 ml Mueller-Hint broth and the MIC 
concentration of the two tested antibiotics. Sampling was performed at 0, 1, 
2, 4, 6, 8 and 24 hours. Aliquots containing 0.1 ml were sub cultured by 
using serial dilutions in duplicate on nutrient agar, incubated at 35 - 37°C 
and colonies were counted after 24 h for all isolates except for Pasteurella 
multocida where the colonies were counted after 48 hours  
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Table 5 : The concentration of the combination antibiotic used against each 
organism  
 
No Organism Combination(A+B) MIC(µg/ml)
1.  E. coli(1) Tetracycline + Erythromycin 2+128 
2.  E. coli (3) Tetracycline + Erythromycin 32+32 
3.  E .coli (5) Tetracycline + Erythromycin 2+32 
4.  Enterobacter Tetracycline + Erythromycin 2+2 
5.  Enterobacter Tetracycline + Ciprofloxacin 2+2 
6.  Klebsiella pneumoniae10  Ampicillin + Ciprofloxacin 2+128 
7.  Klebsiella pneumoniae J  Tetracycline +Ciprofloxacin 2+128 
8.  Klebsiella pneumoniae M Tetracycline +Erythromycin 8+2 
9.  Klebsiella pneumoniae M  Ampicillin +Amoxicillin 2+128 
10. Klebsiella pneumoniae M Tetracycline +Ciprofloxacin 2+2 
11. Klebsiella pneumoniae M Cephalexin +Ciprofloxacin 2+128 
12. Klebsiella pneumoniae M Tetracycline +Trimethoprim 128+2 
13. Pseudomonas aeruginosa Ampicillin +Ciprofloxacin 2+2 
14. Pseudomonas aeruginosa Tetracycline +Trimethoprim 128+2 
15. Pseudomonas aeruginosa 
Sulphamethoxazole 
+Trimethoprim 
8+32 
16. Pasteurella multocida Tetracycline +Erythromycin 0.25+0.125 
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2.10. Effect of single and combination antibiotics on different phases of 
bacterial growth in vitro and in vivo 
The aim of these experiments was to determine the optimum time to 
use a single effective antibiotic and a combination of two antibiotics in vitro 
and using test animals 
2.10.1. Bacterial strains and susceptibility testing 
Pasturella multocida local sensitive strain to most of the antibiotics 
which are commonly used in Sudan had been used in these studies. This 
strain had been supplemented by the Veterinary Research Centre 
(Soba/Khartoum).  
2.10.2. Antibiotics 
Erythromycin and tetracycline each separately and in combination 
were used in these experiments. 
2.10.3. Preparation of bacterial suspensions 
At least two colonies of the test isolates with identical morphologies 
were chosen. The colonies were transferred to bijou bottles containing 10 ml 
of Muller-Hinton broth each, incubated at 37°C for overnight and used as 
inoculum. Colony forming unit (CFU) counts were verified by plating 
serially diluted aliquots on agar plates. 
2.10.4.In vitro studies (growth curve with antibiotics)  
Ten-ml sterile bottles of nutrient broth were inoculated by a colony or 
part of a colony of Pasteurella multocida. The inoculum was emulsified 
carefully and the bottle was incubated at 37°C for 18 hours .Eight bottles 
containing 99 ml Mueller Hinton Broth each were prepared and were 
inoculated with one ml from the overnight culture . The eight were labeled 
time zero, one hour, two hours, four hours, six hours, eight hours and twenty 
four hours. From the first bottle (at zero time) one ml was discarded and 
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replaced by one ml normal saline containing the tested antibiotic of 1 MIC 
concentration (erythromycin =2µgm/ml, tetracycline = 4 µgm/ml and 
combination of erythromycin /tetracycline=0.125/0.25 µgm/ml). The 
antibiotic was allowed to act for 15 minutes then the viable count was done. 
The other seven bottles were incubated at 37°C for 1 hour, 2 hours, 6 hours, 
8 hours and 24 hours respectively. After the inoculum time 1 ml was 
discarded and replaced by 1 ml normal saline containing the antibiotic of 1 
MIC concentration. Then after 15 minutes viable count using Miles and 
Misra (1938) method was done.  
The results of the viable count were compared with a standard curve 
for Pasteurella multocida (control) without the addition of any antibiotic. 
2.10.5. In vivo studies 
2.10.5.1.Animals 
White mice weighing approximately 23-28 g were used throughout 
this study. Animals were allowed, at least 72 h after delivery, to acclimatize 
to laboratory surroundings before experimentation.  
2.10.5.2. Minimum lethal dose determination (MLD)  
  The minimum lethal dose, the lowest dilution of organisms at which 
100% mortality occurred, was determined by intraperitoneal injection of 
groups of mice (three per group) with 0.5 ml of bacteria in Mueller-Hinton 
broth at serial 10-fold dilutions. 
Animals were observed for 24 hours, and the rate and number of 
deaths at each dilution were recorded. 
For each MLD determination, a control group of mice received 
normal saline instead of the bacterial suspension.  
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2.10.5.3. Effect of single and combination antibiotics on different phases 
of bacterial growth  
The aim of these experiments was to determine the optimum time to 
use a single effective antibiotic and a combination of two antibiotics in vivo. 
2.10.5.4. Experimental infection 
Infection was produced in by intraperitoneal injection of 0.1 ml of 
broth containing approximately 1.2x107 CFU of bacteria per ml (10xMLD). 
2.10.5.5. Antibiotics treatment. 
The mice were divided at random into three groups; each group 
contained three sub groups each consisting of three animals. 
  In the first group of experiments (group 1), 0.1 ml of tetracycline was 
administered intravenously at 0 h (= time of infection) and three hours 
afterwards at the indicated dose of 25 mg/kg of body weight to the first sub 
group.  
The second sub group set of experiments 0.1 ml of erythromycin was 
administered intravenously at 0 h (= time of infection) and three hours 
afterwards at the indicated dose of 30 mg/kg of body weight to the second 
sub group.  
 The last sub group was performed with erythromycin and tetracycline 
in combination.  
For each sub group, a control group of mice received normal saline 
instead of the bacterial suspension.  
Animals were observed for 24 hours, and the rate and number of 
deaths at each dilution were recorded. 
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CHAPTER  THREE 
RESULTS 
 
3.1 Identification of isolates 
  Ten Gram negative isolates belonging to the genera Escherichia 
Klebsiella, Pseudomonas, Enterobacter proved to be resistant when 
subjected to preliminary sensitivity tests were chosen from a large number of 
isolates. Pasteurella which was found to be sensitive to most antibiotics was 
chosen for comparison. 
The isolates were identified following (Forbes et al., 1998).The 
identification was confirmed using API 20 identification kits as illustrated 
by Plate 1 (a-j)  
Table 6: Results of the  additional biochemical tests suggested by the 
manufacturer 
Isolate (NO2) (MOB) ( McC) (OF-F) 
E. coli(1) + + - + 
E. coli(3) + + - + 
E. coli(5-1) + + - + 
E. coli(9) + + - + 
E. coli(K) + + - + 
Klebsiella pneumoniae/10 + - - + 
Klebsiella pneumoniae /M + - - + 
Klebsiella pneumoniae /J + - - + 
Enterobacter 267   + + - + 
Pseudomonas (5) + + + + 
Pasteurella multocida + - - + 
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Supplementary tests shown in Table 6:  
? (NO2)   reduction of nitrates to nitrites 
? (MOB)   motility 
? ( McC)   growth on MacConkey agar. 
? (OF-O)   glucose  oxidation  
The results shown in Table 3-2 confirm the identification of the providers. 
 
Table 7: Results of identification of studied isolates. 
No. Present study isolate Confirmatory Result 
1. E. coli(1) E. coli 
2. E. coli(3) E. coli 
3. E. coli(5-1) E. coli 
4. E. coli(9) E. coli 
5. E.coli(K) E. coli 
6. Klebsiella pneumoniae/10 Klebsiella pneumoniae 
7. Klebsiella pneumoniae/M Klebsiella pneumoniae 
8. Klebsiella pneumoniae/J Klebsiella pneumoniae 
9. Enterobacter 267 Enterobacter  
10. Pseudomonas 5 Pseudomonas  
11. Pasteurella multocida Pasteurella multocida 
 
 
 
 
3.2 Effect of Antibiotics  
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3.2.1. Determination of Minimum Inhibitory Concentration (MIC) 
for single antibiotic. 
Tables (8) to (18) show the minimum inhibitory concentrations 
(MICs) of the nine antibiotics used for the eleven study isolates .Most of the 
isolates were found to be highly resistant to all of the nine antibiotics (MIC 
>512µg/ml) except 
1. E.coli (1): MIC for Ciprofloxacin = 512 µg/ml and Trimethoprim = 
256 µg/ml  
2. E.coli (3) and E.coli (5):MIC for Trimethoprim= 256 µg/ml  
3. E.coli (9) MIC for Ciprofloxacin=256 µg/ml , Tetracycline 
=128µg/ml and Trimethoprim=256 µg/ml 
4. E.coli (K) MIC for Ciprofloxacin =512 µg/ml ,Trimethoprim 
=256µg/ml 
5. Klebsiella pneumoniae (10) , MIC for  Ciprofloxacin = 512 µg/ml 
Trimethoprim =256 µg/ml 
6. Klebsiella pneumoniae (M) MIC for Ciprofloxacin = 512 µg/ml 
Trimethoprim =256 µg/ml and Tetracycline = 32. µg/ml 
7. Klebsiella pneumoniae (J) MIC for  Ciprofloxacin = 256 µg/ml 
Erythromycin= 128 µg/ml and Trimethoprim =256 µg/ml 
8. Enterobacter (267) MIC for Tetracycline = 32 µg/ml, Ciprofloxacin 
=128 µg/ml and Trimethoprim =256µg/ml 
9. Pseudomonas MIC for Ciprofloxacin =0.25 µg/ml), Tetracycline =16 
µg/ml, Erythromycin =64 µg/ml) and Trimethoprim =256 µg/ml. 
10. Pasteurella multocida MIC for Ciprofloxacin MIC =0.00023 µg/ml 
Cloxacillin =0. 5 µg/ml, Erythromycin =2.0 µg/ml, Tetracycline =4 
µg/ml, Ampicillin =32 µg/ml, and Amoxicillin =64 µg/ml. 
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3.2.2. Determination of Fractional Inhibitory Concentration (FIC) 
for combination of two antibiotics. 
Tables (19 to 29) show that the following combinations were used in these 
experiments. Their action was investigated on all the studied isolates.  
xii. Ampicillin and Amoxicillin     
xiii.  Ampicillin and Ciprofloxacin  
xiv. Ampicillin and Cloxacillin 
xv. Sulphamethoxazole and Trimethoprim 
xvi. Cephalexin and Ciprofloxacin 
xvii. Cephalexin and Amoxicillin 
xviii. Tetracycline and Erythromycin 
xix. Tetracycline and Amoxicillin 
xx. Tetracycline and Sulphamethoxazole 
xxi. Tetracycline and Trimethoprim 
xxii. Tetracycline  and Ciprofloxacin 
 The tables suggest that these antibiotics in combinations in vitro may act 
substantially as compared to individuals in their activity. 
Those which had shown effective results less than 128/128 µg/ml are 
summarized in Table (30). 
Using data presented in table (31) The Fractional Inhibitory Concentrations 
for the combinations where calculated and results were presented in Table 
(30).  
 
Table (31) shows the following.  
1-The combination of Tetracycline and Erythromycin has synergistic effect 
on E. coli (3), E. coli (5), Klebsiella pneumoniae M, Enterobacter, 
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Pseudomonas 5, and Pasteurella multocida. (FIC=0.3125, 0.25391, 0.03125, 
0.07813, 0.25 and 0.125 respectively). The same combination was found to 
be indifferent to E. coli (1) (FIC=1.00391). 
2- The combination of Tetracycline and Ciprofloxacin has synergistic effect 
on Klebsiella pneumoniae M, and Enterobacter, (FIC=0.07031, 0.07813). 
and indifferent on Klebsiella pneumoniae J( FIC=0.50391) 
3- Checkerboard of Ampicillin combined with Ciprofloxacin showed 
synergistic effect on Klebsiella pneumoniae 10, (FIC=0.025391).  
4- Ampicillin and Amoxicillin are synergistic on Klebsiella pneumoniae j, 
(FIC=0.025391). 
5-Using Ampicillin with Amoxicillin as well as using Sulphamethaxole with 
Trimethoprim are synergistic on Pseudomonas 5(FIC=0.00781 and 
0.014063) respectively. 
6-While using Tetracycline in combination with Trimethoprim has 
antagonistic effect on both Pseudomonas 5 and Klebsiella pneumoniae M. 
(FIC=8.00781 and 4.00781). 
3.3. The growth curves constructions   
3.3. 1. The standard growth curves 
The standard growth curves of all isolates were constructed from the 
results of the viable counts without antibiotic over 24 hours and presented as 
control in Figs (1-52)  
3.3.2. Time-killing curve using single antibiotic 
In determining the minimum inhibitory concentrations (MICs), nine of 
the present studied isolates were found to be affected by ciprofloxacin. at 
high concentrations whereas ten isolates were found to be affected by 
trimethoprim. However, four and three isolates were affected by tetracycline 
and erythromycin at high concentrations respectively. Only one isolate, 
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Pasteurella multocida, was affected by amoxicillin, ampicillin and 
cloxacillin.  
These results were used for construction of time –killing curves using 
single antibiotic. The results are shown in Figures (1-30). In each Figure the 
effect 0.5 X MIC, 1 X MIC and 2 X MIC of antibiotic over the growth of the 
tested isolate for 24 hours were compared with the control (growth without 
addition of antibiotic).  
3.3.2.1 Time-killing curve using ciprofloxacin 
? Fig (1) shows that E. coli (1) was affected with ciprofloxacin at MIC= 
512 µg/ml. When using twice MIC concentration of the antibiotic the 
number of viable bacterial count at time 2 hours decrease and then 
increase reaching maximum after 4 hours and then decrease again 
reaching minimum at 8 hours 
? Fig (2) which shows that using ciprofloxacin (MIC=256 µg/ml) affect 
E. coli (9) using 1MIC decrease the number of viable cells starting 
from the sixth hour. 
? Fig (3) shows that for E. coli (K) MIC for ciprofloxacin =512 µg/ml 
the figure shows that when using 2MIC the number of viable bacterial 
cells decreases from time zero. 
? (Fig 4) shows that for Klebsiella pneumoniae (J) MIC for  
ciprofloxacin = 256 µg/ml  the number of viable cells decrease when 
using 1MIC and 2MIC while it increases after the 8th hour when using 
0.5 MIC 
?  (Fig 5) shows that shows that the number of viable counts of  
Klebsiella pneumoniae (M) when using  ciprofloxacin MIC= 512 
µg/ml decreased after 2 hours when using 1MIC and 2MIC ,when 
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testing 0.5MIC the viable counts decrease after 2hours and increased 
again after 8 hours.  
?  (Fig 6) shows that MIC for  ciprofloxacin = 512 µg/ml for Klebsiella 
pneumoniae (10) , the number of viable cells decreased after 2 hours 
in all concentrations, it starts to increase again after 8 hours when 
using 0.5 MIC. 
? As for Enterobacter (267) it is sensitive to ciprofloxacin (MIC=128 
µg/ml (Fig 7) using 0.5 MIC decreased the viable count after 6 hours. 
? Pseudomonas (5) is susceptible to ciprofloxacin (MIC =0.25 µg/ml) 
as shown in (Fig 8) the number of count decreased when using all 
different concentrations. 
? Pasteurella multocida is most sensitive to ciprofloxacin (MIC 
=0.00023 µg/ml) (Fig 9) which shows that using 0.5MIC has no 
effect. When using 1MIC and 2XMIC the number of viable cells start 
to decrease immediately after the addition of antibiotic reaching the 
lowest count after 8 hours  
3.3.2.2. Time-killing curve using trimethoprim 
? Fig (10) demonstrates the effect of trimethoprim (MIC = 128) on E. 
coli (1). It shows that when using 0.5 MIC the maximum number of 
bacterial cells were killed at 4 hours, after which the number of cells 
increased .Using 2MIC (512 µg/ml) the viable cells slightly  
decreased reaching minimum after 2 hours after which no increase 
occurred. 
? Fig (11) shows that E. coli (3) drastically affected when using the 
concentration of 1 MIC of trimethoprim (128µg/ml), the number of 
viable cells starts increased again after 8 hours. 
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? (Fig 12) shows E. coli (5-1) is also affected by 1 MIC of trimethoprim 
(128µg/ml) the number of cells starts to increase after 6 hours. 
? (Fig 13) shows when  using trimethoprim MIC=256 µg/ml has no 
noticed effect on E. coli (9) 
? (Fig 14) shows that trimethoprim MIC=128µg/ml has no effect on E. 
coli (K). 
? (Fig 15) shows that using trimethoprim (MIC=128µg/ml with 
Klebsiella pneumoniae (10) the number of viable cells decrease after 2 
hours of incubation and start to  increased after 6 hours when using 
2MIC concentration.  
? When studying the effect of trimethoprim (MIC =256 µg/ml) on 
Klebsiella pneumoniae (M) the viable cells count was reduced till 4 
hour and increase reaching its normal growth at 8hours (Fig 16)  
? Using trimethoprim (MIC =256 µg/ml) with Klebsiella pneumoniae 
(J) the viable cells count was reduced till 4 hour and increased 
reaching its normal growth at 8 hours as presented in(Fig 17) 
? (Fig 18) shows that when trimethoprim acts on Enterobacter (267) 
MIC=256µg/ml has no difference in the mode of growth using 
different concentrations. 
? (Fig 19)shows the effect of trimethoprim(MIC=64µg/ml) on 
Pseudomonas(5) , the organism was most sensitive when using 2  X 
MIC at 6 hours where the viable cells decreased  reaching minimum at 
8  hours, but the viable cells increased again thereafter. 
 
3.3. 2.3. Time-killing curve using tetracycline  
?  (Fig 20) shows that when testing 2 X MIC of tetracycline 
(MIC=128µg/ml) on E. coli (9) the number of viable cells was 
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reduced after 2 hours and no re-growth was observed. Testing 1 X 
MIC tetracycline there was no increase in the viable cell count, while 
using 0.5 X MIC the viable cells decreased slightly reaching 
minimum at 8 hours and re-growth occurred at 24 hours. 
? (Fig 21) shows that when 1  X MIC of  tetracycline = 32 µg/ml was 
used with Klebsiella pneumoniae (M) the cell count slightly decreased 
after 6 hours incubation, then increased again. While using other 
concentrations (0.5and 2 X MIC) there were no change in the number 
of viable cells.  
? The effects of tetracycline (MIC= 32 µg/ml) on Enterobacter (267) 
are shown in (Fig 22) when using 0.5 MIC the viable cells decreased 
from the second hour reaching minimum after 4 hours and increased 
again, using 1MIC the minimum count was obtained after 2 hours and 
increased after 8 hours, at 24hours the number of cells is less than at 
zero time, while using 2MIC the reduction of viable cells start at 6 
hours reaching minimum after 8 hours and increased again. 
? However testing tetracycline (MIC =16 µg/ml) Pseudomonas(5) 
shows that the number of viable cells decreased after 4 hours reaching 
minimum at 6 hours and it increased again.(Fig 23). 
? The effect of tetracycline (MIC =4 µg/ml)on Pasteurella multocida of 
is the same as the effect as the effect of ciprofloxacin (Fig 24) which 
shows that using 0.5MIC has no effect. When using 1XMIC and 
2XMIC the number of viable cells started to decrease immediately 
after the addition of antibiotic reaching the lowest count after 8 hours. 
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3.3.2.4. Time-killing curve using erythromycin. 
? (Fig 25) shows that using erythromycin (MIC= 128 µg/ml) had no 
effect along the time on Klebsiella pneumoniae (J) in all 
concentrations. 
? Pseudomonas was also  affected by erythromycin (MIC=64 µg/ml) 
(Fig 26) which shows that using 2 X MIC the viable bacterial cells 
decreased to 2 hours and after that it increased.  
? Pasteurella multocida was affected by erythromycin (MIC =2.0 
µg/ml) (Fig 27), 
3.3.2.5. Time-killing curve using other single antibiotics  
Pasteurella multocida was found to be affected by other antibiotics 
that had been mentioned. 
?  Amoxicillin (MIC =64 µg/ml) (Fig 28), ampicillin (MIC =32 µg/ml) 
(Fig 29), cephalexin (MIC =1 µg/ml) (Fig 30)  and cloxacillin (MIC 
=0.5 µg/ml), and. (Fig 31) all gave the same results, where the 
organism was not affected by 0.5  X MIC and affected by 1 X MIC 
and 2 X MIC.  
3.3.3. Time-killing curve with combination of two antibiotics 
In determining the fractional inhibitory concentrations ( FICs ), seven of 
the present studied isolates were found to be affected synergistically by the 
combination of tetracycline and erythromycin whereas three of the present 
were found to be affected by the combination of ciprofloxacin and 
tetracycline. However, two were found to be affected by ampicillin and 
ciprofloxacin .Synergistic effect was also found in one isolate when using 
ampicillin together with amoxicillin, cephalexin with ciprofloxacin and 
sulphamethaxzole with trimethoprim. 
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Antagonistic effects were observed when tetracycline was used in 
combination with trimethoprim in two different isolates.  
These results were used for construction time killing curves using two 
antibiotics. The concentrations used were the (MICs) of combination. These 
results are represented in figures (32-48). Each figure represents the mode of 
growth within 24 hours in the presence of the combination of two 
antibiotics, which was plot with the standard curve of growth (control) of the 
studied organism. 
Fig (32), Using tetracycline 2 µg/ml + erythromycin 128 µg/ml 
against E. coli (1) showed that there was no increase in the bacterial 
viable count up to 6hours slightly decreased at 8 hours after 24 hours no 
growth was achieved. 
Fig (33) showed that using tetracycline 32µg/ml + erythromycin 
32µg/ml, against E. coli (3) there was no increase of viable cell count up 
to 8 hours at 24 hours no growth was achieved 
Fig (34) using tetracycline 2µg/ml + erythromycin 32µg/ml against E. 
coli (5) and Fig (35) tetracycline 2µg/ml + erythromycin 2µg/ml against 
Enterobacter (267) show that the number of cells decreased after 8 hours.  
Fig (36) Klebsiella pneumoniae (M) tetracycline 8µg/ml + 
erythromycin 2µg/ml, there was a gradual decrease in the cell count. 
Fig (37) when using tetracycline 2µg/ml + erythromycin 2µg/ml 
against Pseudomonas aeruginosa no growth was observed after 6 hours 
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Fig (38): shows that when using tetracycline 0.25µg/ml + 
erythromycin 0.125µg/ml against Pasteurella multocida no growth was 
observed after 4 hours. 
Fig (39): shows that Klebsiella pneumoniae (J) using tetracycline 
2µg/ml + ciprofloxacin 128µg/ml, gave no increase in the number of 
viable cells was observed. 
Fig (40) shows that when using tetracycline 2µg/ml +ciprofloxacin 
2µg/ml against Klebsiella pneumoniae (M) the maximum number of 
bacteria were killed between 4and 6 hours. 
Fig (41) Enterobacter when using ciprofloxacin 2µg/ml +tetracycline 
2µg/ml the viable cell increased at the beginning and after 4 hours 
decreased. 
Fig (42) shows that using ampicillin 2µg/ml +ciprofloxacin 128µg/ml 
against Klebsiella pneumoniae (10) the viable cell count increased at the 
beginning and decreased drastically after 6 hours. 
Fig (43) shows that using ampicillin 2µg/ml + ciprofloxacin 2µg/ml 
against Pseudomonas aeruginosa resulted in complete death of the cells 
at 4 hours.  
Fig (44) Klebsiella pneumoniae M ampicillin 2µg/ml + amoxicillin 
2µg/ml the viable cell count increased at the beginning and decreased 
drastically after 6 hours 
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Fig (45) shows that when using cephalexin 2µg/ml + ciprofloxacin 
128µg/ml against Klebsiella pneumoniae (M) the maximum number of 
bacteria were killed between 6 and 8 hours. 
Fig (46) shows that using sulphamethoxazole 8µg/ml + trimethoprim 
32µg/ml against Pseudomonas aeruginosa no increase in the viable cell 
count occurred. 
Fig (47) shows the effect of using tetracycline 128µg/ml + 
trimethoprim 2µg/ml against Klebsiella pneumoniae (M) the number of 
viable cells decreased from 2 hours and increased again after 4 hours. 
Fig (48) represents the mode of growth of Pseudomonas aeruginosa 
in a medium containing tetracycline 128µg/ml +trimethoprim 2µg/ml, the 
viable cells decreased between 6and 8 hours and increased after that. 
3.4. Effect of using antibiotics on bacterial growth phases 
In these experiments the effects of addition of antibiotics on already 
growing cells of Pasteurella multocida at different phases of growth was 
studied. We studied erythromycin (MIC-=2µg/ml) and tetracycline 
(MIC=4µg/ml) growing in test tubes and in animals each alone and in 
combination (conc=0.25µg/ml Erythromycin=0.125µg/ml Tetracycline). 
To study their effect on animals the minimum lethal dose (MLD) was 
determined. The minimum lethal dose was found to be =1.2 x 106 CFU/ml. 
Therefore, an inoculum size of 1.2x107 (approximately 10 times the 
minimum lethal dose) was selected for in vivo studies. 
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3.4.1. In vitro studies on effect of using single and combination 
antibiotics on different bacterial growth phases. 
The results were represented in (Figs.49, 50 and 51). Fig. ( 49) shows 
that the maximum numbers of viable cells of Pasteurella multocida were 
killed when erythromycin was added to 6 hours growing cells. Addition of 
tetracycline resulted in decrease in the viable cell count at 1-2 hours and 6 
hours Fig (50). When combination of two antibiotics with lower 
concentration than each singly was used, the maximum numbers of bacteria 
were killed at 2 hours and 6 hours Fig. (51)  
3.4.2. In vivo studies on effect of using one or two antibiotics on different 
bacterial growth phases. 
The percentage of survival animals when treated with either 
erythromycin or tetracycline or combination of the two antibiotics are shown 
in Fig (52).The figure shows that 100% of the animals survived when the 
combination was used either half an hour after infection or after 8 hours. 
Using the combination after 3 hours of infection resulted in the cure of 67% 
of the infected animals.  
When using erythromycin alone, only 33% of the infected animals 
survived when the dose was administrated after 3 hours of infection. Where 
as when using tetracycline alone, 33% of the animals survived when the 
dose is administrated at the beginning of infection. 
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Plat 1 : Identification of E. coli (1) using API 20 E 
 
 
 
 
 
Plat 2 : Identification of E. coli (3) using API 20 E 
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Plat 3 : Identification of E. coli (5-1) using API 20 E 
 
 
 
 
 
Plat 1 (d): Identification of E. coli(9) using API 20 E 
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Plat 1 (e): Identification of E. coli (K) using API 20 E 
 
 
 
 
  
Plat 1 (f): Identification of Klebsiella pneumoniae/10 using API 20 E 
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Plat 4 : Identification of Klebsiella pneumoniae/M using API 20 E 
 
 
 
  
Plat 5 : Identification of Klebsiella pneumoniae/J using API 20 E 
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Plat 7 : Identification of Enterobacter (267) using API 20 E 
 
 
 
 
Plat 8 : Identification of Pseudomonas (5) using API 20 E 
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Table 8 :     In vitro MIC for single antibiotic against E. coli (1) 
Antimicrobial agent MIC (Range Tested*) (µg/ml) MIC(µg/ml) 
 Amoxicillin 0.25-1024 >1024 
 Ampicillin 0.25-1024 >1024 
 Cephalexin 0.25-1024 >1024 
 Ciprofloxacin 0.25-1024 512 
 Cloxacillin 0.25-1024 >1024 
 Erythromycin 0.25-128** >128 
 Sulphamethoxazole 0.25-128** >128 
 Tetracycline 0.25-1024 >1024 
 Trimethoprim 0.25-1024 256 
 
*Range tested concentrations (µg/ml);…..1024,512,256,128,64,32,16,8,4,2,1,0.5,0.25. 
**Higher concentrations insoluble 
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Table 9 : In vitro MIC for single antibiotic against E. coli (3) 
Antimicrobial agent MIC (Range Tested*) (µg/ml) MIC(µg/ml) 
 Amoxicillin 0.25-1024 >1024 
 Ampicillin 0.25-1024 >1024 
Cephalexin 0.25-1024 >1024 
 Ciprofloxacin 0.25-1024 >1024 
 Cloxacillin 0.25-1024 >1024 
 Erythromycin 0.25-128** >128 
Sulphamethoxazole 0.25-128** >128 
 Tetracycline 0.25-1024 >1024 
Trimethoprim 0.25-1024 256 
 
*Range tested concentrations (µg/ml);…..1024,512,256,128,64,32,16,8,4,2,1,0.5,0.25. 
** Higher concentrations insoluble 
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Table 10 :   In vitro MIC for single antibiotic against E. coli (5) 
Antimicrobial agent MIC (Range Tested*) (µg/ml) MIC(µg/ml) 
 Amoxicillin 0.25-1024 >1024 
 Ampicillin 0.25-1024 >1024 
Cephalexin 0.25-1024 >1024 
 Ciprofloxacin 0.25-1024 >1024 
 Cloxacillin 0.25-1024 >1024 
 Erythromycin 0.25-128** >128 
Sulphamethoxazole 0.25-128** >128 
 Tetracycline 0.25-1024 >1024 
Trimethoprim 0.25-1024 256 
 
*Range tested concentrations (µg/ml);…..1024,512,256,128,64,32,16,8,4,2,1,0.5,0.25. 
** Higher concentrations insoluble 
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Table 11: In vitro MIC  for single antibiotic against E. coli (9) 
Antimicrobial agent MIC (Range Tested*) (µg/ml) MIC(µg/ml) 
 Amoxicillin 0.25-1024 >1024 
 Ampicillin 0.25-1024 >1024 
Cephalexin 0.25-1024 >1024 
 Ciprofloxacin 0.25-1024 256 
 Cloxacillin 0.25-1024 >1024 
 Erythromycin 0.25-128** >128 
Sulphamethoxazole 0.25-128** >128 
 Tetracycline 0.25-1024 128 
Trimethoprim 0.25-1024 256 
 
*Range tested concentrations (µg/ml);…..1024,512,256,128,64,32,16,8,4,2,1,0.5,0.25. 
** Higher concentrations  insoluble  
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 Table 12: In vitro MIC  for single antibiotic against E. coli (K) 
 
Antimicrobial agent MIC (Range Tested*) (µg/ml) MIC(µg/ml) 
 Amoxicillin 0.25-1024 >1024 
 Ampicillin 0.25-1024 >1024 
Cephalexin 0.25-1024 >1024 
 Ciprofloxacin 0.25-1024 512 
 Cloxacillin 0.25-1024 >1024 
 Erythromycin 0.25-128** >128 
Sulphamethoxazole 0.25-128** >128 
 Tetracycline 0.25-1024 >1024 
Trimethoprim 0.25-1024 256 
 
*Range tested concentrations (µg/ml);…..1024,512,256,128,64,32,16,8,4,2,1,0.5,0.25. 
** Higher concentrations  insoluble  
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Table 13: In vitro MIC for single antibiotic against Klebsiella pneumoniae (10) 
 
Antimicrobial agent MIC (Range Tested*) (µg/ml) MIC(µg/ml) 
 Amoxicillin 0.25-1024 >1024 
 Ampicillin 0.25-1024 >1024 
Cephalexin 0.25-1024 >1024 
 Ciprofloxacin 0.25-1024 512 
 Cloxacillin 0.25-1024 >1024 
 Erythromycin 0.25-128** >128 
Sulphamethaxazole 0.25-128** >128 
 Tetracycline 0.25-1024 >1024 
Trimethoprim 0.25-1024 256 
  
 *Range tested concentrations (µg/ml);…..1024,512,256,128,64,32,16,8,4,2,1,0.5,0.25. 
  ** Higher concentrations insoluble 
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Table 14: In vitro MIC  for single antibiotic against Klebsiella 
pneumoniae (J) 
Antimicrobial agent MIC (Range Tested*) (µg/ml) MIC(µg/ml) 
 Amoxicillin 0.25-1024 >1024 
 Ampicillin 0.25-1024 >1024 
Cephalexin 0.25-1024 >1024 
 Ciprofloxacin 0.25-1024 256 
 Cloxacillin 0.25-1024 >1024 
 Erythromycin 0.25-128** 128 
Sulphamethoxazole 0.25-128** >128 
 Tetracycline 0.25-1024 >1024 
Trimethoprim 0.25-1024 256 
 *Range tested concentrations (µg/ml);…..1024,512,256,128,64,32,16,8,4,2,1,0.5,0.25. 
   ** Higher concentrations insoluble  
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Table 15: In vitro MIC for single antibiotic against Klebsiella pneumoniae (M) 
 
Antimicrobial agent MIC (Range Tested*) (µg/ml) MIC(µg/ml)
Amoxicillin 0.25-1024 >1024 
Ampicillin 0.25-1024 >1024 
Cephalexin 0.25-1024 >1024 
Ciprofloxacin 0.25-1024 256 
Cloxacillin 0.25-1024 >1024 
Erythromycin 0.25-128** >128 
Sulphamethoxazole 0.25-128** >128 
Tetracycline 0.25-1024 32 
Trimethoprim 0.25-1024 256 
 *Range tested concentrations (µg/ml);…..1024,512,256,128,64,32,16,8,4,2,1,0.5,0.25. 
  ** Higher concentrations insoluble 
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                             Table 16: In vitro MIC  for single antibiotic against Enterobacter (267) 
 
Antimicrobial agent MIC (Range Tested*) (µg/ml) MIC(µg/ml) 
 Amoxicillin 0.25-1024 >1024 
 Ampicillin 0.25-1024 >1024 
Cephalexin 0.25-1024 >1024 
 Ciprofloxacin 0.25-1024 128 
 Cloxacillin 0.25-1024 >1024 
 Erythromycin 0.25-128 >128 
Sulphamethoxazole 0.25-1024 >128 
 Tetracycline 0.25-1024 32 
Trimethoprim 0.25-1024 256 
                       *Range tested concentrations (µg/ml);…..1024,512,256,128,64,32,16,8,4,2,1,0.5,0.25  
 ** Higher concentrations insoluble 
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              Table 17: In vitro MIC for single antibiotic against Pseudomonas aeruginosa (5) 
 
Antimicrobial agent MIC (Range Tested*) (µg/ml) MIC(µg/ml)
 Amoxicillin 0.25-1024 >1024 
 Ampicillin 0.25-1024 >1024 
Cephalexin 0.25-1024 >1024 
 Ciprofloxacin 0.125-1024 0.25 
 Cloxacillin 0.25-1024 >1024 
 Erythromycin 0.25-128** 64 
Sulphamethoxazole 0.25-128** >128 
 Tetracycline 0.25-1024 16 
Trimethoprim 0.25-1024 256 
                             
 *Range tested concentrations (µg/ml); 1024,512,256,128,64,32,16,8,4,2,1,0.5,0.25,0.125 
                               ** Higher concentrations insoluble 
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                        Table 18: In vitro MIC for single antibiotic against Pasteurella multocida 
 
Antimicrobial agent MIC (Range Tested*) (µg/ml) MIC(µg/ml)
 Amoxicillin 0.25-128 64 
 Ampicillin 0.25-128 32 
Cephalexin 0.25-128 >128 
 Ciprofloxacin 0.000168-128 0.00023 
 Cloxacillin 0.25-128 0.5 
 Erythromycin 0.25-128 2 
Sulphamethoxazole 0.25-128 >128 
 Tetracycline 0.25-128 4 
Trimethoprim 0.25-128 >128 
 *Range tested concentrations (µg/ml): 
128,64,32,16,8,4,2,1,0.5,0.25,0.125,0.0625,0.0312,0.0312, 
0.0156, 0.0078,0.0039,0.0019,0.0009,0.00045,0.00023,0.00011 
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 Table 19: In vitro (MIC) for combination ampicillin /amoxycllin 
 
Organisms  MIC(µg/ml) 
E.coli(1) 4096/256, 
E.coli(3) 4096/259 
E.coli(5-1) 4096/1024 
E.coli(9) 4096/1024 
E.coli(K) 4096/1024 
Klebsiella pneumoniae(10) 2/128 
Klebsiella pneumoniae(M) 4096/256 
Klebsiella pneumoniae(J) 4096/4096 
Enterbacter( 267) 4096/256, 
Pseudomonas (5) 2.0/2.0 
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             Table 20: In vitro (MIC) for combination ampicillin/ciprofloxacin 
 
Organisms  MIC(µg/ml) 
E. coli(1) >4096/4096 
E .coli(3) >4096/4096 
E. coli(5-1) >4096/4096 
E .coli(9) >4096/4096 
E. coli(K) >4096/4096 
Klebsiella pneumonae/10 2/128 
Klebsiella pneumoniae/M >4096/4096 
Klebsiella pneumoniae/J >4096/4096 
Enterobacter 267 >4096/4096 
Pseudomonas 5 2/2 
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Table 21: In vitro (MIC) for combination ampicillin/cloxacillin 
 
Organisms MIC(µg/ml) 
  
E.coli(1) >4096/4096 
E.coli(3) >4096/4096 
E.coli(5-1) >4096/4096 
E.coli(9) >4096/4096 
E.coli(K) >4096/4096 
Klebsiella pneumoniae/10 >4096/4096 
Klebsiella pneumoniae/M >4096/4096 
Klebsiella pneumoniae/J >4096/4096 
Enterobacter 267 >4096/4096 
Pseudomonas 5 >4096/4096 
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                 Table 22: In vitro (MIC)  for combination sulphamethaxole /trimethoprim 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Organisms MIC(µg/ml) 
E. coli(1) >4096/4096 
E. coli(3) >4096/4096 
E. coli(5-1) >4096/4096 
E. coli(9) >4096/4096 
E. coli(K) >4096/4096 
Klebsiella pneumonae/10 >4096/4096 
Klebsiella pneumoniae/M >4096/4096 
Klebsiella pneumoniae/J >4096/4096 
Enterobacter 267 >4096/4096 
Pseudomonas 5 8/32 
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Table 23: In vitro (MIC) for combination cephalexin/ciprofloxacin 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Organisms  MIC(µg/ml) 
E. coli(1) >4096/4096 
E .coli(3) >4096/4096 
E. coli(5-1) >4096/4096 
E. coli(9) >4096/4096 
E. coli(K) >4096/4096 
Klebsiella pneumoniae/10 >4096/4096 
Klebsiella pneumoniae/M 2/128 
Klebsiella pneumoniae/J >4096/4096 
Enterobacter 267 2/128 
Pseudomonas(5) 2/2 
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Table 24: In vitro (MIC) for combination cephalexin/amoxicillin 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Organisms MIC(µg/ml) 
E.coli(1) >4096/4096 
E.coli(3) >4096/4096 
E.coli(5-1) >4096/4096 
E.coli(9) >4096/4096 
E.coli(K) >4096/4096 
Klebsiella Pneumonae/10 >4096/4096 
Klebsiella Pneumonae/M >4096/4096 
Klebsiella Pneumonae/J >4096/4096 
Enterbacter 267 >4096/4096 
Pseudomonas 5 >4096/4096 
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Table 25: In vitro (MIC) for combination tetracycline/erythromycin 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Organisms MIC(µg/ml) 
E. coli(1) 2/128 
E. coli(3) 32/32 
E. coli(5-1) 2/32 
E. coli(9) 128/8 
E. coli(K) >4096/4096 
Klebsiella pneumoniae/10 >4096/4096 
Klebsiella pneumoniae/M 8/2 
Klebsiella pneumonae/J 128/128 
Enterobacter 267 2/2 
Pseudomonas (5) 2/8 
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Table 26: In vitro (MIC) for combination tetracycline /amoxicillin 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Organisms  MIC(µg/ml) 
E. coli(1) >4096/4096 
E. .coli(3) >4096/4096 
E. coli(5-1) >4096/4096 
E .coli(9) >4096/4096 
E. coli(K) >4096/4096 
Klebsiella pneumoniae/10 >4096/4096 
Klebsiella pneumoniae/M 32/2 
Klebsiella pneumoniae/J >4096/4096 
Enterobacter 267 32/2 
Pseudomonas 5 128/2 
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Table 27: In vitro (MIC) for combination tetracycline / sulphamethaxole  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Organisms  MIC(µg/ml) 
E.coli(1) >4096/4096 
E.coli(3) >4096/4096 
E.coli(5-1) >4096/4096 
E.coli(9) 128/2 
E.coli(K) >4096/4096 
Klebsiella pneumoniae/10 >4096/4096 
Klebsiella pneumoniae/M 32/2 
Klebsiella pneumoniae/J >4096/4096 
Enterobacter 267 >4096/4096 
Pseudomonas 5 32/2 
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Table 28: In vitro (MIC) for combination tetracycline/trimethoprim 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Organisms MIC(µg/ml) 
E .coli(1) >4096/4096 
E. coli(3) >4096/4096 
E. coli(5-1) >4096/4096 
E. coli(9) >4096/4096 
E. coli(K) >4096/4096 
Klebsiella pneumoniae/10 >4096/4096 
Klebsiella pneumoniae/M 128/2 
Klebsiella pneumoniae/J >4096/4096 
Enterobacter 267 32/2 
Pseudomonas 5 32/2 
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Table 29: In vitro (MIC) for combination tetracycline / sulphamethoxazole  
 
Organisms MIC(µg/ml) 
E. coli(1) >4096/4096 
E. coli(3) >4096/4096 
E. coli(5-1) >4096/4096 
E. coli(9) >4096/4096 
E. coli(K) >4096/4096 
Klebsiella pneumoniae/10 >4096/4096 
Klebsiella pneumoniae/M 2/2 
Klebsiella pneumoniae/J 2/128 
Enterobacter 267 2/2 
Pseudomonas 5 2/2 
 
 
 
 
 
 130
 
Table 30: Effective MIC for combinations of antibiotics 
 
Organism Combinations MIC (µg/ml)
Pseudomonas 5 ampicillin /amoxicillin 2/2 
Pseudomonas 5 sulphamethoxazole/trimethoprim 8/32 
Klebsiella pneumoniae (M) cephalexin /ciprofloxacin 2/128 
Klebsiella pneumoniae (10) ampicillin /ciprofloxacin 2/128 
Klebsiella pneumoniae(M) ampicillin /amoxicillin 2/128 
E.coli 1 tetracycline/erythromycin 2/128 
E.coli 3 tetracycline/erythromycin 32/32 
E.coli 5 tetracycline/erythromycin 2/32 
Klebsiella pneumoniae(M) tetracycline/erythromycin 8/2 
Entrobacter (267) tetracycline/erythromycin 2/2 
Pseudomonas 5 tetracycline/erythromycin 2/8 
Klebsiella pneumoniae(M) tetracycline/ciprofloxacin 2/2 
Klebsiella pneumoniae(J) tetracycline/ciprofloxacin 2/128 
Enterobacter (267) tetracycline/ciprofloxacin 2/2 
Pseudomonas(5) tetracycline/trimethoprim 128/2 
Klebsiella pneumoniae(M) tetracycline/trimethoprim 128/2 
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Table (31): Fractional Inhibitory Concentration (FIC) for combination 
of two antibiotics 
Organism Combinations MIC µg/ml MIC (A)  Drug MIC (B)  Drug B FIC 
    combination combination alone combination alone   
Pseudomonas 5 ampicillin /amoxicillin 2/2 2 512 2 512 0.0078 
Pseudomonas 5 sulphamethoxazole/ trimethoprim 8/32 8 512 32 256 0.1406 
Klebsiella pneumoniae M cephalexin /ciprofloxacin 2/128 2 512 128 256 0.5039 
Klebsiella pneumoniae 10 ampicillin /ciprofloxacin 2/128 2 512 128 512 0.2539 
Klebsiella pneumoniae j ampicillin /amoxicillin 2/128 2 512 128 512 0.2539 
E. coli 1 tetracycline/erythromycin 2/128 2 512 128 128 1.0039 
E. coli 3 tetracycline/erythromycin 32/32 32 512 32 128 0.3125 
E. coli 5-1 tetracycline/erythromycin 2/32 2 512 32 128 0.2539 
Klebsiella pneumoniae M tetracycline/erythromycin 8/2 8 512 2 128 0.0313 
Enterobacter 267 tetracycline/erythromycin 2/2 2 32 2 128 0.0781 
Pseudomonas 5 tetracycline/erythromycin 2/8 2 16 8 64 0.25 
Klebsiella M tetracycline/ciprofloxacin 2/2 2 32 2 256 0.0703 
Klebsiella J tetracycline/ciprofloxacin 2/128 2 512 128 256 0.5039 
Enterobacter 267 tetracycline/ciprofloxacin 2/2 2 32 2 128 0.0781 
Pseudomonas 5 tetracycline/trimethoprim 128/2 128 16 2 256 8.0078 
Klebsiella M tetracycline/trimethoprim 128/2 128 32 2 256 4.0078 
Pasteurella multocida tetracycline/erythromycin 0.25/0.125 0.25 4 0.125 2 0.125 
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Table (31): Fractional Inhibitory Concentration (FIC) for combination 
of two antibiotics 
Organism Combinations MIC µg/ml MIC (A)  Drug MIC (B)  Drug B FIC 
    combination combination alone combination alone   
Pseudomonas 5 ampicillin /amoxicillin 2/2 2 512 2 512 0.0078 
Pseudomonas 5 sulphamethoxazole/ trimethoprim 8/32 8 512 32 256 0.1406 
Klebsiella pneumoniae M cephalexin /ciprofloxacin 2/128 2 512 128 256 0.5039 
Klebsiella pneumoniae 10 ampicillin /ciprofloxacin 2/128 2 512 128 512 0.2539 
Klebsiella pneumoniae j ampicillin /amoxicillin 2/128 2 512 128 512 0.2539 
E. coli 1 tetracycline/erythromycin 2/128 2 512 128 128 1.0039 
E. coli 3 tetracycline/erythromycin 32/32 32 512 32 128 0.3125 
E. coli 5-1 tetracycline/erythromycin 2/32 2 512 32 128 0.2539 
Klebsiella pneumoniae M tetracycline/erythromycin 8/2 8 512 2 128 0.0313 
Enterobacter 267 tetracycline/erythromycin 2/2 2 32 2 128 0.0781 
Pseudomonas 5 tetracycline/erythromycin 2/8 2 16 8 64 0.25 
Klebsiella M tetracycline/ciprofloxacin 2/2 2 32 2 256 0.0703 
Klebsiella J tetracycline/ciprofloxacin 2/128 2 512 128 256 0.5039 
Enterobacter 267 tetracycline/ciprofloxacin 2/2 2 32 2 128 0.0781 
Pseudomonas 5 tetracycline/trimethoprim 128/2 128 16 2 256 8.0078 
Klebsiella M tetracycline/trimethoprim 128/2 128 32 2 256 4.0078 
Pasteurella multocida tetracycline/erythromycin 0.25/0.125 0.25 4 0.125 2 0.125 
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Figure (1): Effect of ciprofloxacin on E . coli (1)
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FIG.( 2).  Effect of  ciprofloxacin E.coli  (9)
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Figure (3): Effect of ciprofloxacin on E.coli (k)
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Figure (4) : Effect of ciprofloxacin on Klebsiella pneumoniae (J)
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Figure (5): Effect of ciprofloxacin on Klebsiella pneumoniae  (M)
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Figure (6): Effect of ciprofloxacin on Klebsiella pneumoniae (10) 
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Figure (7): Effact of ciprofloxacin on Entrobacter  267
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Figure (8): Effect of ciprofloxacin on Pseudomonas (5)
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Figure (9) Effect of ciprofloxacin on Pasteurella multocida
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Figure (10) the effect of trimethoprim against E.coli (1)
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Figure(12) : Effect of trimethoprim on E.coli  (5-1)
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Figure (11) Effect of trimethoprim E.coli  (3)
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Figure (13): Effect of trimetoprim on  E.coli  (9)
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Figure(14): Effect of trimethoprim on E.coli  (K)
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Figure (15) : Effect of trimethoprim against Klebsiella pneumoniae  (10)
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Figure (16):Effect of trimethopim on Klebsiella pneumonae ( M)
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Figure (17):Effect of trimethoprim against Klebsielle pneumonae (J)
0
1
2
3
4
5
6
7
8
9
10
0 2 4 6 8 10 12 14 16 18 20 22 24
Time ( Hours)
L
og
10
 C
FU
/m
l
0.5MIC(128µgm/ml)
1MIC(256µgm/ml)
Control
* 2 MIC insoluble
 
 
Figure (18:)Effect of trimethoprin on Enterbacter  (267)
* 2 MIC insoluble
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Figure (19) : Effect of trimethoprim on Pseudomonas  (5)
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Figure(20): Effect of tetracycline on E.coli (9)
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Figure (21): Effect of tetracycline on Klebsiella pneumoniae  (M)
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Figure (22): Effect of tetracycline on Enterobacter (267)
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Figure (23):Effect of tetracycline on Pseudomonas  (5)
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Figure(24): Effect of tetracycline on Pasteurella multocida
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Figure(25): Effect of erythromycin on Klebsiella (J)
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Figure (26):Effect of Erythromycin on Pseudomonas  (5)
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Figure (27): Effect of erythromycin on Pasteurella multocida
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Figure (28): Effect of amoxycillin on Pasteurella  multocida
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Figure (29):Effect of ampicillin on Pasteurella multocida
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Figure (30): Effect of cephalexin against Pasteurelle multocida
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Fig (32):Effect of  combination of tetracycline and erythromycin against E coli (1)
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Figure (31):Effect of cloxacillin on Pasteurella multocida
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Fig(33):Effect of combination of tetracycline+erythromcin against E.coli  (3)
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Fig (34):Effect of combination of tetracycline+erythromycin against E.coli  (5)
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Figure (35): Effect  of tetracycline + erythromycin on Enterobacter  (267)
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Figure(36):Effect of combination of tetracycline+erythromycin on 
Klebsiella pneumonia (M)
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Figure (37): Effect of combintion of tetracycline +erythromycin on Pseudomonas  (5)
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Figure(38): Effect of combination of tetracycline +erythromycin on Pasteurella multocida
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Figure(39):Effect of combination of ciprofloxacin+tetracycline on Klebsiella (J)
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Figure (40): Effect of ciprofloxacin c+tetracyclinet on Klebsiella   (M)
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Figure (41):Effect of combination of ciprofloxacin +tetracycline on Entrobacter (267)
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Figure (42):Effect of combination of ampicillin +ciprofloxacin  on Klebsiella (10) 
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Figure( 43): Effect of combination of ampicillin+ciprofloxacin on Pseudomonas  (5)
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Figure (44): Effect of combination of ampicillin+amoxicillin on Klebsiella   (M)
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Figure (45): Effect of combination of cephalexin +ciprofloxacin on Klebsiella (M) 
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Fig.(46):Effect of combination of sulphamethoxazole+trimethoprim on Pseudomonas (5)
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Figure(47): Effect of combination of tetracycline+trimethoprimm on Klebsiella (M) 
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Figure (48): Effect of combination of tetracycline + trimethoprim on Pseudomonas (5) 
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Figure(49): Effect of erythromycin on different phases of growth of Pasteurella 
multocida
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Figure (50): Effect of tetracycline on different phases of growth of Pasteurella multocida 
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Figure(51):Effect combination of tetracycline and erythromycin on different phases of 
growth of Pasteurella multocida
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Figure (52) Invivo effect of using`one or  two antibiotics on different phases of bacterial 
growth
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CHAPTER FOUR 
DISCUSSION 
 
The resistance of bacteria to commonly prescribed antibiotics is 
increasingly alarming in developing as well as in developed countries. 
Resistance has emerged even to newer more potent antimicrobial agents. 
Gram-negative bacteria are in general more resistant to a large number 
of antibiotics and chemotherapeutic agents than are Gram-positive bacteria. 
This fact has been reported by some workers surveying antibiotics of natural 
origin including Vaara (1982) who found that more than 90% lacked activity 
against Escherichia coli, though they were active against Gram-positive 
bacteria. 
4.1. Effect of antibiotics  
Multidrug resistant microorganisms are not easily treated with narrow 
spectrum antibiotics resulting in the use of broader and usually more 
expensive agents (Liu, 1999). It has thus become necessary to stay up-to-
date on bacterial antibiotic resistance patterns because they change over 
time. It is therefore recommended that there should be routine susceptibility 
testing of organisms, and that their mechanisms of resistance are studied. 
This allows the best balance in avoiding unnecessary use of broad-spectrum 
antibiotic therapy while aggressively treating resistant pathogens (Liu, 
1999).  
4.1.1 Minimum Inhibitory Concentration (MIC) for single antibiotic 
Minimum inhibitory concentrations (MICs) are considered the “gold 
standard” for determining the susceptibility of organisms to antimicrobials 
and are therefore used to judge the performance of all other methods of 
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susceptibility testing. MICs are used in diagnostic laboratories to confirm 
unusual resistance, to give a definitive answer when a borderline results is 
obtained by other methods or when disc diffusion methods are not 
appropriate (Andrews, 2001) 
The range of antibiotic concentrations used for determining MICs is 
universally accepted to be in doubling dilution steps up and down from 
1mg/l as required (Andrews, 2001).  
When determining the minimum inhibitory concentrations (MICs) the 
present investigation studied the effect of very high concentrations of the 
antibiotics. The high values of MICs reported during the present study 
confirm the multi-drug resistance of the organisms to the commonly used 
antibiotics in Sudan.  
4.1.1.1. Escherichia coli strains  
Depending on the resistance breakpoints defined by the National 
Committee for Clinical Laboratory Standards (NCCLS) for E. coli, all 
studied strains of E. coli were found to be highly resistant to all investigated 
antibiotics which are commonly used in Sudan namely amoxicillin, 
ampicillin, cephalexin, ciprofloxacin, cloxacillin, erythromycin, 
sulphamethoxazole, tetracycline, and trimethoprim. (Tables 3 to 7). The 
present results are not in agreement with Ahmed et al. (2000) and Saeed 
(2002) working in Sudan. They found that all isolates of E. coli were highly 
sensitive to ciprofloxacin but resistant to other antibiotics with multiple 
resistance was particularly high in urinary pathogens. 
In addition they reported that Escherichia coli had 58% resistance rate 
to at least four of ten antimicrobial agents tested.  
The present results confirm the multi-resistance of the studied strains 
to ciprofloxacin which may indicate a multiple mutation. This is in 
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accordance with Javier et al. (1999) who suggested that MICs more than 64 
µg /ml indicates the presence of multiple mutations.  
The present results also indicate that there is a rapid increase in the 
ciprofloxacin resistance of E .coli in Sudan as well as in other countries. In 
the United Kingdom David et al. (2002) reported that for E. coli, 
ciprofloxacin resistance rose from 0.8% in 1990 to 3.7% in 1999 and 
became widely scattered among reporting hospitals. Widespread 
ciprofloxacin resistance followed introduction of ciprofloxacin into the 
medical field had been reported by many investigators (Blandino et al., 
1990; Gairau et al., 1999; Diekema, 1999; Jamal, 1999; van Belkum, 2001). 
In Netherlands, van Belkum (2001) found that the incidence of 
ciprofloxacin-resistant E. coli increased from <0.5% in 1996 to 20.7% in 
1999. Even more notable, he found that the incidence of ciprofloxacin-
resistant E. cloacae rose from <0.5% to 64% during the same period. 
In the United States, Canada, Latin America, Sicily, Spain, and 
Kuwait, for example, ciprofloxacin is no longer the most effective drug for 
treating bloodstream infections caused by gram negative bacilli. The number 
of strains that are resistant, especially to antibiotics that are frequently used 
for selective decontamination, is increasing. (Gairau et al., 1999; Blandino  
et al., 1990; Diekema, 1999; Jamal, 1999).  
4.1.1.2. Klebsiella pneumoniae strains 
All stains of Klebsiella pneumoniae used in this study were resistant 
to all antibiotics investigated (Tables 8, 9 and 10). The lowest MIC reported 
was for tetracycline (=32 µg/ml) indicates resistance according to (NCCLS) 
guide lines. 
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Multi drug resistance of Klebsiella pneumoniae is well known and had 
been reported previously in Sudan as well as in other countries.  Ahmed  et 
al.(2000) working in antimicrobial agent resistance in bacterial isolates from 
patients with diarrhea and urinary tract infection in the Sudan found that K. 
pneumoniae showed high resistance (52 %) to five antimicrobial agents. In 
their work they also tested ampicillin, amoxicillin and tetracycline. They 
also found that all the strains they tested were sensitive to ciprofloxacin 
which is in contrast with our findings. The occurrence and increase of 
ciprofloxacin resistance in K. pneumoniae is now well known and, indeed, 
exceeds 5% in many centers in North America, Europe, and Asia ( Turnidge, 
1995; Jones  et al., 1996; Blondeau, 1999). In the United Kingdom David et 
al. (2002) reported that the prevalence of resistance in Klebsiella spp. rose 
from 3.5% in 1990, to 9.5% in 1996 and 7.1% in 1999. Although it is also 
common in Turkey, Argentina and the United States, no cases of bacteremia 
due to ciprofloxacin-resistant K. pneumoniae were detected in South Africa, 
Australia or Belgium. (David et al. 2002) 
4.1.1.3. Enterobacter strain  
The strain of Enterobacter which had been used in this study is a 
multi drug resistant strain, (Table 11). This result is in agreement with 
Ahmed  et al., (2000) who found that resistance in Enterobacter isolates 
ranged between 22%-67% to the most commonly used antibiotics in Sudan. 
They also found that there is 100% susceptibility of this genus to amikacin 
an antibiotic which had not been investigated in this study.  
In the United Kingdom David et al. (2002) reported that the 
prevalence of resistance to ciprofloxacin (the most widely used 
fluoroquinolone) in Enterobacter spp. rose from 2.1% in 1990 to 10.5% in 
1996 and 10.9% in 1999. 
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  Sanders and Sanders (1997) reviewing microbiology, epidemiology, 
antimicrobial susceptibility and resistance, clinical manifestations, and 
outcomes of therapy of the genus Enterobacter concluded that its resistance 
to each of the major groups of antimicrobial agents varied widely among 
published reports. For the β-lactam antibiotics for example, the percentage 
of strains resistant to specific agents ranges from 9 to 50% for ticarcillin, 6 
to 54% for piperacillin, 5 to 63% for cefotaxime. For the aminoglycosides, 
the percentage of strains resistant to gentamicin ranged from 0 to 51%, the 
percentage resistant to tobramycin ranged from 0 to 43%, and the percentage 
resistant to amikacin ranges from 0 to 34. For ciprofloxacin, resistance 
varies from 0 to 36% of strains tested, and for trimethoprim-
sulphamethoxazole, resistance varies from 0 to 60% of strains. The present 
writer agrees with Sanders and Sanders (1997) that these wide ranges 
suggest that numerous factors impact the occurrence of antimicrobial 
resistance among strains of Enterobacter.  
4.1.1.4. Pseudomonas aeruginosa strain 
Ciprofloxacin is usually perceived to have the greatest activity against 
Pseudomonas aeruginosa on the basis of lower MICs (Bauernfeind, 1997). 
The strain which has been used in this study was found to be resistant to all 
investigated antibiotics except ciprofloxacin (MIC=0.25 µg/ml, Table 3-12). 
The present findings confirmed those of Ahmed et al. (2000) and Saeed 
(2002) of the high sensitivity of Pseudomonas aeruginosa to ciprofloxacin. 
Saeed (2002) also reported that 80% of the Pseudomonas aeruginosa strains 
used in his study were found to be resistant to erythromycin, amoxicillin, 
cephalexin and cephradine. 
Although our strain was found to be sensitive to ciprofloxacin, slow 
rate of increase of resistance of Pseudomonas to ciprofloxacin and other 
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antibiotics had been reported elsewhere. Henwood et al., (2001) surveying 
resistance of Pseudomonas in the United Kingdom  found that resistance 
rates to the β-lactam, aminoglycoside and quinolone agents tested in P. 
aeruginosa in the UK remained low (<12%), and were mostly unchanged 
since a previous survey conducted in 1993. 
 Pseudomonas aeruginosa strains are well known to be highly 
resistant to trimethoprim (Hitchings et al., 1966), a finding that we 
confirmed (Table 12). 
4.1.1.5. Pasteurella multocida strain 
This strain had been chosen for its known susceptibility to the 
commonly used antibiotics. When determining the minimum inhibitory 
concentrations (MICs) for commonly used antibiotics it was found to be 
resistant to cephalexin, sulphamethoxazole, tetracycline and trimethoprim. It 
is most sensitive to ciprofloxacin (Table 13). The present author is not aware 
of any published work done in Sudan concerning the susceptibility of 
Pasteurella multocida. The present results are not in conformity with results 
reported by Andrews  et al.(2004) in the United Kingdom who determined 
the mode MICs for Pasteurella multocida for each of the antibiotics tested 
were: penicillin, 0.06 mg/litre; ampicillin, 0.12 mg/litre; cefotaxime, 0.004 
mg/litre; ciprofloxacin, 0.008 mg/litre; and tetracycline, 0.25 mg/litre. 
Stevens et al., (1979) found that the most active drugs against 
Pasteurella multocida with respect to the minimal inhibitory concentration 
were tetracycline, penicillin G, ampicillin , carbenicillin, cephalothin and 
chloramphenicol  The semisynthetic penicillins clindamycin, erythromycin, 
and aminoglycosides had relatively low activities, suggesting that these 
agents would be poor choices for the treatment of P. multocida infections 
(Stevens et al., 1979). According to Goldstein et al., (1988), erythromycin 
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resistance is fairly widespread among P. multocida strains. In our present 
study, erythromycin had a high MIC (2 µg/ml), while ciprofloxacin was 
found to be the most active antibiotic against P. multocida (MIC 
=0.00023µg/ml). In conformation with our results Goldstein et al. (1988) 
also reported that studying twenty different isolates of P. multocida were 
found uniformly susceptible to penicillin, ampicillin, tetracycline, 
minocycline, sulphamethoxazole, and chloramphenicol. Isolates were 
uniformly resistant to dicloxacillin, cephalexin, cefadroxil, cefaclor, 
erythromycin, and clindamycin.  
 On the basis of these data , with the very high MICs reported in this 
study we can conclude that the overall prevalence of resistance of 
microorganisms to antimicrobial agents was notably higher in the current 
study, than  the findings in previous studies reported by Hassan (1985), 
Shears et al. (1988), Ahmed et al. (2000) and Saeed (2002 ). However these 
findings reflect the high level of antibiotic resistance in the country as a 
whole, when compared to other countries (Shears et al., 1988). 
It can be concluded that selection for drug resistance has been 
associated with an increased and inappropriate use of antibiotics. This 
conclusion is based on the interesting findings of Doczeova et al. (2003) 
working in a rural hospital in Mapuordit, a remote area in southern Sudan 
where there are ~50,000 refugees displaced by the civil war. The hospital 
which is the only one in an area of ~50,000 km2 had been isolated until the 
year 2000 because of 18 years of civil war in south Sudan; where there had 
been no access to health care and medication. Doczeova et al. (2003) found 
that 0% of pneumococci were resistant to penicillin or erythromycin, 0% of 
Streptococcus  pyogenes strains were resistant to erythromycin, and 0% of 
Haemophilus. influenzae strains were resistant to ampicillin The absence of 
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antibiotic resistance in this small, pilot surveillance study can be explained 
by the isolation of the area resulting from 18 years of civil war, total lack of 
infrastructure and communication systems, and absence of antibiotics, even 
as over-the-counter drugs (Doczeova et al., 2003). 
4.1.2 Antibiotic combinations 
The use of antibiotic combinations was undoubtedly far more 
justifiable in the early days of the antibiotic era, when there were so few 
active substances available (Gunnison et al., 1950; Jawetz et al.,1952; 
Lacey, 1960). This practice become less necessary during the 1960's when 
there was a rapid expansion of antimicrobially active compounds, such as 
the whole range of semi-synthetic β-lactam compounds. Now perhaps, the 
tide has turned and the exploration of using combinations is again justified, 
as the possibility has to be considered that there are no more naturally 
occurring antibiotics awaiting discovery, and thus we may have to depend in 
the future upon the more cunning use of existing drugs. 
The choice of drug combination usually appears to have been made in 
an entirely arbitrary fashion, both in laboratory (Chabbert and Patte, 1960) 
and in clinical studies (McCabe and Jackson, 1965; Klastersky et al., 1977).  
Dowling (1967) and Jawetz (1967) recommended that the choice of 
individual antibiotic combinations should be oriented along proven and 
critical guidelines, and only such substances should be combined which 
broaden the antibacterial spectrum as well as show a synergistic effect. 
These requirements necessitate careful testing of every antibiotic 
combination with regard to its characteristic pattern of action indifferences, 
antagonism, or synergism. Proven methods for the assessment of antibiotic 
combinations in vitro are the checkerboard technique, the interaction index, 
time killing curves, agar diffusion paper-strip and disc methods (Hallander  
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et al., 1982), as well as models of infection in animals (Scheld and Sande, 
1983). In the final analysis, however, it is the controlled therapeutic 
application in well-defined infections in man that is decisive.  
For a variety of reasons, the use of antibiotic combinations is 
becoming a common practice in clinical medicine in Sudan, particularly in 
the treatment of seriously ill patients. For the most part, such use has been 
empirical, occasionally based on general principles derived from well-
defined bacterial traits or predictable antibiotic activities. Recent 
developments, however, now justify re-examination of testing antibiotic 
combinations. First, the dissemination of antibiotic resistance determinants 
which also confer resistance to synergism has made it necessary to 
reconsider the predictability of certain antibiotic interactions, such as 
penicillin-gentamicin synergism against enterococci (Eliopoulos and 
Eliopoulos, 1988). In addition, there has been increasing awareness of the 
fact that some antibiotic combinations may be actually antagonistic. This 
appreciation of undesirable antibiotic interactions has arisen in parallel with 
a more sophisticated understanding of bacterial resistance mechanisms such 
as inducibility (derepression) of beta lactamase production upon exposure to 
beta-lactam antibiotics. Requests for testing combinations could, therefore, 
be directed at excluding antagonistic effects between two antimicrobial 
agents.  
We had not found in the literature any results of testing the 
susceptibility of pathogenic organisms to combination antibiotics in Sudan. 
Most of the work in antibiotic resistance was a kind of surveys to determine 
the prevalence of certain antibiotic resistance to local isolates (Hassan, 1985; 
Shears et al., 1988; Musa and Shears, 1998, Ahmed et al., 2001). 
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We set out to study the susceptibility of resistant isolates belonging to 
different species of pathogenic Gram negative bacilli to logical combination 
of two commonly used antibiotics in Sudan, which when combined, could 
offer the prospect of a powerful broad-spectrum oral antibiotic.  
4.1.2.1. Fractional inhibitory concentration (FIC) for combination of 
two antibiotics.  
Tetracyclines and erythromycin are inexpensive antibiotics, which 
have been used extensively in Sudan in the prophylaxis and therapy of 
human and animal infections. 
As presented in Table 26 we found that the combination of 
tetracycline and erythromycin is synergistic against E. coli (3), E. coli (5), 
Klebsiella pneumoniae M, Enterobacter, Pseudomonas 5, and Pasteurella 
multocida. (FIC=0.3125, 0.25391, 0.03125, 0.07813, 0.25 and 0.125 
respectively), the same combination was found to be indifferent to E. coli (1) 
(FIC=1.00391) while none of the agents used alone was capable of. The 
same combination has no effect on other tested organisms  
Chopra and Roberts (2001) reported that tetracycline resistance occurs 
in an increasing number of pathogenic, opportunistic, and commensal 
bacteria. Macrolide antibiotics (including erythromycin) inhibit bacterial 
protein synthesis by binding to the 50 S ribosomal subunit.  
Macrolides are mainly bacteriostatic, but can be bacteriocidal 
depending on bacterial sensitivity and antibiotic concentration (Goldman  et 
al., 1990). Generally, macrolides are active against gram-positive cocci 
(mainly staphylococci and streptococci) and bacilli, and to lesser-extent 
gram-negative cocci. With the exception of Bordetella pertussis, 
Campylobacter, Chlamydia, Helicobacter, and Legionella species, gram-
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negative bacilli are generally resistant to the macrolides (Gryczan et al., 
1984). 
Macrolides resistance of Gram-negative bacilli, in particular, 
members of the family Enterobacteriaceae, Pseudomonas spp., and 
Acinetobacter spp., is probably due to the relative impermeability of the 
cellular outer membrane to these hydrophobic compounds, as indicated by 
the erythromycin sensitivity of Escherichia coli ribosomes in cellular 
systems (Gryczan et al., 1984). Macrolides antibiotics cannot therefore be 
used in the treatment of systemic infections caused by these microorganisms. 
However, oral erythromycin is locally active in the intestinal tract, in which 
the concentrations achieved are far higher than the MICs (2 to 256 µg/ml) 
against most strains of enterobacteria (Arthur and Courvalin, 1986). This 
observation supports the use of this drug for intestinal decontamination in 
the prevention of traveler's diarrhea and of septicemia caused by Gram-
negative bacilli in neutropenic patients (Arthur and Courvalin, 1986).  
The presence of tetracycline-resistant and erythromycin -resistant 
pathogens limits the use of these agents in treatment of diseases. Both 
erythromycin and tetracycline have bacteriostatic action on bacteria. 
 Tetracyclines act against microorganisms by inhibiting protein 
synthesis; their site of action is the bacterial ribosome, while erythromycin 
and other macrolide antibiotics inhibit protein synthesis through reversible 
binding to the 50S ribosomal subunits of susceptible microorganisms.  
On the bases of this data and our findings we can conclude that the 
synergistic effects of the combination of erythromycin and tetracycline on 
the studied strains may be a result of the augmented action of both 
antibiotics on protein synthesis in these isolates. We had not found any 
results in the literature which support our findings  
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In the present study we found that the combination of tetracycline and 
ciprofloxacin has synergistic effect on Klebsiella pneumoniae M, and 
Enterobacter, (FIC=0.07031, 0.07813) but slightly indifferent on Klebsiella 
pneumoniae J( FIC=0.50391)(Table 26) 
Ciprofloxacin has a bacteriocidal effect, while tetracycline has a 
bacteriostatic effect. Mathies (1968) reported that it is generally believed 
that, using two drugs, bactericidal and bacteriostatic antibiotics should not 
be combined because of their in vitro and in vivo antagonism. Antibiotic 
antagonism, especially between the penicillins chloramphenicol and 
tetracycline could be demonstrated in various clinical studies (Mathies, 
1968). Some experimental studies question the concept of general 
antagonism between bacteriostatic and bactericidal drugs. Michel et al. 
(1975) found striking examples of synergism between 
tetracyclines/cephaloridine on Serratia and between tetracycline/kanamycin 
on Enterobacter. Daschner (1976) found that drug interaction patterns 
between bactericidal and bacteriostatic drugs are highly dependent on 
bacterial species, strains, and drug concentrations used. 
Checkerboard of ampicillin combined with ciprofloxacin showed 
synergistic effect on Klebsiella pneumoniae 10, (FIC=0.025391, Table 3-
26). Ampicillin and ciprofloxacin are both bactericidal, but they act through 
different mechanisms and at different sites on bacteria cells. Ampicillin 
inhibit the formation and integrity of the bacteria cell wall while 
ciprofloxacin inhibit DNA – gyrase (Smith, 1986). Jawtez and Gunnison, 
(1952) observed that concomitant use of two bactericidal antibiotics is likely 
to produce synergistic effect 
Our work does not support the work of Nworu and Esimone (2006) 
who reported that either synergism or additive interaction between 
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ampicillin and ciprofloxacin against the Staphylococcus aureus (ATCC 
12600) and E. coli (ATCC 11775), an interaction which was not observed in 
our studied E. coli strains.    
Contrary to our findings Douglas et al. (2002) reported that 
combinations of β- lactam plus a fluoroquinolone achieve in vitro synergy in 
60–80% of tested P. aeruginosa clinical isolates. 
In Our present studies we found that using ampicillin and amoxicillin 
in combination has synergistic effect on Klebsiella pneumoniae j, 
(FIC=0.025391) as well as Pseudomonas 5 (FIC=0.00781; Table 26). 
The work of Sabath et al. (1967) substantiates our results since they 
reported synergistic effects of combinations of penicillins for a number of 
bacterial species. Other investigators have reported in vitro synergistic, 
indifferent, and antagonistic effects with a variety of beta-lactam antibiotic 
combinations against a variety of Gram negative bacilli (Gutmann et al., 
1986).   
  In most cases, mechanisms of synergistic and antagonistic interactions 
have not been studied. Presumably, in such situations, synergism is due 
either to binding to complementary penicillin binding proteins (PBPs) or to 
one agent serving as a beta-lactamase inhibitor, protecting the second 
intrinsically more active drug from hydrolysis. The latter explanation is 
more likely for combinations of penicillins with expanded-spectrum 
cephalosporins (Eliopoulos and Eliopoulos, 1988).  
A possible explantation is that which had been suggested by Edmund  
et al. (1973) who reported antibacterial effects of ß-lactam antibiotics, singly 
and in combination. His findings support the hypothesis that the synergistic 
antibacterial effects of combinations of ß-lactam antibiotics on the tested 
organisms were due to inhibition of the enzyme by one of the agents and 
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killing of the organism by the other, which was protected from enzymatic 
hydrolysis, rather than the alternative possibility that the synergistic effects 
were due simply to the combined antibacterial actions of the two drugs.  
Testing sulphamethoxazole with trimethoprim we found that it has 
synergistic effect on Pseudomonas 5 (FIC= 0.014063) (Table 3-26) but has 
no effect on the other tested organisms. 
 With the introduction of trimethoprim-sulfamethoxazole (TMP-
SMX), which acts synergistically on bacterial folic acid synthesis (Burchall, 
1973; Hitchings, 1973), it was believed that the development of resistance 
among bacterial species susceptible to the combination was highly unlikely, 
because it would require two independent mutational events (Hitchings, 
1973). Since then the antibiotic combination of trimethoprim and 
sulfamethoxazole is used to treat a wide variety of bacterial infections and 
some infections due to parasites. Trimethoprim- sulphamethoxazole has 
been regarded as the first-line drug for the curative and prophylactic 
management of patients with urinary tract infection (Gutman, 1984, Murray, 
1982). As early as 1972, Lacey et al. had found a 2.5% incidence of 
resistance to trimethoprim among urinary bacterial isolates, and later 
Freuensgaard and Komer (1974) and Huovinen and Toivonen (1980) 
reported increasing resistance, up to 30.1%, to trimethoprim or 
trimethoprim-sulphamethoxazole . In 1982, Murray et al. reported a high 
incidence of resistance to trimethoprim-sulphamethoxazole among fecal 
enterobacteria, particularly Escherichia coli strains isolated during a diarrhea 
prevention study.  
The degree of synergy observed for trimethoprim- sulphamethoxazole 
in our study is in accordance with  that obtained with the established 
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combination trimethoprim- sulphamethoxazole, which is often in the order 
of tenfold (EFIC = 0.01) (Bushby, 1969)  
Our result contradicts with (Fass, 1996) who reported that 
trimethoprim- sulphamethoxazole was active against most nonfermentative 
Gram-negative bacilli except   Pseudomonas aeruginosa which was found to 
be sensitive in our present study. 
Using Tetracycline in combination with Trimethoprim has 
antagonistic effect on both Pseudomonas 5 and Klebsiella pneumoniae M. 
(FIC=8.00781 and 4.00781; Table 3-26).Tetracycline and trimethoprim are 
both bacteriostatic antibiotics.  
This result is also in agreement with what Winslow and 
Pankey,(1983)  had reported that the bactericidal action of trimethoprim is 
antagonized by the addition of ampicillin, doxycycline, and rifampin.   
         Based on the results obtained and referring to the published literature 
we have to emphasizes, that each bacterial strain reacted differently to the 
antibiotic mixtures so that no generalization can be made about which pairs 
of drugs exhibit synergism even against a given bacterial species. There was 
no correlation between the frequency of synergism and the species or genus 
of bacteria. These results is in conformity with Jawetz, (1968) who 
suggested that testing of individual organisms would be necessary, since an 
antibiotic combination which is generally synergistic against all strains of 
the same organism may has not been found .  
Actual clinical experiences are needed to conclude on possible clinical 
benefits of using any two antibiotics in combination.  
4.1.3. Time-killing curve 
Figures 1-48 show the bacteriostatic and bacteriocidal kinetics of the 
commonly used antibiotics in Sudan against the test strains using single and 
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combinations of antibiotics. An antimicrobial was considered to have 
bactericidal activity when a decrease of at least 3 logs from the starting 
inoculum was observed (Drago et al., 2001). 
4.1.3.1 Time-killing curve using single antibiotic  
Depending on the results obtained in determining minimum inhibitory 
concentrations, time-killing curves with single antibiotic against strains 
which were affected by an antibiotic were performed (see Figures 1-31). The 
antibiotics which show effects on our studied strains are ciprofloxacin, 
trimethoprim, tetracycline, and erythromycin. In addition to ampicillin, 
amoxicillin and cloxacillin which affect Pasteurella multocida.  
4.1.3.1.1. Time kill curves using ciprofloxacin 
Presented in (Figures 1-9) are time killing curves with ciprofloxacin 
against affected strains.  
We found that using 0.5X MIC concentrations of ciprofloxacin had 
little activity on tested E. coli (1) and E. coli (9) isolates, with the curves 
closely resembling growth control for both strains. However, when using 2 
X MIC the number decreased. Since the decrease in number is less than 3 
logs from the starting inoculum it is not unreasonable to assume 
bacteriostatic effect (Drago  et al.,2001). 
For Klebsiella sp. partial killing was noted at 8 h, with regrowth at 24 h 
when using concentrations of ciprofloxacin 0.5 X MIC. With drug 
concentrations of 1X or 2 X the MIC, no regrowth was noted at 24 hour. 
This result may indicate that using sub-inhibitory concentrations of 
ciprofloxacin for Klebsiella sp is unsafe and may lead to emergence of 
resistant strains. This is in conformity with Rodin et al. (1984) who tested 
the effect of different concentrations of ciprofloxacin on Klebsiella and 
resistant strains of Pseudomonas aeruginosa. Others workers have made 
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similar observations regarding the importance of antibiotic concentration in 
the development of resistance to ciprofloxacin. Eliopoulos et al(1984) were 
able to produce significant resistance in Pseudomonas aeruginosa strains by 
initial exposure to ciprofloxacin at a concentration equal of 0.5 X MIC and 
subsequent serial transfer to agar containing twofold incremental 
concentrations of the drug. Chin and Neu (1984) found a low frequency of 
resistance in Pseudomonas aeruginosa when the organism was exposed to 
concentrations of ciprofloxacin at 4 - 8 X MIC.  These observations and our 
data coroborated by other workers, who suggested that, if adequate multiples 
of the MIC for the infecting organism can be obtained in serum and tissue, 
resistance to ciprofloxacin may not be a frequent occurrence. 
Pseudomonas aeruginosa and Pasteurella multocida were sensitive 
strains to ciprofloxacin and the decrease of the viable cells started after 2 
hours for the former and at zero time for the latter. Using 0.5 X MIC was the 
least effective for both strains. For Pseudomonas aeruginosa using 0.5 X 
MIC decreased the number of viable cells till 8 hours and regrowth was 
observed at 24 hours. With concentrations of ciprofloxacin 1 X MIC killing 
was noted at 2 h, with no regrowth at 24 h (Fig. 8). This result is in 
accordance with Eliopoulos  et al.(1984) who reported that resistant colonies 
of Pseudomonas aeruginosa were recovered at 24 hours from mixtures 
containing high inocula and lower concentrations of ciprofloxacin. No 
ciprofloxacin resistant colonies were recovered when high inocula of 
bacteria were incubated with ciprofloxacin at high concentrations or when 
lower inocula were incubated with lower concentration.   
For Pasteurella multocida being sensitive to ciprofloxacin the killing 
effect started from zero time when using 1 X MIC and 2 X MIC. However, 
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with a lower drug concentrations 0.5 X MIC, the rate of growth of viable 
cells was slightly less than control at 24 h. (Fig. 9).  
4.1.3.1.2. Time kill curves using trimethoprim 
When studying the effect of different concentrations of trimethoprim 
along time it has a bacteriostatic effect on all the strains of E. coli and 
Klebsiella pneumoniae as shown in Figures (10-17). The same effect was 
noted when tested on Enterobacter as in Figure (18).  
When testing high concentration of trimethoprim 2 X MIC on Pseudomonas 
aeruginosa the number of viable cells at 6 hours decreased, dropping to 
minimum at 8 hours and regrowth occurred at 24 hours. 
4.1.3.1.3. Time kill curves using tetracycline  
In our present study we found that E. coli (9) was affected by 
tetracycline. At low concentrations of tetracycline the number of viable cells 
did not increase, while using 2 X MIC concentration of tetracycline reduced 
the number of viable cells from zero time to reach a minimum after 2 hours 
and no re-growth was observed thereafter (Figure 20). This result is  in 
agreement with Cunha (2000) who tested Doxycycline against selected 
Gram-positive pathogens, e.g. Staphylococcus aureus and Streptococcus 
pneumoniae and Gram-negative pathogens, e.g. Pasteurella. multocida and 
E. coli. In the present investigations, time-kill studies were performed with 
each of these organisms at various concentrations representing two, four, 
eight, and 16 times the MIC of each test organism. The growth of the 
organisms was assessed by colony counts at various time points during a 24 
h period to determine if doxycycline kills susceptible organisms by 
concentration or time-dependent kinetics. Escherichia coli (ATCC 25922), 
Staphylococcus aureus (ATCC 25923), Pasteurella multocida, and 
Streptococcus pneumoniae (ATCC 49619) were used as the test bacteria.  
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The data indicate that at low concentrations of doxycycline, i.e. at 2 to 4 
times the MIC, inhibition of the organisms tested occurs in a time-dependent 
fashion. However, at higher concentrations, i.e. 8 to 16 times the MICs of 
the organisms, doxycycline exhibits concentration-dependent killing (Cunha, 
2000). 
 In our present study we found that tetracycline has a bacteriostatic on 
Pasteurella multocida (MIC =4.0 µg/ml) when 0.5X MIC was  used, where  
there was no increase in the viable cell count up  to 24 hours, while when 
using 1 X MIC concentration and 2X MIC concentration bacteriocidal effect 
was noted. The viable cells decrease after 2 hours and no regrowth of the 
cells occurred. These results indicate that the change from bacteriostatic to 
bacteriocidal effect depends on the concentration of the antibiotics. Our 
results contradict with Norica et al., (1999) who reported that tetracycline 
has a bacteriostatic effect when tested on Pasteurella multocida, when using 
1 X MIC concentration of tetracycline. 
4.1.3.1.4. Time kill curves using erythromycin 
Erythromycin is known to be a bacteriostatic agent; it can be 
bacteriocidal depending on concentration. Our present study shows that 
using high concentrations of erythromycin (MIC= 128 µg/ml) has 
bacteriostatic effect along the time on Klebsiella pneumoniae (J). In all 
concentrations no increase in viable cells count was observed, the effect 
had not changed to bacteriocidal even when using double MIC 
concentration (256 µg/ml; see Fig 25). The same effect was not observed 
when testing erythromycin (MIC=64 µg/ml) on Pseudomonas. Figure 26 
which shows that when 2 X MIC (128 µg/ml) was used the viable 
bacterial cells decreased at 2 hours while re -growth occurred thereafter. 
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Pasteurella multocida is affected by erythromycin even at lower 
concentrations (MIC =2.0 µg/ml). A decrease in CFU/ml was noted 
immediately after the addition of the antibiotic at all concentrations, 
when 2 X MIC showing the greatest effect (Fig 27). It is rather 
interesting that the antibiotic which is known as a bacteriostatic has a 
bacteriocidal effect on our studied organism. This information is in 
contradiction with what Norica et al. (1999) had found that erythromycin 
is bacteriostatic on strains of Pasteurella multocida.  
4.1.3.1.5. Time kill curves using other antibiotics against Pasteurella 
multocida  
Figures (28-31) show the effect of amoxicillin, ampicillin, cloxacillin and 
cephalexin against Pasteurella multocida using time –kill curves. In these 
figures we noticed that the effect of the penicillins tested had the same 
effect. Using 0.5 X MIC of amoxicillin (32µg/ml), ampicillin (16 µg/ml), 
cephalexin (1µg/ml) and cloxacillin (0.25µg/ml) has bacteriostatic effect, 
while using either 1X MIC or 2X MIC of each has bactericidal effect. 
Testing the effect of cephalexin on Pasteurella multocida, it was found 
that the number of viable counts decreased after two hours and only 
slight regrowth was observed when using 0.5X MIC, the effect being  
bacteriocidal for all concentrations.  
 
4.1.4. Time-killing curve with combination of two antibiotics  
Checkerboard titrations to determine fractional inhibitory 
concentrations have been shown to be less discriminatory than time-kill 
testing for the detection of synergy against members of the family 
Enterobacteriaceae, and Gram-negative, non fermenting bacteria. It 
should also be noted that checkerboard titrations reveal bacteriostatic 
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activity only, while the time-kill method reveals both bacteriostatic and 
bactericidal activities (Bajaksouzian et al., 1997; Visalli et al., 1997).  
On the other hand although time-killing curve with combination of 
antibiotics offers an advantage over checkerboard tests in that both rate and 
extent of killing can be assessed, the time-kill procedure is often more labor 
intensive. The writer agrees with Eliopoulos et al. (1984) that for any 
organism studied, only a limited number of antibiotic concentrations (alone 
and in combination) can be examined. Proper execution of a synergism 
study by this technique may require one or more preliminary experiments to 
establish the concentrations of individual agents most likely to permit 
detection of any synergistic interaction. In our present study we were not 
able to establish the time killing curves for each component of the 
combinations, since the MICs  experiments revealed insusceptibility of the 
studied strains to the tested antibiotics even at very high concentrations. 
As determined by Eliopoulos and Moellering (1996) an interpretation of 
‘synergy’, required more than or  equal to ( ) 2 log10 decrease in CFU/mL by 
the drug combination when compared with its most active constituent after 
24 h and a 2 log10 decrease in the CFU/mL below the starting inoculum. 
Likewise, the drug combination was considered to be ‘antagonistic’ if there 
was a 2 log10 increase in CFU/mL and ‘no interaction’ was the 
interpretation of a <2 log10 change in CFU/mL 
We found that using the combination of tetracycline and erythromycin 
had a bacteriostatic effect on E. coli (1) (Figure 32). The same combination 
shows indifferent reaction when determining the fractional inhibitory 
concentration. However the fractional inhibitory concentration results for the 
same combination were confirmed when it was tested against E. coli (3),    
E. coli (5-1) and Enterobacter (267). For the three strains, after 8 h of 
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antibiotic exposure the combination of tetracycline and erythromycin 
showed enhanced activity , no regrowth was obtained after 24 hours.  These 
findings are in accordance with Friedland (1994) who reported that after the 
exposure resistant pneumococcal strains to combinations of penicillin plus 
vancomycin and ceftriaxone plus gentamicin for 8 hours showed enhanced 
activity. Friedland (1994) also suggested that time-kill studies over 8 hours 
may be useful in predicting in-vivo antibiotic interactions in resistant 
pneumococcal infection. 
The exposure of Klebsiella pneumoniae (M) to combination of 
erythromycin and tetracycline resulted in approximately no change in the 
number of viable cells (Fig 36).It is evident from Table (26) that  the same 
combination when tested against the same organism using checkerboard, 
resulted in synergistic effect. This result confirms what Petersen et al. (2006)   
found that tigecycline, tested at 0.5 mg/litre, in combination with 
azithromycin, tested at 16 mg/litre, was synergistic by fractional inhibitory 
concentration against a strain of K. pneumoniae (PT 9266); however, when 
assayed by time-kill kinetics this combination failed to meet the criteria for 
synergy.   
 Rand (1993) reported that the drug concentrations used in the time-kill 
kinetic studies, based on the MIC determined in the FIC analysis, were 
expected to have an effect on the growth assay. The fact that these 
concentrations do not result in synergy in the more constrained experimental 
format suggests again, that the checkerboard analysis overestimates synergy, 
possibly due to the reproducibility issue inherent in the test. 
In our present study we observed synergistic effect on tested organisms 
when erythromycin and tetracycline were used together. When 
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Pseudomonas aeruginosa was tested the number of viable cells decreased 
after 4 hours and no regrowth was observed. However when we tested 
Pasteurella multocida the decrease started at 2 hours with no regrowth.   
This result is in conformity with what Saiman et al. (2002) reported that 
when macrolides were paired with ceftazidime, quinolones, or agents that 
interfere with protein synthesis such as chloramphenicol, tetracycline, or 
tobramycin, modest synergistic and additive activities were observed.  
Over fifty years ago Jawetz and Gunnison (1952) observed that the 
bacteriostatic antibiotics may antagonize the actions of bactericidal drugs, 
and this conclusion has been observed as an important general principle of 
antibiotic therapy since then (Rahal, 1978). However, on the contrary in our 
present study when tetracycline was combined with ciprofloxacin persistent 
inhibitory effects were noted for at least 24 h. It was observed that this 
combination has a bacteriostatic effect on Klebsiella pneumoniae (J) (see 
Fig 39) and Enterobacter ( see Fig 41).The same combination has a 
bacteriocidal effect on using against Klebsiella pneumoniae (M) ( see Fig 
40), the magnitude of inhibition is consistent with the criteria of synergism. 
To our knowledge, this is the first report of an in vitro study of the effect of 
the combination of ciprofloxacin (a bactericidal drug) and tetracycline (a 
bacteriostatic drug) against Klebsiella pneumoniae and Enterobacter in 
Sudan. 
In the available literature we could not find any reports which suggest the 
use of the combination of tetracycline and erythromycin for either Klebsiella 
pneumoniae or Enterobacter. However, Kinsara (1999) suggested that 
tetracycline in combination with ciprofloxacin should be started with, while 
susceptibility tests for brucellosis are evaluated.  
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Our data confirm those of Mouton and Koelman (1966) and Jawetz 
(1968), who found that drug interaction patterns between bactericidal and 
bacteriostatic drugs are highly dependent on bacterial species, strains, and 
drug concentrations used. 
Figure 42 shows that using ampicillin in combination with ciprofloxacin 
against Klebsiella pneumoniae (10), the viable cell count increased at the 
beginning and decreased drastically after 6 hours. However the use of the 
same combination against Pseudomonas aeruginosa resulted in complete 
death of the cells at 4 hours (see Fig 43). The combination had synergistic as 
well as bacteriocidal effect on both strains. No antibiotic proved to be 
bactericidal against the strains when used alone. These results are in 
accordance with what had been reported by Tripodi (1996) who observed 
that when testing the same combination on E. faecium,  the combination was 
synergistic against six of seven isolates that exhibited a ciprofloxacin MIC 
<4 mg/L and resistance to ampicillin (MIC > 32 mg/litre). Both synergistic 
and bactericidal activity was demonstrated in five of the studied strains 
while the sixth showed synergism but not a bactericidal response to the 
combination. (Tripodi, 1996).  Bactericidal activity between ciprofloxacin 
and ampicillin has also been reported for gentamicin resistant E. faecium 
whose ciprofloxacin MIC was < 8 µg/ml (Landman et al., 1993) 
The effect of using the combination of ampicillin and amoxicillin against 
Klebsiella pneumoniae (M) along time was studied. The viable cell count 
increased at the beginning but decreased drastically after 6 hours (see Fig 
44).  The combination has a bacteriocidal effect. Forty years ago Sabath et 
al.(1967) reported that synergistic effects have been shown with 
combinations of two penicillins. The improved action of two penicillins in 
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comparison to individual substances was usually limited to certain pathogens 
that produce β-lactamase, to circumscribe localized infections 
(predominantly urinary tract infections), and mixed infections. However, in 
addition to predominantly indifferent effects, isolated synergistic and 
numerous antagonistic in-vitro effects have also been reported by many 
authors (Fu and Neu, 1981; Neu and Fu, 1978; Sanders and Sanders, 1980), 
who found  that antagonistic effects of such combinations occurred in vitro 
with Ps. aeruginosa, Serratia and  Enterobacter  
In summary, one can conclude that the basic principle which holds true is 
that the combination of two β-lactam antibiotics can usefully broaden the 
spectrum of antibacterial action.  Every combination of β-lactam antibiotics 
should be tested in vitro with regard to its action characteristics, to eliminate 
undesirable effects of combinations.  
When using cephalexin in combination with ciprofloxacin against 
Klebsiella pneumoniae (M) the maximum number of bacteria was killed 
between 6 and 8 hours and no regrowth occured at 24 hours. The 
combination was bacteriocidal and synergistic against this strain. This result 
substantiates the finding of Mayer and Nagy, (1999) who found that the 
fluoroquinolone ciprofloxacin in combination with third-generation 
cephalosporins had a high activity against Pseudomonas spp. They reported 
that all combinations used of ciprofloxacin in combination with third-
generation cephalosporins exerted a synergic effect against some of the 18 
Pseudomonas spp they studied; their isolates belonged to the different 
species and were selected on the basis of their different resistance patterns. 
They also suggested that measurement of the time- killing of the bacteria 
was the most reliable means of assessing the existence of a synergic effect.  
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Using the combination of sulphamethoxazole and trimethoprim 
against Pseudomonas aeruginosa, in the present study it was found that 
there was no increase in the viable cell count.  The combination had 
bacteriostatic effect (see Fig 46).   
In our present study when we tested the effect of a using combination 
of tetracycline and trimethoprim on Klebsiella pneumoniae (M), the 
combination was found to be antagonistic when the fractional inhibitory 
concentration was determined. When the effect of the same combination was 
studied by time kill method and it was found that the viable bacterial cell 
decreased between 2 and 4 hours and increased again up to 24 hours (see Fig 
47). The same effect was noticed when using either tetracycline alone using 
(MIC= 32 µg/ml) Fig (21), or trimethoprim alone using 1 X MIC (256µg/ml, 
Fig 16). The same combination (tetracycline and trimethoprim) had shown 
antagonistic effect when tested Pseudomonas aeruginosa using 
checkerboard. When the effect of the combination was studied along time it 
was found that the number of viable cells was minimum at 6 and 8 hours but 
increased continually thereafter till 24 hours Fig (48). The same effect was 
also noticed when using either tetracycline alone using (MIC= 16µg/ml, Fig 
23), or trimethoprim alone using 2 X MIC (32µg/ml, Fig, 19). From the 
above findings it can be concluded that the antagonistic effect can only be 
demonstrated using checkerboard technique. 
 
4.2. Effect of using antibiotics on bacterial growth phases 
In these experiments the effects of addition of erythromycin (MIC-
=2µg/ml) and Tetracycline (MIC=4µg/ml) on already growing cells of 
Pasteurella multocida at different phases of growth growing in test tubes 
and in animals each alone and in combination (conc=0.25µg/ml 
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Erythromycin=0.125µg/ml Tetracycline) were studied. The minimum lethal 
dose (MLD) was <1.2 x 106 CFU/ml. Therefore, an inoculum size of 1.2x107 
(approximately 10 times the minimum lethal dose) was selected for in vivo 
studies. 
4.2.1. In vitro studies on effect of using single and combination 
antibiotics on different bacterial growth phases.  
The effectiveness of an antimicrobial agent is measured by its ability to 
inhibit and kill bacteria. However, tests of this ability are usually performed 
on log-phase bacteria or those in a very rapid-growth phase in media 
supplying all of the necessary nutrients for optimal growth (NCCLS, 1990). 
Clinically, microorganisms in some infected tissues may be walled off 
quickly by host leukocytes, followed by fibrin deposits, and thus the growth 
of the bacteria may be less optimal and controlled by the limited access to 
nutrition (Sheldon, 1988). Other evidence for the importance of studying 
dormant organisms is available. For Staphylococcus epidermidis, Widmer et 
al. (1990) showed that only data on antibiotic killing of static organisms 
correlated with successful therapy. Isolates of S. aureus from chronic 
subcutaneous cage infections in rats were shown to be in a state of dormancy 
(Churd  et al.,1991). In these scenarios, the organisms multiply at a less-
than-optimal rate and the effectiveness or lack of effectiveness of antibiotics 
against organisms in such a growth state is just being recognized. It is well 
known that a β-lactam antibiotic exerts its maximum effect on rapidly 
growing bacteria, but the limits of its activities against non growing and 
slowly growing bacteria need to be defined (Robert et al., 1991). 
In our present study the viable count of Pasteurella multocida was done 
before and after the addition of the antibiotic. The viable count of the cells at 
different times of growth represents the different phases of growth. We 
 186
found that the maximum numbers of viable cells were killed when 
erythromycin was added to 6 hours growing cells Fig (49) that is at the 
stationary phase. The same bacterium when subjected to tetracycline the 
most critical time was found to be 1- 2 hours (lag phase) and 6 hours 
(stationary phase) Fig (50). When combination of two antibiotics with lower 
concentration than each singly was used, the maximum numbers of bacteria 
were killed at 2 hours and 6 hours Fig. (51).  
In our present study we found that erythromycin was most effective when 
the cells of Pasteurella multocida were at stationary phase. This result is in 
accordance with what Taiseir (1990) who stated that the bacterial cells were 
more susceptible to drugs in the stationary phase. However, our finding is in 
disagreement with Saeed, (2002) who reported that the cells of Pasteurella 
multocida were found to be more susceptible to ciprofloxacin in the lag 
phase.  
When we studied the effect of tetracycline on Pasteurella multocida at 
different phases of growth, we observed that a critical time for the bacteria 
was “1-2 hours” the lag phase and the most critical was “6 hours” the start of  
the stationary phase. This result is in accordance with Taiseir (1990) and  
Saeed (2002) findings . 
It is interesting to note that using a combination of tetracycline and 
erythromycin, when the cells of Pasteurella multocida were greatly affected 
at 2 hours and 6 hours, an observation which may indicate that the 
combination has an additive effect (see Fig 51) . 
From the above observation it could be concluded that the effect of 
antibiotics on bacteria at different phases of growth depends on the type of 
the antibiotic used as well as the growth phase of the organism.   
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4.2.2. In vivo studies on effect of using one or two antibiotics on 
different bacterial growth phases. 
Testing combinations of antimicrobial agents on animal models are 
generally performed to achieve one of the following purposes: (i) to increase 
the bactericidal activity and/or the rate of killing in vivo, (ii) to prevent the 
emergence of drug resistance, (Fantin and Carbon 1992).  
The advantage of discriminative models of infection is that, besides the 
fact that they closely simulate the characteristics of the infection in humans, 
they provide clear endpoints which allow statistical comparisons among 
different antibiotic regimens. These endpoints include the number of CFU of 
bacteria per unit weight of tissue, the frequencies of emergence of resistance, 
the presence or absence of positive blood cultures, death versus survival, and 
the percentage of observed relapses that occur once treatment is 
discontinued.  
Microbiologists have defined in vitro synergism by various bacteriostatic 
and bactericidal techniques (Krogstad and Moellering, 1986). In contrast, in 
vivo synergism is still an undefined concept. The phrase "in vivo synergism" 
is generally avoided in the literature, and the phrase "enhanced antibacterial 
activity of the combination in vivo when it is compared with that of either 
agent alone" has been used instead (Fantin and Carbon, 1992).In practice, 
most investigators use statistical methods to evaluate the in vivo 
effectiveness of combinations, and they call in vivo synergism “a 
statistically significant difference between the activity of a combination and 
that of the most effective agent alone”. However, the fact that a combination 
of two antibiotics is more effective than either agent alone does not 
necessarily mean that the combination has synergistic activity in vivo, but it 
could reflect an additive effect. In contrast, "a bactericidal effect of the drug 
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combination is significantly more pronounced than the sum of the 
bactericidal effect of each agent alone in comparison with the effect in 
untreated animals" might be a reasonable definition of in vivo synergism, 
since it implies that the combination induces a bactericidal effect that is 
more pronounced than expected by the simple addition of the bactericidal 
effect of each agent alone.  
In vitro, it is recommended to use that at least one of the drugs in a 
concentration which does not affect the growth curve of the test organism 
when it is used alone. The aim is to use sub-inhibitory concentrations of at 
least one agent in order to demonstrate the presence of in vitro synergism 
that would not otherwise be apparent with higher concentrations. 
However, no recommendation has been made on drug levels for use in 
the investigation of synergism in vivo. Since the aim of antibiotic 
combination studies in experimental models of infection is to evaluate in 
vivo efficacy and to generate data that might be extrapolated to the clinical 
situation, it therefore seems necessary to use clinically relevant 
concentrations of and optimal dosing regimens for both agents of the 
combination (Fantin and Carbon, 1992). 
In our present study, the percentage of survivals of infected mice with 
Pasteurella multocida was calculated after treatment with erythromycin and 
tetracycline singly or in combination with lower doses. Treatment by 
antibiotics was given   half an hour after infection, after 3 hours and after 8 
hours of infection. Depending on our data from in vitro experiments the 
bacteria would be at lag phase (after half an hour), log phase (3 hours) and 
stationary phase (8 hours).  
In our present study we found that 33% of the animals survived when 
treatment with erythromycin was started 3 hours after infection when the 
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cells are in the log phase. Tetracycline treated about 33% of the animals 
when the dose was used against cells in the lag phase. When treatment with 
combination of erythromycin and tetracycline with lower concentrations was 
used, all the animals survived when treatment was given to the animals 
either half an hour   or 8 hours after infection. Two thirds of the animals 
survived when they were injected with a combined dose of erythromycin and 
tetracycline 3 hours after infection Fig (52). 
From the above results we can conclude that Pasteurella multocida is 
sensitive to combination of erythromycin and tetracycline in vivo as well as 
in vitro. We can also conclude that different antibiotics have different effects 
on the cells of Pasteurella multocida at different phases of growth. 
We were not able to pursue any similar research in the literature.  This 
may suggest that this work seems to be the first of its type.  
The experiments reported here also suggest that the variable of bacterial 
growth phase should be further evaluated and standardized for quantitative 
testing of antibiotic susceptibility in vitro. Additional information is needed 
concerning the importance of the growth phase in killing by agents other 
than what we used either singly or in combination and on the correlations 
between the responses of bacteria to antimicrobial agents in vitro and in 
vivo. 
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CONCLUSION 
 
The following conclusions were derived from this study  
1. The selection for drug resistance is been associated with an increased and 
inappropriate use of antibiotics.  
2. The overall prevalence of resistance of microorganisms to antimicrobial 
agents such as ciprofloxacin is notably higher in the current study, than 
the findings in previous studies.  
3. Pseudomonas aeruginosa and Pasteurella multocida were sensitive 
strains to ciprofloxacin 
4. Using sub-inhibitory concentrations of ciprofloxacin against Klebsiella 
sp. and Pseudomonas aeruginosa may lead to emergence of resistant 
strains 
5. If adequate multiples of the MIC for the infecting organism can be 
obtained in serum and tissue, resistance to ciprofloxacin may not be a 
frequent occurrence. 
6. Trimethoprim along time has a bacteriostatic effect on strains of E.coli, 
Klebsiella pneumoniae and Enterobacter. 
7. Erythromycin is always bacteriostatic against Klebsiella pneumoniae and 
does not change to bacteriocidal at high concentrations. 
8. Tetracycline had bacteriostatic effect at low concentrations and 
bacteriocidal effect at high concentrations against some strains of E. coli 
and Pasteurella multocida. 
9. Combination therapy could potentially be used in a clinical setting to 
limit the emergence of resistance in susceptible strains. 
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10. A combination of erythromycin and tetracycline is synergistic and has 
bacteriocidal effect against some strains of E. coli, Enterobacter 
Pseudomonas aeruginosa and Pasteurella multocida. 
11. A combination of tetracycline with ciprofloxacin is synergistic and has 
bacteriostatic effect on Klebsiella pneumoniae and Enterobacter. The 
same combination has a bacteriocidal effect when tested against 
Klebsiella pneumoniae; the magnitude of inhibition is consistent with the 
criteria of synergism. 
12. Using ampicillin in combination with ciprofloxacin against Klebsiella 
pneumoniae and Pseudomonas aeruginosa has synergistic as well as 
bacteriocidal effect on both strains. 
13.  A combination of two penicillins such as ampicillin and amoxicillin 
against some strains of Klebsiella pneumoniae   along time shows 
bacteriocidal and synergistic effects. 
14. Using cephalexin in combination with ciprofloxacin against Klebsiella 
pneumoniae has synergistic and bacteriocidal effect. 
15. Sulphamethoxazole with trimethoprim has synergistic and bacteriostatic 
effect on Pseudomonas aeruginosa 
16. Tetracycline and trimethoprim combination is antagonistic against some 
strains of Klebsiella pneumoniae and Pseudomonas aeruginosa.  
17. Drug interaction patterns between bactericidal and bacteriostatic drugs 
are highly dependent on bacterial species, strains, and drug 
concentrations used. 
18. Every combination of antibiotics should be tested in vitro with regard to 
its action characteristics, to avoid undesirable effects of combinations.  
19. Practical clinical experiences are needed to decide on possible clinical 
benefits of using any two antibiotics in combination.  
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20. . There is a significant difference in the efficacy of antibiotics at different 
phases of growth of bacteria in vitro and in vivo. The difference in 
efficacy of antibiotics that affects bacteria at different phases of growth 
depends on the type of the antibiotic as well as the phase of growth of 
bacteria. 
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